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Nothing in life is to be feared, it it only to be understood. 
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1. INTRODUCTION 
The Flaviviridae family includes four genera: Flavivirus, Hepacivirus, 
Pegivirus and Pestivirus. This virus family contains human and animal 
pathogens of global significance, e.g. the human flaviviruses yellow fever 
virus (YFV), dengue virus (DENV), West-Nile virus (WNV), Japanese 
encephalitis virus (JEV), tick-borne encephalitis virus (TBEV), Zika virus 
(ZIKV), Murray Valley encephalitis (MVEV), St Louis encephalitis (SLEV) 
as well as hepacivirus hepatitis C virus (HCV). The name Flaviviridae refers 
to the jaundice occurring in course infection caused by YFV, the first 
identified virus of this family 
1
. In humans, infection with Flaviviridae may 
lead to fulminant, hemorrhagic diseases (YFV, DENV), viral encephalitis 
(WNV, JEV, TBEV) or chronic hepatitis (HCV). Viruses belonging to the 
pestivirus genus [e.g. bovine viral diarrhea virus (BVDV)], infect only 
animals, leading to severe disease of the host, usually followed by death, 
causing significant economic losses 
2, 3
.  
Specific antiviral therapies are currently available only for the treatment 
of HCV infections 
4
 and, to date, there is no specific treatment for any 
flavivirus and pestivirus infections, though commercially available vaccines 
for some viruses exist. The overall strategy against pestivirus mainly involves 
identification and removal of infected animals and vaccination. Despite 
therapy for pestivirus infections is not believed to be an option, current 
vaccines do not completely prevent the spread of infection and antiviral 
therapy could potentially supplement vaccination 
5
. 
On the contrary, due to the global threat of flaviviral pandemics 
6
, there is an 
urgent need for specific antiviral drugs for the treatment of flavivirus 
infections since, in many countries, patients with severe cases of infections 
are treated only by supportive care, which includes intravenous fluids, 
hospitalization, respiratory support, and prevention of secondary infections. 
8 
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2. PATHOGENESIS AND CLINICAL SIGNIFICANCES 
 
2.1. Flavivirus 
 Most Flaviviruses are transmitted through the bite of infected 
mosquitoes of the species Aedes aegypti (YFV, DENV) and Culex Vishnu 
(JEV), or through the bite of the tick Ixodes ricinus (Western Europe), Ixodes 
persulcatus (Eastern Europe and Asia) or Ixodes ovatus (China and Japan) 
6-7
.  
The geographical distribution of each virus is likely to be affected by its 
vector distribution. Therefore, climate change and development of 
transportation systems have allowed flaviviruses to invade new areas. 
Currently, many people are exposed to flaviviruses worldwide. In addition, 
traveling through endemic countries increases the opportunity of exposure to 
flaviviruses 
8
.  
Mosquitoes are the most important vector for flaviviral diseases 
affecting humans, as well as being the crucial intermediate replicative vector 
for the normal enzootic cycle through birds and pigs, which amplify these 
viruses. Mosquito-borne flaviviruses and their associated diseases are found 
in Asia, Africa, Europe, the US and Australia, and are concentrated in wetland 
areas where mosquitoes abound 
9
. Consequently, flavivirus-induced disease 
attack rates increase with rising mosquito population densities, and are further 
increased by human contact with amplifying vertebrate hosts, such as birds or 
pigs. This is associated with farming activities, such as deforestation and 
irrigation 
10
, as well as by the effects of global warming, associated with 
increasing temperatures and precipitation, as occurs during extended monsoon 
periods 
11, 12
. 
 As indicated in Table 1, an etiologic classification within the genus 
Flavivirus might be performed by knowing the vector. 
10 
 
Table 1. Classification of Flavivirus by carrier 
13, 14
 
FLAVIVIRUS WITH KNOWN VECTOR 
Classification Vector Species 
Mammalian viruses Tick 
Gadgets Gully virus, Kadam 
virus, Kyasanur Forest disease 
virus, Langat virus, Louping ill 
virus, Omsk hemorrhagic fever 
virus, Powassan virus, Royal 
Farm virus, Tick-borne 
encephalitis virus 
Aroa Mosquito Aroa virus 
Dengue Mosquito Dengue virus, Kedougou virus 
Japanese encephalitis Mosquito 
Cacipacore virus, Japanese 
encephalitis virus, Koutango 
virus, Murray Valley encephalitis 
virus, St. Louis encephalitis virus, 
Usutu virus, West Nile virus, 
Yaounde virus 
Kokobera Mosquito Kokobera virus 
Ntaya Mosquito 
Israel turkey virus, Ntaya virus, 
Tembusu virus 
Spondweni Mosquito Zika virus 
Yellow fever Mosquito 
Banzi virus, Bouboui virus, Edge 
Hill virus, Jugra virus, Sapoya 
virus, Sepik virus, Uganda S virus, 
Wesselsbron virus, Yellow fever 
virus 
FLAVIVIRUS WITH UNKNOWN VECTOR 
Gender Species 
Flavivirus 
Entebbe bat virus, Yokose virus, Apoi virus, Cowbone Ridge virus, 
Jutiapa virus, Modoc virus, Sal Vieja virus, San Perlita virus, Bukalasa 
bat virus, Carey Island virus, Dakar bat virus, Motana myotis 
leukoencephalitis virus, Phnom Penh bat virus, Rio Bravo virus 
 
 Due to their significant pleiotropism within the vertebrate host, 
Flavivirus can be broadly grouped into viruses that have the capacity to cause 
vascular leakage and hemorrhage (e.g. YFV and DENV), and those that cause 
encephalitis (e.g. WNV, JEV, TBEV) (Table 2). After entering through the 
skin via the bite of an infected arthropod, the virus starts to proliferate locally 
11 
 
and then spreads to become generalized within a short period of time, usually 
with a significant viremia. Despite the route of progression through the 
vertebrate host has not been clearly established, it seems that the virus 
progresses from the site of the bite to draining lymph nodes, where it 
replicates and is amplified before, in case of encephalitic flaviviruses, 
crossing the blood-brain barrier (BBB) 
15
. Several hypotheses have been 
presented to explain the mechanism of central nervous system (CSN) 
penetration. These include virus entry as a result of inflammation and damage 
to vascular integrity 
16
, penetration through the olfactory bulb 
17
, toll-like 
receptor-mediated entry 
18
 and transcytosis across vascular endothelial cells 
16
. BBB crossing is an important factor for the pathogenesis and unfavorable 
clinical outcome of the neurotropic viral infection 
19
. Studies suggest that 
macrophages could serve as a reservoir for WNV, spreading the virus from 
the periphery to the CNS 
20, 21
, while other reports have shown that WNV is 
able to enter the CSN via anterograde axonal transport
 22
. It has been shown 
that JEV virions bound to the endothelial surface of the CSN are internalized 
by endocytosis 
23
. The mechanisms by which encephalitic flaviviruses induce 
neuronal injury in vivo are still unknown. However, in vitro studies have 
started to elucidate the pathways involved in WNV-induced cell death. It has 
been demonstrated that WNV infection triggers apoptosis in different 
transformed cell lines, resulting in caspase 3 activation, cytochrome c release, 
and exposure of phosphatidylserine on the outer leaflet of the plasma 
membrane 
24, 25
. The cellular outcome of WNV replication depends on 
interactions between host and viral factors. UV-inactivated WNV failed to 
induce cell death, suggesting that viral replication is required to trigger 
apoptosis 
25
. Several WNV proteins may contribute directly to this process. 
Ectopic expression of the WNV NS3 protein or its helicase or protease 
domain induced apoptosis and activation of caspase 3 and 8 
26
. Expression of 
12 
 
WNV capsid protein either in vitro or in the striata of mouse brain also 
triggered apoptosis downstream of caspase 3 and caspase 9 activation 
27
. It is 
known that programmed cell death could have opposing functions during viral 
infection: it may be antiviral by inducing the death of infected cells, or it may 
enhance viral spread and progeny release. Cell death can also be pathological 
if it occurs in non-renewing cell populations, such as neurones. Thus, it has 
been postulated that virus-induced apoptosis may contribute to neuronal death 
in vivo and the pathogenesis of encephalitic flaviviruses 
28, 29
. However, direct 
evidence for this mechanism has been lacking, and the pathways involved in 
the flavivirus-mediated death of neurones are not well understood.  
Other pathogenic flaviviruses, principally DENV and YFV, cause a 
syndrome of fever and malaise, „capillary leak‟ with loss of plasma volume 
and coagulation defects which can lead to bleeding. The 15–20 different types 
of viral haemorrhagic fever appear to share a similar pathogenesis, in which 
macrophages and dendritic cells, rather than acting as barriers to an invading 
pathogen, serve as the principal sites of viral replication, supporting the rapid 
spread of infection 
30, 31, 32
. Although direct cytopathic effects can also 
contribute to disease severity (hepatic injury in case of YFV infection), most 
features of the illness are often caused by innate immune responses, as the 
systemic spread of virus to macrophages and dendritic cells leads to the 
release of mediators that modify vascular function and have procoagulant 
activity.  
Human YFV infections exhibit three clinical stages 
33
. Following a 3–6-
day incubation period, illness begins with fever, headache, myalgia and 
viremia characterized as the “infection period”, although the majority of cases 
are thought to result in asymptomatic infections. Following recovery from a 
3–5-day “infection period”, a “remission period” can occur in some patients 
with liver and renal failure. Finally, an “intoxication period” begins with 
13 
 
hemorrhagic fever and multi-organ failure, where patients also develop 
jaundice and thrombocytopenia. Approximately 15% of cases develop 
moderate/severe manifestations. The World Health Organization (WHO) 
estimates 200‟000 cases with 30‟000 deaths occur annually, mostly in Africa 34. 
DENV is a flavivirus of global public health importance; an estimated 
2.5 billion people in more than 100 countries are at risk of acquiring dengue 
viral infection with more than 50 million new infections being projected 
annually 
35
. The economic importance of dengue in the developing world is 
also a major concern 
36
. After the bite of an infected mosquito vector, DENV 
can cause a mild and self-limiting infection but may induce more severe 
symptoms such as dengue fever (DF) or it may progress to a potentially lethal 
dengue haemorrhagic fever (DHF) and in the worst cases, dengue shock 
syndrome (DSS). The characteristic features of DHF are increased capillary 
permeability without morphological damage to the capillary endothelium, 
thrombocytopenia, altered number and functions of leucocytes, altered 
haemostasis and liver damage. The pathogenesis of DHF is not fully 
understood, despite extensive work carried out in recent decades, due mainly 
to the absence of an appropriate animal model. Various mechanisms have 
been suggested for DHF enhancement including a role for non-neutralizing 
enhancing antibodies in secondary dengue infections with heterologous 
serotypes, memory T-cell-mediated pathogenesis, immune complex disease or 
complement and its products, anti-NS1 antibodies that cross-react with 
vascular endothelium. A cytokine Tsunami and other soluble mediators such 
as high concentrations of soluble IL-2 receptor, soluble CD4, soluble CD8, 
TNF receptors, IL-10 and macrophage migration inhibition factor are also 
considered important factors in dengue pathogenesis. Finally, selection of 
virulent virus strains (South East Asian type DENV-2) and host genetic 
polymorphism are others important factors largely described and certainly 
involved in DHF 
37, 38
. 
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Table 2. Main pathogenic flaviviruses for humans. 
Virus Abbreviation 
Location of 
isolation 
Geographic 
distribution 
Human diseases 
Dengue 1 DENV-1 Hawai Tropics, subtropics Fever, rash, 
vasculopathy, 
hemorrhagic fever 
Dengue 2 DENV-2 New Guinea Tropics, subtropics Fever, rash, 
vasculopathy, 
hemorrhagic fever 
Dengue 3 DENV-3 Philippines Tropics, subtropics Fever, rash, 
vasculopathy, 
hemorrhagic fever 
Dengue 4 DENV-4 Philippines Tropics, subtropics Fever, rash, 
vasculopathy, 
hemorrhagic fever 
Kyasanur Forest 
disease 
KFDV India India Hemorrhagic fever 
Omsk hemorrhagic 
fever 
OHFV Russia Western Siberia Hemorrhagic 
fever/encephalitic 
Yellow fever YFV Ghana Sub-Saharan 
Africa, South 
America 
Pantropic 
Powassan virus POWV  Western United 
States, Western 
Canada, Siberia 
Encephalitis 
Japanese encephalitis JEV Japan Asia Encephalitis 
Langat LGTV Makaysia Malaysia, 
Thailand, Siberia 
Encephalitis 
Louping ill LIV Scotland Uk, Ireland Encephalitis  
Murray Valley 
encephalitis 
MVEV Australia Australia, New 
Guinea 
Encephalitis 
St Louis encephalitis SLEV USA South and Central Encephalitis 
Tick-borne 
encephalitis 
TBEV Russia Europa, Asia Encephalitis 
West Nile WNV Uganda Old World and 
New World 
Encephalitis 
 
 
2.2. Pestivirus  
The genus Pestivirus includes three species: bovine viral diarrhea virus 
(BVDV), classical swine fever disease virus (CSFV), and ovine border 
disease virus (OBV). Pestiviruses infect many species of domestic and wild 
animals, BVDV is a prototypical representative of the pestiviruses of 
ruminant animals.  
15 
 
There are multiple methods of BVDV transmission: the virus can 
spread horizontally within a herd as well as transmit vertically from cow to 
calf. Horizontal transmission can occur via transiently infected (TI) animals 
that shed virus during acute infection, it can also occur due to persistently 
infected (PI) animals that shed virus throughout their lifespan in all bodily 
secretions (nasal and ocular discharges, milk/colostrum, semen, urine, and 
feces) 
39
. Studies show that BVDV environmental survival is dependent upon 
temperature and moisture levels with a maximum survival in bovine farm 
slurry at 5°C for 3 weeks and at 20°C for 3 days 
40
. There are also reports of 
indirect BVDV transmission from contaminated pens, rectal examination 
gloves, hypodermic needles, nose tongs, and ambient air 
41
. 
 Vertical transmission may occur from a PI dam in utero to her 
offspring. In vertical transmission the outcome of infection is determined by 
the stage of fetal maturation when exposed to the virus in utero. If the fetus is 
infected in the first trimester, it will likely abort, mummify, or show a variety 
of congenital defects. Infection during the second trimester results in a PI 
animal: in these feti, the virus is recognized as self, resulting in an immune-
tolerant state and persistent viremia without seroconversion. By the third 
trimester of gestation (>180 days), the fetus is immune-competent and will 
mount an immune response that may result in abortion, or the birth of a 
healthy or weak and seropositive calf 
42
.  
BVDV is known for causing a variety of disease presentations in cattle 
and other ungulates.There are two genotypes of the virus: BVDV-1 and 
BVDV-2, both of which have also been isolated from non-bovine species. 
The genotypes are further divided into cytopathic (CP) and non-cytopathic 
(NCP) subtypes. Acute infection occurs when seronegative, 
immunocompetent cattle are exposed to the virus. The disease is characterized 
by ulceration of the nose, mouth and gastrointestinal mucosa which helps the 
16 
 
virus to spread quickly, due to the continuous salivation, coughing, nasal 
discharge or diarrhea 
43
. These symtoms are consequences of the damage 
caused by the virus to its target organs such as the lymphoid sistem, the cells 
of the gastrointestinal tract, glands and neurons 
44, 45
. 
Control of pestiviral diseases is particularly difficult due to the constant 
viremia and viral shedding of PI animals, which must be identified and 
eliminated to prevent disease transmission. Existing vaccines are limited by 
the delay between vaccination and the onset of protection, the difficulty of 
differentiating serologically between vaccinated and naturally infected 
animals and the need for broad vaccine cross-protection against diverse virus 
strains. Antiviral therapy could potentially supplement vaccination by 
providing immediate protection in the case of an outbreak 
46
.  
 
2.3. Hepacivirus 
Hepatitis C virus (HCV) is the only member of the Hepacivirus genus, 
identified in 1989 
47
. HCV is found worldwide but the most affected regions 
are Africa and Central an East Asia. The distribution varies locally and can be 
concentrated in certain populations (drug addicts or blood products recipients) 
or in general population. HCV infections are largely diffused in the world and 
around 55-85% of infected people will develop a chronic infection; according 
to the World Health Organization (WHO) the number of people suffering 
from chronic HCV infection is between 130-150 million people globally.  
HCV is a bloodborne virus, most commonly transmitted to intravenous-
drug users through the sharing of syringes, transfusion of unscreened blood 
and blood products, reuse or inadequate sterilization of medical, tattoing or 
body piercing equipment 
48, 49
. This virus can also be transmitted sexually and 
through perinatal transmission but these modes are much less common. HCV 
17 
 
does not spread through water, food or breast milk or by casual everyday 
contact such as hugging, kissing and sharing food and drinks with an infected 
individual. Since actually there is no available vaccine, prevention is crucial 
in reducing the risk of infection, especially in high-risk population and 
settings 
50
.  
The incubation period is between 2 weeks and 6 months, even after this 
period the majority of infected  people show no symptoms while those who 
are acutely sympthomatic may exhibit fever, fatigue, nausea, vomiting, 
abdominal pain, decreased appetite, dark urine, grey-coloured faeces, joint 
pain and jaundice (yellowing of skin and yellowing of the sclera). Since HCV 
infection is usually asymptomatic, just a few people are diagnosed during the 
acute phase, even in those who develop a chronic HCV infection this usually 
remains undiagnosed for decades until secondary symptoms of serious liver 
damage occur. To correctly decide the treatement and manage the disease, 
people diagnosed with chronic HCV infection should have an assessment of 
the degree of liver damage (fibrosis and cirrhosis) and a test to identify the 
genotype of the HCV strain. There are 6 different HCV genotypes which 
respond differently to treatement, and it is possible to be infected with more 
than one of them. 
About 15-45% of people infected with HCV spontaneously clear the 
infection thanks to a strong immune reaction and some people with chronic 
infection do not develop liver damage, but when treatement is necessary, the 
goal of HCV treatment is cure. Antiviral medicines can cure 90% of persons 
with HCV infection, thus reducing the risk of death, but access to diagnosis 
and treatment is usually low 
51, 52, 53
. Until recently HCV treatment was based 
on 48 weeks therapy with interferon and ribavin; this therapy cured 
approximately half of the treated patients but caused frequent and sometimes 
life-threatening adverse reactions. The standard care for HCV is rapidly 
18 
 
changing and, recently, new antiviral drugs, called direct antiviral agents 
(DAA) have been developed. These medicines can cure most persons with 
HCV infection and treatment is safer, shorter (usually 12 weeks) and better 
tolerated than old treatments. The production cost of DAAs is low but in 
many high and middle-income countries these medicines are very expensive 
but due to the introduction of generic versions of this drug prices have 
substantially dropped in some countries, primarily low income ones 
54
.  
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3. VIROLOGY 
 The genus Flavivirus comprises an unusually large number of 
taxonomically recognised species (more than 70 at the present time, of which 
more than 40 are human pathogens) with a global distribution. This genus 
also includes a large, and increasing, number of unclassified or “tentative” 
species that have very different characteristics from those currently 
recognized as members of the genus 
55, 56
. 
Flaviviruses have historically been associated with changes in 
taxonomy to reflect newly-identified viruses and advances in analytical 
methods. Initially, the term arborviruses (later changed to arboviruses to avoid 
confusion with the Latin word “arbor”, meaning tree) was derived as a 
taxonomic criterion following the discovery of several arthropod-borne 
viruses, later due to morphological information obtained using electron 
microscopy, it was possible to support the hypothesis of the existence of at 
least two groups of viruses:  
1. A group of non-enveloped viruses, which are currently classified within 
the family Reoviridae (genera Orbivirus, Coltivirus and Seadornavirus), 
namely viruses with an overall diameter of 60–80 nanometers, icosahedral 
symmetry and several concentric capsid layers that surround a segmented 
double-stranded RNA (dsRNA) genome. 
2. A group of enveloped viruses with a diameter of 50-60 nanometers and 
infectious single-stranded RNA (ssRNA) of positive polarity. The 
development of serological methods led to the identification of two 
antigenically distinct sub-groups. This division was subsequently 
confirmed by analysis of the genome sequences and the viruses were 
divided as follows: 
20 
 
(a)  The "A group of Arbovirus" which currently includes viruses 
classified within the genus Alphavirus, family Togaviridae (together 
with the non-arboviral genus Rubivirus). 
(b) The "B group of Arbovirus" which currently includes viruses 
classified within the genus flavivirus, family Flaviviridae (together 
with non-arboviral genera Hepacivirus and Pestivirus). 
 
3.1. Viral genome 
The flavivirus genome is a plus-sense, single stranded RNA of about 
11000 nucleotides, consisting of a 5‟ untranslated region (UTR) carrying a 
canonical cap structure, a single open reading frame (ORF) and a 3‟ UTR 
which is not polyadenylated (with the exception of TBEV) but instead forms a 
functionally equivalent complex RNA fold
 57
. The genome is packaged by the 
viral capsid protein (C) in a host-derived lipid bilayer containing the viral 
envelope protein (E) and the protein M. The first is crucial in receptor 
binding, membrane fusion and viral assembly while the second is processed 
from a larger precursor protein (Pre-M), which acts as a stability factor that 
protects the E protein during the replication in the infected cell (Figure 1). 
The single ORF encodes a large polyprotein that is co-translationally 
and post-translationally processed by viral and host proteases into 10 mature 
viral proteins that are required for replication and assembly of new virions. 
The N-terminal end of the polyprotein encodes the three structural proteins C, 
prM/M and E, followed by seven non-structural (NS) proteins NS1, NS2a, 
NS2b, NS3, NS4a, NS4b, and NS5 (Figure 2) 
58
. 
NS3 (70kDa) and NS5 (104kDa) are the most fully characterized non-
structural proteins with multiple enzyme activities essential for viral 
replication. Mutations that affect each activity impair viral replication 
59
. NS3 
protein has three distinct enzymatic activities: serine protease together with 
21 
 
Figure 2. Schematic representation of flavivirus genome and 
polyprotein organization. 
 
Figure 1. Flavivirus structure. 
22 
 
the cofactor NS2B, necessary for the polyprotein processing 
60, 61, 62
; helicase / 
NTPase activity, required for unwinding the double-stranded replicative dorm 
of RNA; RNA triphosphatase, needed for capping nascent viral RNA 
63
.  
NS5 is the largest and most highly conserved flaviviral protein, 
with sequence identity greater than 75% across all DENV serotype. It 
contains two distinct enzymatic activities, separated by an interdomain 
region: an S-adenosylmethyltransferase and an RNA-dependent RNA 
polymerase (RdRp) 
64
.  
The NS1 protein (16 kDa) is required for flavivirus replication and is 
presumably involved in negative-strand RNA synthesis by a mechanism not 
yet entirely clarified. The fundamental role played by this protein in viral 
replication is confirmed by the fact that its deletion prevents the replication of 
YFV 
65
.  
NS2A (22 kDa) is a small hydrophobic transmembrane protein that is 
involved in generating virus-induced membranes during virus assembly 
66
. 
NS4A (16 kDa) is an integral membrane protein which induces 
membrane rearrangements to form the viral replication complex 
67
. 
NS4B (27 kDa) is a protein which inhibits the type I interferon 
response of host cells and may modulate viral replication through an 
interaction with the NS3 protein 
68, 69
. 
 
 
3.2. Replication cycle 
 Host cells for flaviviral infection include monocytes, macrophages and 
dendritic cells 
70
. The virus attaches to the cell surface, mediated by the E 
protein, and enters the cell via receptor-mediated endocytosis 
71, 72
 (Figure 3). 
The low pH in the endosomal compartment triggers fusion of the viral host 
cell membrane mediated by the structural reorganization of E protein, which 
23 
 
promotes the release of the nucleocapsid and viral RNA into the cytoplasm 
(uncoating) 
73
. The positive-sense RNA is translated into a single polyprotein 
that is co-and post-translationally cleaved by the viral protease NS2B/NS3 
and by host proteases in order to produce three structural proteins and seven 
non-structural proteins in the following order: C - prM -E - NS1 - NS2A - 
NS2B - NS3 - NS4A - NS4B - NS5. The host cell peptidase, located in the 
lumen of the endoplasmic reticulum (ER), cleaves the sites C - PrM, PrM - E, 
E - NS1, NS4A - NS4B while the viral protease NS3 cleaves the sites NS2A - 
NS2B, NS2B - NS3, NS3 - NS4A, NS4B - NS5 
74
. The non-structural 
Figure 3. Flavivirus replication cycle. 
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proteins are involved in viral genome replication, which occurs in the rough 
endoplasmic reticulum (RER) and in the membranes from Golgi complex, 
called vesicular packets (VP). The RNA-dependent RNA polymerase (RpRd) 
NS5 generates a copy of the viral genome in the form of single-stranded 
negative-sense RNA devoid of cap, which serves as a template for the 
synthesis of new ssRNA (+) genome. The new synthesized RNA is extruded 
through the intermembrane space of the VP and from here out into the 
cytoplasm by a not yet completely clarified mechanism 
75
. The assembly of 
virus particles occurs in the lumen of the RER. The first step in this process is 
the coating of the newly synthesized viral RNA with the C protein 
76, 77, 78
. 
Next, E and PrM proteins hetero-dimerize and envelope the nucleocapsid, 
forming an immature virus particle that buds from the lumen of the RER into 
the Golgi complex 
79
. However, the mechanism of interaction of the C protein 
within the nucleocapsid is still not clear. Maturation of virus particle occurs in 
the trans-Golgi network, where prM is cleaved to M by furin, along with 
conformational rearrangements of E protein 
80, 81
. Mature virions are 
subsequently released by exocytosis. 
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4. CURRENT TARGETS AND PERSPECTIVES ON 
FLAVIVIRUS CHEMOTERAPY 
Despite the large number of people that annually suffer from severe 
flavivirus infections, no clinically approved antiviral therapy is currently 
available to manage these diseases and only a palliative FANS therapy is 
provided to treat fever and pain. Vaccination is considered a reasonable 
method to prevent flavivirus infections; effective flavivirus vaccines against 
YFV, JEV and TBEV infections have been developed, but WNV and DENV 
vaccines have not been licensed for human use 
82
. However vaccines may 
cause adverse effects ranging from headaches, gastrointestinal disturbances, 
myalgia and local reactions, to neurotropic and viscerotropic syndromes 
whose outcome can be fatal. Moreover, vaccination is not recommended in 
immunocompromised patients; unfortunately regions with the highest number 
of HIV infections (Africa Central and Eastern Europe) are also the most hit by 
YFV 
83
. The aforementioned problems linked to vaccination and the absence 
of a specific therapy, have pushed towards the search for effective drugs in 
the treatment of infections by flaviviruses. For this purpose, useful targets can 
be the viral proteins (Tables 3 and 4) or the host proteins that play a key role 
in the virus replication (Tables 5 and 6).  
Currently, interest in developing inhibitors is limited to those viruses 
that cause chronic disease, viruses that have the potential to cause large-scale 
epidemics, or ubiquitous viruses for which the treatment of acute infection 
would be beneficial even if the infection was ultimately self-limiting.  
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4.1. Compounds targeting viral proteins  
 
Envelope proteins. The structural proteins of the flavivirus, especially 
those of the envelope, are excellent targets for the development of antiviral 
drugs, for this purpose modeling studies have been used to identify potential 
inhibitors of these proteins 
84
.  
The monoclonal antibody mAb 2A10G6 has been shown to be 
effective on YFV, DENV, WNV, JEV and TBEV recognizing an epitope 
within the fusion loop of the E protein, thus arresting the steps of the 
replication cycle after binding 
85
.   
Compounds that interact with the envelope proteins could be used to 
prevent entry of the virus into the host cell. Many thiazole derivatives that 
target the envelope proteins have shown a high activity against YFV in cell 
cultures, in particular S-methyl-2-(4-chlorophenyl)-4-(dibromomethyl) 
thiazole-5-carbothioate is moderately nontoxic (CC50 = 369 µM) with an 
EC50 = 1.4 µM and has a selectivity index (EC50/CC50) of 263 
86
. 
 
S-methyl-2-(4-chlorophenyl)-4-(dibromomethyl)thiazole-5-carbothioate 
 
 NS1. The primary function of this protein remains unclear, despite the 
recent unveiling of its atomic structure 
87
 and a growing list of host molecules 
with which it has been found associated. It has been found that NS1 plays an 
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important role in the mechanisms of immune-evasion of various Flavivirus. 
This non-structural protein forms a complex with C1S and C4 proteins, 
promoting the cleavage of C4 into C4b 
88
. NS1 is also a fundamental 
component for the synthesis of viral RNA, therefore molecules that inhibit 
this protein could be potential viral replication inhibitors. Further 
understanding of the interplay between flaviviruses and the immune system 
will be critical to the development of new antiviral strategies. 
NS3. Inhibitors of this protease are currently designed by either 
competing with substrate binding or by disrupting the interaction between 
NS2B and the NS3 protease domain 
89
. Despite a wealth of structural and 
biochemical informations available on the NS2B–NS3 protease substrate-
binding pocket, no compound has progressed to the preclinical stage yet.  
A competitive non peptidic inhibitor (Compound 14) with an EC50 of 5 
µM and a CC50 greater than 300 µM has been recently identified using a 
computational approach that included elaboration of a pharmacophore model, 
the NS2B–NS3 protease X-ray crystallographic structure and a docking 
protocol 
90
. 
 
 
Compound 14 
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In another study, flavonoids were found to be non-competitive inhibitors of 
DENV NS2B–NS3 protease serotypes 2 and 3 with IC50 (compound 
concentration giving a 50% inhibition in enzymatic assay) of 15–44 µM 91. 
 
 
 
Finally, an interesting study provided evidences for the possibility of 
targeting the interaction between NS2B and NS3 as an effective antiviral 
strategy. This study reports that compound SK-12 acts by blocking the 
NS2B/NS3 protease interaction, inhibiting DENV-4 replication with an EC50 
of 3.8 µM as well as JEV with EC50 of 14.4 µM 
92
. 
 
SK-12 
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By screening a library of compounds, the anthelmintic drug ivermectin 
has been shown to interact with the helicase activity of the NS3; this is 
surprising considering that this drug is approved for the treatment of 
nematodes infections. Ivermectin showed a high potency against YFV in cell 
cultures and a lower one against a wide range of other flavivirus 
93
.  
 
 
Ivermectin 
 
 NS4B. This non-structural protein has recently emerged as a valid 
antiviral drug target. The aminothiazole NITD-618 (Novartis Institute for 
Tropical Diseases) was identified as a potent and pan-serotype DENV 
inhibitor with EC50 ranging from 1.0 to 4.1 µM. Transient transfection studies 
using a luciferase DENV-2 replicon as shown that NITD-618 acts by 
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suppression of viral RNA synthesis. Unfortunately the high lipophilicity of 
NITD-618 resulted in poor pharmacokinetic properties which hindered testing 
of its in vivo efficacy in the DENV-AG129 mouse model 
94
. 
 
 
NITD-618 
 
It has been reported the identification of a δ opioid receptor antagonist, 
SDM25N, which inhibits DENV (EC50 = 1.9 µM) at the step of viral RNA 
replication. A single amino acid substitution (F164L) in the NS4B protein that 
confers compound resistance was found by culturing the DENV-2 replicon 
cells for several passages under selection of SDM25N. Moreover, this 
compound exhibits antiviral activity only in mammalian cells, but not in the 
C6/36 mosquito cells, suggesting that SDM25N targets a function of NS4B 
that is only required for efficient replication in mammalian cells but not in 
mosquito cells, and that host environment plays a role in mediating the 
compound efficacy 
95
. 
 
 
SDM25N 
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It was recently reported a compound class with a spiropyrazolo-
pyridone core displaying a promising antiviral activity against dengue virus. 
In particular the Compound 14a has shown a good in vivo pharmacokinetic 
profile (EC50 = 0.042 µM) in fact treatment of DENV-2-infected AG129 mice 
with Compound 14a suppressed viremia, even when the treatment started 
after viral infection 
96
.  
 
 
 
Compound 14a 
 
NS5. This protein contains two fundamental enzymatic activities: an S-
adenosyl methyltransferase and an RNA-dependent RNA polymerase (RdRp). 
2'-C-methylcytidine is an RNA polymerase inhibitor which reached the 
clinical trial fase for the treatment of HCV
 
infections
 
but was later abandoned 
due to its high toxicity in long term treatment 
97
. Interestingly, this compound 
has also shown activity against YFV both in vivo and in vitro. In a research 
conducted on hamsters the treatment with 2'-C-methylcytidine showed its 
effectiveness when administered two days after YFV inoculation 
98
. Several 
other derivatives of the 2'-C–methylcytidine showed different activities 
against YFV in cell cultures and hopefully a similar less toxic compound 
which maintains anti-YFV activity will be developed
 99
. 
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2’-C- methylcytidine 
 
 The pyrazinecarboxamide derivatives T-705 (favipiravir) and T-1106 
have showed a broad spectrum of activity on RNA viruses, including some 
flaviviruses (WNV, YFV). In a study, T-705 has been reported to be a potent 
inhibitor against influenza A, B and C viruses in vitro; it has been also 
proposed that T-705 is converted intracellularly to the ribonucleotide T-705-
ribofuranosyl-5-monophosphate (T-705 RMP) by a phosphoribosyl 
transferase and, upon phosphorylation, to its 5-triphosphate. This metabolite 
would inhibit the influenza virus RdRp in a GTP-competitive manner 
100
. In 
addition to inhibiting YFV and WNV replication in vitro, improvements in 
survival and disease parameters were also observed after the addition of T-
705 to YFV- or WNV-infected rodents 
101
. It may be assumed that the 
mechanism by which T-705 inhibits viruses other than influenza is similar to 
the mechanism by which it is believed to inhibit influenza virus‟ replication, 
but this remains subject of further studies. Although T-705 is slightly less 
effective than T-1106 in a hamster model of yellow fever virus infection 
102
, it 
is currently under clinical trial for the treatment the influenza virus 
103
 and its 
possible approval could represent an off label therapeutic strategy to patients 
with yellow fever. In a recent study, T-705 also showed limited in vivo 
efficacy against zika virus (ZIKV) 
104
. 
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The compound NITD008 showed a potent anti-DENV activity in mice 
and has also shown in vivo activity (rodents) against YFV 
105
. NITD008 is an 
adenosine nucleoside analog that contains a carbon substitution for N-7 of the 
purine and an acetylene at the 2′ position of ribose; the triphosphate form of 
NITD008 competes with natural adenosine triphosphate substrates to 
incorporate into the growing RNA chain and, upon incorporation, terminates 
RNA elongation. It has been demonstrated that NITD008 is also a potent 
inhibitor of ZIKV and can be used as reference inhibitor for future ZIKV 
antiviral drug screen and discovery 
106
. 
 
 
NITD008    
 
Two 2,3-dihydro-4H-pyridine derivatives, cis-3,5-dimethyl-1-(4-
nitrophenyl)-2-[4-(trifluoromethyl)phenyl]-2,3-dihydropyridin-4(1H)-one 
and 2-(4-chlorophenyl)-4-ethoxy-3,5-dimethyl-1-(4-nitrophenyl)-1,2,3,4-
tetrahydropyridine, have shown moderate activity against the YFV in cell 
cultures, with selectivity index of 5.6 and 10 respectively 
107
. 
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2-(4-chlorophenyl)-4-ethoxy-3,5-dimethyl-1-(4-nitrophenyl)-1,2,3,4-tetra 
hydropyridine was able to inhibit in vitro the HCV replicon as well as NS5B 
protein of the same virus, suggesting that the inhibition of RNA-dependent 
RNA polymerase could be at the basis of its mechanism of action. 
 
 
Cis-3,5-dimethyl-1-(4-nitrophenyl)-2-[4-(trifluoromethyl)phenyl]-2,3-dihydropyridin-4(1H)-one 
 
 
2-(4-chlorophenyl)-4-ethoxy-3,5-dimethyl-1-(4-nitrophenyl)-1,2,3,4-
tetrahydropyridine 
 
Anti-flavivirus compounds with other or unknown mechanisms of action. 
 Ribavirin is a broad spectrum antiviral drug which has been widely used 
for the treatment of HCV infections in combination with pegylated interferons 
108 
and in aerosol form for the treatment of pediatric respiratory syncytial virus 
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(RSV) infections. Almost all RNA viruses and even some DNA viruses are 
sensitive to the in vitro antiviral activity of ribavirin and some viruses are 
more susceptible to the action of this drug than others; flaviviruses, for 
example, are much less sensitive than the paramyxovirus RSV
 109
. The 
antiviral activity of ribavirin was reported almost four decades ago, but the 
molecular mechanism by which the compound exerts its antiviral activity still 
remains a matter of debate. 
Ribavirin 5-monophosphate inhibits Inosine 5-monophosphate (IMP) 
dehydrogenase, a cellular enzyme which converts IMP to xanthosine 5-
monophosphate in the de novo synthesis pathway of GMP 
110
. As a 
consequence, intracellular GTP pools are depleted, resulting in inhibition of 
viral (but also cellular) RNA synthesis. This compound has also shown other 
mechanisms of action including inhibition of viral RdRp on influenza virus 
111 
and inhibition of viral capping (via an effect on the viral GTase or MTase 
activities) on dengue virus 
112
. 
 
Ribavirin 
Ribavirin is particularly active in animal models of hamster 
113
; the 
effect of this drug was also studied in rhesus monkeys infected with YFV or 
DENV-1. Either therapeutic or prophylactic protocols were studied. Overall, 
no effect on viremia and survival was noted 
114, 115, 116
. Since the mechanism 
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of anti-flavivirus activity of ribavirin is based on an aspecific mechanism, the 
design of safe and more potent analogues of ribavirin will likely be very 
difficult to achieve. 
The mechanisms of action of many compounds that have shown an in 
vitro anti-flavivirus activity are still not clear. For example 6-methyl 
mercaptopurine riboside (6MMPr) showed the ability to inhibit in vitro the 
replication of YFV and other Flaviviruses like WNV. However it has been 
shown that this compound is able to exacerbate WNV infection in mice 
117
. 
 
 
 
6MMPr 
 
4.2. Compounds targeting host cells functions 
One of the fundamental characteristics of viral diseases, including those 
caused by flavivirus, is the immunopathogenesis connected to the infection. 
Animal models inoculated with YFV have shown that pathological events 
which mostly threaten the animal's survival are those that occur in the late 
stage of the disease, suggesting that the later phases have a strong 
immunological component 
118
. Many studies have turned their attention to the 
immunopathogenic mechanism of yellow fever in cell cultures, proving that 
there is a net reduction of cytokine induction in cells infected with the wild-
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type strain of YFV, compared to cells infected with the vaccine 17-D, 
suggesting that decreased immune response can be a mechanism of 
pathogenesis 
119
. Therefore the stimulation of the inflammatory response with 
the use of immunomodulators could represent a convenient way for the 
treatment of yellow fever.  
Previously it has been cited the combination of ribavirin and interferons 
for the treatment of HCV infections and how this combination can also be 
used in YFV infections, the resulting reduction of the doses and duration of 
treatment could avoid the toxic effects; however, the therapeutic window for 
the use of interferon is limited. Both interferon alfacon-1 and adenovirus-
vectored interferon DEF201 were tested on hamsters infected with YFV, 
demonstrating therapeutic activity when administered two/three days after the 
inoculation of the virus and thus before the manifestation of pathological 
symptoms 
120, 121
. The same result is obtained by initiating treatment seven 
days prior to inoculation of the virus, thus suggesting the potential 
prophylactic use in the case of YFV epidemics. 
The compound CCG-4088 recently showed anti YFV activities 
122
. In 
fact this compound is structurally similar to a class of inhibitors of RNAase L, 
an antiviral protein involved in humoral immune response and in ssRNA 
cleavage.  
 
 
CCG-4088 
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A further therapeutic strategy, together with the modulation of the 
humoral immune response, is represented by the use of antibodies. In addition 
to having important implications in the development of a vaccine, it was 
demonstrated that antibody therapy is also effective in the treatment of YFV 
and other viruses‟ infections, both in animal models and in humans. 
Another useful strategy for the arrest of viral replication is to inhibit the 
enzymes of the host cell that are necessary for the replication of the virus. For 
example the inhibitor of the kinase broad spectrum SFV785 showed activity 
against HCV, DENV and YFV acting on the virus assembly in the 
endoplasmic reticulum. This inhibitor, at a concentration of 5 µM, is able to 
reduce by 5 logarithmic units the viral title of YFV in cell cultures 
123
.  
 
 
 
SFV785 
 
 Even some natural products showed anti-flavivirus activity. For 
example, phospholipases A2 (PLA2), found in the venom of the rattlesnake 
(Crotalus durissis terrificus), has shown in vitro activity against YFV and 
DENV, mainly in the pre-treatment/inactivation stages of viruses 
124
. The 
toxin contained in the venom (crotoxin) seems to significantly inhibit 
inflammatory edema and cell migration when administered before or after 
carrageenan injection in mice, thus suggesting an anti-inflammatory activity 
for this compound 
125
. 
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Table 3. Compounds targeting viral proteins – activity in cell cultures. 
Compound Mechanism Effect 
mAb 2A10G6 Binding to the E protein Neutralization 
S-methyl-2-(4-chlorophenyl)-4-
(dibromomethyl)thiazole-5-
carbothioate 
Binding to the E protein 
 
Inhibition 
 
SK-12 Action on the NS2B-NS3 protease 
Inhibition of interaction between 
NS2B and NS3 
Ivermectin Action on the NS3 helicase Inhibition of replication 
NITD-618 Action on the polymerase NS4B Inhibition of replication 
SDM25N Action on the polymerase NS4B Inhibition of replication 
2’-C-methylcytidine Action on the polymerase NS5 Inhibition of replication 
NITD008 Inhibition of the polymerases Reduces the viremia 
T-705 Inhibition of the polymerases  
Cis-3,5-dimethyl-1-(4-
nitrophenyl)-2-[4-
(trifluoromethyl)phenyl]-2,3-
dihydropyridin-4(1H)-one 
Inhibition of the polymerases Reduces the viremia 
2-(4-chlorophenyl)-4-ethoxy-3,5-
dimethyl-1-(4-nitrophenyl)-
1,2,3,4-tetrahydropyridine 
Inhibition of the polymerases Reduces the viremia 
Ribavirin Inhibition of IMP dehydrogenase 
Reduction of GTP and 
inhibition of RNA synthesis 
  
 
Tabel 4. Compounds targeting viral proteins – activity in animal models.  
Compound Model Mechanism Effect 
Compound 14a Mouse 
Action on the polymerase 
NS4B 
Survival/protection 
from disease 
2’-C-methylcytidine Hamster 
Action on the polymerase 
NS5 
Survival/protection 
from disease 
T-705  Hamster 
Action on the 
polymerases 
Survival/protection 
from disease 
T-1106  Hamster 
Action on the 
polymerases 
Survival/protection 
from disease 
Ribavirin Hamster 
Inhibition of IMP 
dehydrogenase 
Survival/protection 
from disease 
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Table 5. Compounds targeting host cell functions – activity in cell culture. 
Compound Mechanism Effect 
CCG-4088 Inhibiting RNAase Inhibition of replicon 
SFV785 Inhibition of kinases Reduction in viral power 
PLA2 Viral inactivation (?) Reduction in viral power 
 
 
 
Table 6. Compounds targeting host functions – activity in animal models. 
Compound Model Mechanism Effect 
Alfacon-1 Hamster Action on INF 
Survival/protection from 
disease 
DEF201 Hamster Action on INF 
Survival/protection from 
disease 
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5. SUBJECT OF PRESENT RESEARCH  
Viruses belonging to Flaviviridae family are a major cause of 
infectious diseases, worldwide. The global, social and economic impact due 
to morbidity and even mortality associated with these infections, urgently 
demands effective therapeutic interventions. Success has been recently 
achieved with the introduction in therapy of the direct-acting antiviral agents 
(DAAs) for the treatment of hepatitis C. However, to date no specific drug 
has been approved to combat Flavivirus and Pestivirus infections, and patient 
care remains symptomatic. 
Following the researches undertaken in our laboratory on heterocyclic 
compounds with antiviral activity, in the present PhD thesis the design, 
synthesis and antiviral evaluation of new classes of pyrazole and pyrazoline 
derivatives with potent and selective anti-Flavivirus or anti-BVDV activity is 
described. 
 
5.1. Pyrazole-based antiviral agents  
By the antiviral screening of an in house library of 
pyrazole compounds, (N-(1,3-diphenyl-1H-pyrazol-4-yl)methyl)anilines (4a-
v) were identified as a new class of potent and selective inhibitors of human 
respiratory syncytial virus (RSV) replication
 1
. Some derivatives were also 
endowed with a moderate activity against BVDV, representative of Pestivirus 
genus, and against significant human pathogens belonging to the Flavivirus 
genus such as YFV, Dengue Virus (DENV) and West Nile Virus (WNV). The 
hit compounds exhibited activity in the micromolar range coupled with no 
cytotoxicity (CC50 > 100 µM) against the cell lines (MDBK and BHK-21) 
utilized for the in vitro assays 
1
.  
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Human respiratory syncytial virus (RSV) is the leading cause of acute 
lower respiratory tract infections in infants and young children worldwide. 
Severe clinical manifestations due to RSV include both pneumonia and 
bronchiolitis that represent the most frequent causes of childhood 
hospitalization in developed countries 
1
. Despite the incidence of RSV 
infection is higher during the first years of life, RSV disease can also occur in 
individuals of all ages. Unfortunately, due to the lack of long-lasting 
immunity, re-infections are common throughout life 
2-4
. Prematurity, chronic 
conditions, such as congenital heart disease and chronic lung disease, and 
immunodeficiency disorder increase both the frequency and the severity of 
the infection associated with this pathogen, as well as mortality attributable to 
RSV 
4-6
. In recent years, extrapulmonary manifestations associated with 
severe RSV infection have been frequently described. Indeed, in addition to 
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respiratory tract, RSV can infect heart, liver and CNS producing severe 
cardiopathy, hepatitis and encephalitis, respectively 
7-9
. Neither vaccines nor 
specific antiviral drugs are currently available to prevent or to treat RSV 
infection. To date, current preventive strategy involves passive immunization 
with Palivizumab, a humanized monoclonal antibody targeting the F- protein 
of RSV. Despite its usefulness in preventing severe RSV disease, the use of 
Palivizumab is limited to high risk patients, because of its high cost and the 
need of monthly injection during the epidemic season 
10-11
. Ribavirin, a broad 
spectrum antiviral agent, was the first drug licensed for the treatment of RSV 
infection. However, its clinical use is now limited, due to poor efficacy and 
elevated risk of severe side effects 
12
. Therefore, there is an urgent need of 
identifying and developing new potent and selective antiviral drugs to treat 
RSV infection. Following our research on the antiviral activity of heterocyclic 
compounds 
13-16
, in this paper we report the synthesis and the anti-RSV in 
vitro activity of N-((1,3-diphenyl-1H-pyrazol-4-yl)methyl)aniline derivatives 
(4a–v). In addition, all the compounds were evaluated against a large panel of 
RNA viruses representative of single-stranded, negative-sense (ssRNA
-
), and 
positive-sense (ssRNA
+
), or double stranded (dsRNA) viruses, as well as 
against two DNA viruses. 
 
5.1.1.1. Results and discussion 
5.1.1.1.1. Chemistry 
As depicted in the Scheme 1, the compounds 4a–v were prepared with 
some modification of the general synthetic route reported by Huang et al.
17
 
Initially, the required hydrazones 1a-e were synthesized by condensation of 
the suitable acetophenones with phenylhydrazine hydrochloride, in the 
presence of anhydrous sodium acetate in ethanol. Following the procedure 
described by Kira et al.
18
 the obtained hydrazones 1a-e were treated with 
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Vilsmeier–Haack reagent (DMF–POCl3), leading to the corresponding 1,3-
diphenyl-1H-pyrazole-4-carboxaldehydes 2a-e. 
The subsequent condensation of 2a-e with the appropriate anilines, performed 
in refluxed dry ethanol and dry benzene with traces of glacial acetic acid, 
provided the corresponding azomethines 3a-v, which were finally converted 
into the desired N-((1,3-diphenyl-1H-pyrazol-4-yl)methyl)anilines (4a–v) by 
reduction with sodium borohydride.  
 
57 
 
5.1.1.1.2. Antiviral tests 
Derivatives 4a–v were evaluated in cell based assays for their 
cytotoxicity and antiviral activity against a panel of RNA and DNA viruses. 
Among single-stranded, positive RNA viruses (ssRNA
+
), we considered a 
retrovirus (Human Immunodeficiency Virus type 1, HIV-1), two 
Picornaviruses (Coxsackie Virus type-5, CVB-5, and Poliovirus type-1, Sabin 
strain, Sb-1), and viruses representative of two of the three genera of the 
Flaviviridae family, that is, a Flavivirus (Yellow Fever Virus, YFV), and a 
Pestivirus (Bovine Viral Diarrhea Virus, BVDV). Among single-stranded, 
negative RNA viruses (ssRNA
-
) a Paramyxoviridae (Respiratory Syncytial 
Virus, RSV) and a Rhabdoviridae (Vesicular Stomatitis Virus, VSV) were 
selected as representatives. Among double-stranded RNA (dsRNA) viruses, a 
Reoviridae family member (Reo-1) was included. Finally, two representatives 
of DNA virus families were also included: Herpes Simplex Virus type-1, 
HSV-1 (Herpesviridae) and Vaccinia Virus, VV (Poxviridae). Efavirenz 
(EFV), pleconaril, ribavirin, 6-azauridine (NM 299), 20-C-methylcytidine 
(NM 107), ACG (acyclovir), and mycophenolic acid (M 5255) were used as 
reference inhibitors of ssRNA+, ssRNA-, dsRNA and DNA viruses 
respectively. Cytotoxicity and antiviral activity of the compounds 4a–v and 
reference inhibitors are reported in Tables 1 and 2. 
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Table 1. Cytotoxicity and antiviral activity of N-((1,3-diphenyl-1H-pyrazol-4-yl)methyl) 
anilines 4a–v against ssRNA+ (BVDV, YFV) and ssRNA- (RSV) viruses. 
 
 
 
Compds R R1 
MDBK 
aCC50 
(µM) 
BVDV 
bEC50 
(µM) 
cSI 
CC50/
EC50 
BHK-21 
dCC50 
(µM) 
YFV 
eEC50 
(µM) 
cSI 
CC50/
EC50 
Vero76 
hCC50 
(µM) 
RSV 
iEC50 
(µM) 
cSI 
CC50/
EC50 
4a CH3 H >100 >100 - >100 38.0±6.0 >2.6 52 23.0±2.5 2.3 
4b Br H >100 >100 - >100 20.0±4.0 >5.0 52 9.0±1.5 5.8 
4c H Br >100 31.0±0.5 >3.2 >100 32.0±4.0 >3.1 52 9.0±2.0 5.8 
4d Cl Br >100 >100 - >100 28.0±5.0 >3.6 43 7.0±1.5 6.1 
4e CF3 Br 64 >64 - 28 >28 - 17 5.0±0.5 3.4 
4f CH3 Br >100 >100 - >100 >100 - 92 11.0±4.5 8.4 
4g Br Br >100 >100 - >100 54.0±6.0 >1.8 88 8.0±2.5 11.0 
4h H Cl >100 29.0±1.5 >3.4 >100 29.0±3.5 >3.4 65 6.0±1.0 10.8 
4i Cl Cl >100 31.0±2.0 >3.2 73 >73 - 90 13.0±2.5 6.9 
4j CF3 Cl 44 >44 - 31 >31 - 10 > 10 - 
4k CH3 Cl >100 >100 - >100 34.0±0.5 >2.9 >100 14.0±1.5 >7.1 
4l Br Cl >100 ≥100 - >100 43.0±0.5 >2.3 >100 9.0±0.5 >11.1 
4m H CH3 >100 53.0±3.0  >1.9 >100 65.0±5.0 >1.5 >100 28.0±2.5 >3.6 
4n Cl CH3 >100 55.0±5.0 >1.8 >100 >100 - >100 13.0±2.5 >7.7 
4o CF3 CH3 >100 54.0±4.0 >1.8 88 >88 - 82 25.0±3.0 >3.3 
4p CH3 CH3 >100 >100 - >100 >100 - >100 28.0±2.5 >3.6 
4q Br CH3 >100 >100 - >100 >100 - >100 11.0±1.0 >9.1 
4r H CF3 34 >34 - 37 >37 - 17 >17 - 
4s Cl CF3 31 >31 - 17 >17 - 18 >18 - 
4t CF3 CF3 26 >26 - 27 >37 - 26 >26 - 
4u CH3 CF3 >100 >100 - 88 >100 - 45 >45 - 
4v Br CF3 46 >46 - 20 >28 - 28 >28 - 
Ref. compounds          
NM 299    >100 46.0±3.3 >2.2 10.0±1.6 0.9±0.4 11.1 
Ribavirin 57.0±6.2  19.0±5.3 3.0    >100 35.0±5.0 >2.8 
NM 108    60      
Data represent mean values for three independent determinations. Variation among duplicate samples was less than 15%. 
aCompound concentration required to reduce the viability of mock-infected MDBK (Bovine normal kidney) cells by 50%, as determined 
by the MTT method. bCompound concentration required to achieve 50% protection of MDBK cells from the BVDV-induced 
cytopathogenicity, as determined by the MTT method. cSelectivity index (SI) was the ratio between CC50 and EC50. d Compound 
concentration required to reduce the viability of mock-infected BHK (Hamster normal kidney fibroblast) monolayers by 50%, as 
determined by the MTTmethod. eCompound concentration required to reduce the viability of mock-infected BHK cells from the YFV-
induced cytopathogenicity, as determined by the MTT method. fCompound concentration required to achieve 50% protection of BHK 
cells from DENV-2 induced cytopathogenicity, as determined by the MTT method.  gCompound concentration required to achieve 50% 
protection of BHK cells from WNV induced cytopathogenicity, as determined by the MTT method. hCompound concentration required 
to reduce the viability of mock-infected VERO76 (monkey normal kidney) monolayers by 50%. iCompound concentration required to 
reduce the plaque number of RSV (Respiratory Syncytial Virus) by 50% in VERO76 monolayers.  
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Data listed in Table 1 showed that most of the tested compounds 
exhibited antiviral activity against RSV in the micromolar range (EC50s 
ranging from 5 µM to 28 µM). Only the analogues bearing a trifluoromethyl 
group in R
1
 (4r–4v) and 4j, (where R = CF3), were inactive against this virus 
up to the CC50 for Vero76 cells, a nonhuman cell line suitable for the 
replication of RSV. Moreover, the presence of this group whether in position 
R
1
 (4r–1v) or R (4e, 4j, 4o) seems to increase the compound cytotoxicity not 
only on Vero76 cells but also on the other nonhuman cell lines (MDBK and 
BHK-21) utilized in this study. When tested against these last two cell lines, 
the removal of the trifluoromethyl group or its replacement with a methyl 
group or with a halogen completely abolished the compound cytotoxicity up 
to the highest concentration tested (100 µM). The only exception to this 
generalization was represented by 4i, (where R = R
1 
= Cl), that exhibited a 
low cytotoxicity against BHK-21 cells (CC50 = 73 µM). Moreover, several N-
((1,3-diphenyl)-1H-pyrazol-4-yl)methyl)aniline derivatives have already been 
reported to have remarkable antiproliferative effects against MCF-7 and B16-
F10 cancer cell lines and potent cyclin dependent kinase 2 (CDK2) inhibitory 
activities
 1
. The antiproliferative effects seem to be associated to the presence 
of a strong electron-withdrawing substituent in R
1
, however, trifluoromethyl 
derivatives had not been tested. Interestingly, as reported in Table 2, all the 
compounds 4a–v, included the trifluoromethyl analogues, are devoid of 
toxicity for the human MT-4 cell line up to the highest concentration tested 
(100 µM).  
Concerning the anti-RSV activity (Table 1), all the compounds able to 
interfere with RSV replication exhibited an interesting potency, comparable 
or better than ribavirin (EC50 = 35 µM). Unfortunately, all derivatives were 
found less potent than 6-Azauridine, used as reference drug. SAR studies 
showed that the replacement of the trifluoromethyl group in R
1
 with the 
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methyl group (4m–q) strongly reduced the cytotoxicity and led to the 
appearance of anti-RSV activity in the micromolar concentrations (EC50s 
ranging from 11 µM to 28 µM). More potent compounds were obtained with 
the introduction in R
1
 of an electron-withdrawing group such as a chlorine 
(4h–1l) or a bromine (4c–1g) atom (EC50s ranging from 5 µM to 14 µM). 
However, both these substitutions generally resulted in compounds with 
increased cytotoxicity against Vero76 cells with respect to the corresponding 
4-methylanilines (4m–1q). In particular, 4e, where R = CF3 and R
1
 = Br, 
exhibited the most potent anti-RSV activity (EC50 = 5 µM) of the entire series 
of compounds, however, its selectivity was modest (SI = 3.4) due to its 
significant cytotoxicity against Vero76 cells (CC50 = 17 µM). Among 
analogues showing anti-RSV activity, only 4a and 4o exhibited a lower 
selectivity index (SI = 2.26 and 3.28, respectively) than 1e. Although less 
potent than 4e, the halo substituted anilines 4g, 4h and 4l (EC50 = 8 µM, 6 
µM, and 9 µM, respectively) presented comparable or higher selectivity (SI = 
11.00, 10.83, and >11.1, respectively) than the reference drug 6-Azauridine 
(SI = 11.1).  
When tested against HIV-1, Reo-1, CVB-5, Sb-1, VV, HSV-1 and 
VSV, all the compounds were devoid of antiviral activity up to the highest 
concentration tested (100 µM) (Table 2), while some analogues showed a 
moderate protection against BVDV and YFV, representative of Pestivirus and 
Flavivirus genera, respectively, of the Flaviviridae family (Table 1). In 
particular, six compounds (4c, 4h, 4i, 4m–o) inhibited BVDV with EC50s 
ranging from 29 µM to 55 µM and nine compounds (4a–d, 4g, 4h, 4k–m) 
inhibited YFV with EC50s ranging from 20 µM to 65 µM. All the active 
compounds were non cytotoxic against the proper cell line (MDBK and BHK-
21, respectively) at concentration up to 100 µM. Although no evident 
relationship can be observed between the structure of compounds and the 
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appearance of the activity against BVDV and YFV, it should be noted that 
only derivatives 4c, 4h, 4m, unsubstituted in R, were found to be active 
against BVDV, YFV, and RSV. Whereas these compounds exhibited a 
modest and similar potency against the two viruses representative of two of 
Compds R R1 
MT-4 
aCC50 
(µM) 
HIV-1 
bEC50 
(µM) 
BHK-21 
cCC50 
(µM) 
Reo-1 
dEC50 
(µM) 
Vero76 
eCC50 
(µM) 
CVB-5 Sb-1 VV HSV-1 VSV 
fEC50 
(µM) 
4a CH3 H >100 >100 >100 >100 52 >52 >52 >52 >52 >52 
4b Br H >100 >100 >100 >100 52 >52 >52 >52 >52 >52 
4c H Br >100 >100 >100 >100 52 >52 >52 >52 >52 >52 
4d Cl Br >100 >100 >100 >100 43 >43 >43 >43 >43 >43 
4e CF3 Br >100 >100 28 >28 17 >17 >17 >17 >17 >17 
4f CH3 Br >100 >100 >100 >100 92 >92 >92 >92 >92 >92 
4g Br Br >100 >100 >100 >100 88 >88 >88 >88 >88 >88 
4h H Cl >100 >100 >100 >100 65 >65 >65 >65 >65 >65 
4i Cl Cl >100 >100 73 >73 90 >90 >90 >90 >90 >90 
4j CF3 Cl >100 >100 31 >31 80 >80 >80 >80 >80 >80 
4k CH3 Cl >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 
4l Br Cl >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 
4m H CH3 >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 
4n Cl CH3 >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 
4o CF3 CH3 >100 >100 88 >88 82 >82 >82 >82 >82 >82 
4p CH3 CH3 >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 
4q Br CH3 >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 
4r H CF3 >100 >100 37 >37 75 >75 >75 >75 >75 >75 
4s Cl CF3 >100 >100 17 >17 18 >18 >18 >18 >18 >18 
4t CF3 CF3 >100 >100 27 >27 26 >26 >26 >26 >26 >26 
4u CH3 CF3 >100 >100 88 >88 45 >45 >45 >45 >45 >45 
4v Br CF3 >100 >100 20 >20 28 >28 >28 >28 >28 >28 
Ref. compounds           
EFV 37.0±0.01 0.002±0.0001         
NM 107   >100 6.0±2.9       
Pleconaril     80.0±6.0 0.005±0.002 2.2±0.6    
ACG     >100    2.8±0.2  
M5255     19.0±3.0   1.5±0.2   
Data represent mean values for three independent determinations. Variation among duplicate samples was less than 15%. 
aCompound concentration required to reduce the viability of mock-infected MT-4 (cd4+ Human T-cells containing an integrated HTL V-
1 genome) cells by 50%, as determined by the MTT method. bCompound concentration required to achieve 50% protection of MT-4 cells 
from the HIV-1 induced cytioathigenicity, as determined by the MTT method. c Compound concentration required to reduce the viability 
of mock-infected BHK (hamster normal kidney fibroblast) monolayers by 50%, as determined by the MTT method. dCompound 
concentration required to achieve 50% protection of BHK cells (kideney fibroblast) from the Reo (Reovirus 1), induced 
cytopathogenicity, as determined by the MTT method. eCompound concentration required to reduce the viability of mock.infected 
VERO76 (monkey normal kidney) monolayers by 50%. fCompound concentration required to reduce the plaque number of CVB-5 
(Coxsackievirus B5), Sb-1 (Poliovirus 1), VV (Vaccina virus), HSV-1 (Herpesvirus 1) and VSV ( Vescicular Stomatitis Virus) by 50% in 
VERO76 monolayers. 
 
Table 2. Cytotoxicity and antiviral activity of N-((1,3-diphenyl-1H-pyrazol-4-yl)methyl) 
anilines 4a–v against ssRNA+ (HIV-1, CVB-5, Sb-1), ssRNA- (VDV), dsRNA (Reo-1) and 
DNA (VV, HSV-1) viruses. 
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the three genera of the Flaviviridae family, the activity against RSV was 
always higher.  
 In conclusion, a series of N-((1,3-diphenyl-1H-pyrazol-4- yl)methyl) 
anilines were synthesized and tested in cell-based assays against a large panel 
of RNA and DNA viruses. Results of cytotoxicity and antiviral activity 
showed that most of the analogues were endowed with promising and 
selective activity against RSV. Initial SAR studies indicated that the presence 
of trifluoromethyl group in R
1
 negatively impact both potency and 
cytotoxicity, whereas the halo-substituted analogues can be considered good 
candidates for the development of new potent and selective anti-RSV agents. 
 
5.1.1.2. Experimental 
5.1.1.2.1. Chemistry 
Chemicals were purchased from Sigma-Aldrich and used without 
further purification. Melting points were determined on a Stuar Scientific 
SMP1 apparatus and are uncorrected. 
1
H NMR spectra were recorded on a 
Bruker AM-400 spectrometer (400MHz) in CDCl3 or DMSO-d6, and 
chemical shifts were reported in ppm (). All compounds were routinely 
checked by thin-layer chromatography (TLC). TLC was performed on silica 
gel or aluminium oxide fluorescent coated plates (Fluka, DC-Alufolien 
Kieselgel or aluminum oxide F254). Compound purity was determined by 
elemental analysis and was confirmed to be > 95% for all the tested 
compounds. Analytical results are within ±0.40% of the theoretical values. 
1-phenyl-2-(1-phenylethylidene)hydrazones 1a-e 
19
 and 1,3-diphenyl-
1H-pyrazole-4-carbaldehydes 2a-e 
17
 were synthesized according to literature 
procedures. 
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5.1.1.2.2.       General procedure for the synthesis of N-((1,3-diphenyl-1H-
pyrazol-4-yl)methyl)anilines (4a-v).  
The appropriate aniline (17 mmol) was added to a solution of the 
appropriate 1,3-diphenyl-1H-pyrazole-4-carbaldehyde 2a-e (17 mmol) in dry 
ethanol (100 ml), dry benzene (50 ml) and 2 drops of glacial acetic acid. The 
mixture was refluxed for 12 h and the water formed during the reaction was 
eliminated using a Dean-Stark apparatus. After cooling, the solvent was 
evaporated under reduced pressure to give the crude (E)-N-[(1,3-diphenyl-1H-
pyrazol-4-yl)methylene]aniline 3a-v which was used without further 
purification. To a solution of compound 3a-v (4 mmol) in tetrahydrofuran 
(100 ml) sodium borohydride was added (40 mmol) and the mixture was 
refluxed for 4 h. The solvent was then evaporated under reduced pressure and 
the residue was distributed between water and chloroform. The organic layer 
was separated, washed with water, dried over anhydrous sodium sulfate and 
evaporated to dryness. The residue was crystallized with suitable solvent.  
 
5.1.1.2.2.1. N-((1-Phenyl-3-(p-tolyl)-1H-pyrazol-4-yl)methyl)aniline (4a). 
Yield 48%; m.p. = 103 – 106°C from EtOH. Anal. Calc. for C23H21N3: C 
81.38, H 6.24, N 12.38; found C 81.36, H 6.25, N 12.39. 
1
H-NMR δ (ppm) 
(CDCl3): 8.02 (s, 1H), 7.75 (d, 2H, J = 7.6 Hz), 7.70 (d, 2H, J = 7.6 Hz), 7.22 
– 7.48 (m, 7 H), 6.81 (t, 1H, J = 7.6 Hz), 6.73 (d, 2H, J = 6.8 Hz), 4.40 (s, 
2H), 2.42 (s, 3H). 
13
C NMR (CDCl3):  (ppm) 150.51, 148.63, 139.51, 
137.23, 130.11, 129.52, 129.17, 128.87, 128.73, 127.27, 126.01, 118.88, 
117.97, 116.12, 112.34, 38.24, 20.80. 
 
5.1.1.2.2.2. N-((3-(4-Bromophenyl)-1-phenyl-1H-pyrazol-4-yl)methyl) 
aniline (4b). Yield 43%; m.p. = 124 – 127 °C from CH3CN. Anal. Calc. for 
C22H18BrN3: C 65.36, H 4.49, Br 19.76; N 10.39; found C 65.36, H 4.50, Br 
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19.76; N 10.38. 
1
H-NMR δ (ppm) (CDCl3): 8.06 (s, 1H), 7.74 (d, 2H, J = 7.6 
Hz), 7.68 (d, 2H, J = 6.8 Hz), 7.48 – 7.58 (m, 4H), 7.24 – 7.34 (m, 3H), 6.85 
(t, 1H, J = 6.8 Hz), 6.75 (d, 2H, J = 6.8 Hz), 4.38(s, 2H). 
13
C NMR (DMSO-
d6):  (ppm) 149.25, 148.57, 139.34, 132.11, 131.55, 129.57, 129.26, 129.19, 
128.86, 126.28, 121.27, 119.10, 118.10, 116.21, 112.40, 38.15. 
 
5.1.1.2.2.3. 4-Bromo-N-((1,3-diphenyl-1H-pyrazol-4-yl)methyl)aniline 
(4c) Yield 59%; m.p. = 107 – 110 °C from CH3CN. Anal. Calc. for  
C22H18BrN3: C 65.36, H 4.49, Br 19.76; N 10.39; found C 65.35, H 4.50, Br 
19.76; N 10.39.  
1
H-NMR δ (ppm) (CDCl3): 8.01 (s, 1H), 7.74 – 7.76 (m, 4H), 
7.28 – 7.47 (m, 8H), 6.58 (d, 2H, J = 7.6 Hz), 4.37 (s, 2H). 13C NMR 
(DMSO-d6):  (ppm) 150.45, 147.79, 139.43, 132.82, 131.37, 129.55, 128.93, 
128.60, 127.94, 127.33, 126.17, 118.56, 118.06, 114.22, 106.78, 38.12. 
 
5.1.1.2.2.4. N-((3-(4-bromophenyl)-1-phenyl-1H-pyrazol-4-yl)methyl)-
4-chlorobenzenamine (4d) 
17
. Yield 83%; m.p. = 125 – 128 °C from CH3CN. 
The compound exhibited spectroscopic data identical to those previously 
reported 
17
. Anal. Calc. for C22H17BrClN3; C 60.22, H 3.91, Br 18.21, Cl 8.08, 
N 9.58; found C 60.21, H 3.90, Br 18.22, Cl 8.08, N 9.59. 
 
5.1.1.2.2.5. 4-Bromo-N-((3-(4-(trifluoromethyl)phenyl)1-phenyl-
1H-pyrazol-4-yl)methyl)aniline (4e). Yield 42%; m.p. = 126 – 129 °C 
from C6H12. Anal. Calc. for C23H17BrF3N3: C 58.49, H 3.63, Br 16.92, F 
12.07, N 8.90; found C 58.50, H 3.62, Br 16.92, F 12.08, N 8.89. 
1
H-NMR δ 
(ppm) (CDCl3): 8.05 (s, 1H), 7.91(d, 2H, J = 6.8 Hz), 7.75 (d, 2H, J = 8.0 
Hz), 7.70 (d, 2H, J = 7.2 Hz), 7.29 – 7.49 (m, 5H), 6.60 (d, 2H, J = 6.4 Hz), 
4.38 (s, 2H). 
13
C NMR (DMSO-d6):  (ppm) 148.84, 147.72, 139.26, 136.80, 
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131.36, 129.59, 129.43, 128.14 (q, JC-F = 31 Hz), 127.78, 126.50, 125.50 (q, 
JC-F = 3 Hz), 124.91 (q, JC-F = 270 Hz), 119.15, 118.24, 114.30, 106.93, 38.05. 
 
5.1.1.2.2.6. 4-Bromo-N-((1-phenyl-3-(p-tolyl)-1H-pyrazol-4-yl)methyl) 
aniline (4f) 
1
.Yield 48%; m.p. = 110 – 111 °C from CH3CN. The compound 
exhibited spectroscopic data identical to those previously reported 
1
. Anal. 
Calc. for C23H20BrN3: C 66.04, H 4.82, Br 19.10, N 10.04; found C 66.02, H 
4.83, Br 19.10, N 10.05. 
 
5.1.1.2.2.7. 4-Bromo-N-((3-(4-bromophenyl)-1-phenyl-1H-pyrazol-4-yl) 
methyl)aniline (4g) 
17
. Yield 74%; m.p. = 124 – 128°C from EtOH. The 
compound exhibited spectroscopic data identical to those previously reported 
17
. 
 
Anal. Calc. for C22H17Br2N3: C 54.68, H 3.55, Br 33.07, N 8.70; found C 
54.68, H 3.54, Br 33.07, N 8.71.  
 
5.1.1.2.2.8. 4-Chloro-N-((1,3-diphenyl-1H-pyrazol-4-yl)methyl)aniline (4h). 
Yield 46%; m.p. = 105 – 108 °C from CH3CN. Anal. Calc. for C22H18ClN3: C 
73.43, H 5.04, Cl 9.85, N 11.68; found C 73.45, H 5.03, Cl 9.85, N 11.67.  
1
H-NMR δ (ppm) (CDCl3): 4.38 (s, 2H), 6.62 (d, 2H, J = 8.0 Hz), 7.16 (d, 2H, 
J = 7.6 Hz), 7.28-7.47 (m, 6H), 7.74-7.76 (m, 4H), 8.01 (s, 1H). 
13
C NMR 
(DMSO-d6):  (ppm) 150.45, 147.46, 139.44, 132.84, 129.55, 128.95, 128.60, 
128.57, 127.94, 127.33, 126.17, 119.38, 118.60, 118.05, 113.64, 38.21. 
 
5.1.1.2.2.9. 4-Chloro-N-((3-(4-chlorophenyl)-1-phenyl-1H-pyrazol-4-yl) 
methy)aniline (4i) 
17
. Yield 78%; m.p. = 110 – 113 °C from CH3CN. The comp-
ound exhibited spectroscopic data identical to those previously reported 
17
. 
Anal. Calc. for C22H17Cl2N3: C 67.01, H 4.35, Cl 17.98, N 10.66; found C 
67.00, H 4.36, Cl 17.98, N 10.66. 
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5.1.1.2.2.10.     4-Chloro-N-((3-(4-trifluoromethyl)phenyl)1-phenyl-1H-
pyrazol-4-yl)methyl)aniline (4j). Yield 50%; m.p. = 111 – 115 °C from 
C6H12. Anal. Calc. for C23H17ClF3N3: C 64.57, H 4.00, Cl 8.29, F 13.32, N 
9.82; found C 64.56, H 4.02, Cl 8.28, F 13.32, N 9.82. 
1
H-NMR δ (ppm) 
(CDCl3): 8.05 (s, 1H), 7.92 (d, 2H, J = 8.0 Hz), 7.76 (d, 2H, J = 8.4 Hz), 7.71 
(d, 2H, J = 8.4 Hz), 7.50 (t, 2H, J = 8.0 Hz), 7.35 (t, 1H, J = 7.6 Hz), 7.18 (d, 
2H, J = 8.8 Hz), 6.65 ( d, 2H, J = 8.8 Hz), 4.38 (s, 2H). 
13
C NMR (DMSO-
d6):  (ppm) 148.84, 147.39, 139.26, 136.81, 129.59, 129.43, 128.55, 128.13 
(q, JC-F = 31 Hz), 127.78, 126.49, 125.49 (q, JC-F = 3 Hz), 124.26 (q, JC-F = 270 
Hz), 119.53, 119.19, 118.23, 113.73, 38.15. 
 
5.1.1.2.2.11. 4-Chloro-N-((1-phenyl-3-(p-tolyl)-1H-pyrazol-4-yl)methyl) 
aniline (4k) 
17
. Yield 77%; m.p. = 106 – 108 °C from CH3CN. The compound 
exhibited spectroscopic data identical to those previously reported 
17
. Anal. 
Calc. for C23H20ClN3: C 73.89, H 5.39, Cl 9.48, N 11.24; found C 73.88, H 
5.40, Cl 9.48, N 11.24. 
 
5.1.1.2.2.12. N-((3-(4-Bromophenyl)-1-phenyl-1H-pyrazol-4-yl)methyl)-
4-chloroaniline (4l) 
17
. Yield 62%; m.p. = 125 – 127 °C from CH3CN. The 
compound exhibited spectroscopic data identical to those previously reported 
17
.  Anal. Calc. for  C22H17BrClN3: C 60.22, H 3.91, Br 18.21, Cl 8.08, N 9.58; 
found C 60.22, H 3.90, Br 18.22, Cl 8.08, N 9.58. 
 
5.1.1.2.2.13. N-((1,3-Diphenyl-1H-pyrazol-4-yl)methyl)-4-methylaniline 
(4m).  Yield 35%; m.p. = 95 – 97 °C from EtOH. Anal. Calc. for  C23H21N3: C 
81.38, H 6.24, N 12.38; found C 81.39, H 6.25, N 12.36. 
1
H-NMR δ (ppm) 
(CDCl3): 8.01 (s, 1H), 7.85 (d, 2H, J = 7.6 Hz), 7.77 (d, 2H, J = 7.6 Hz), 7.29 
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– 7.48 (m, 6H), 7.06 (d, 2H, J = 7.6 Hz), 6.65 (d, 2H, J = 7.6 Hz), 4.39 (s, 
2H), 2.30 (s, 3H, CH3). 
13
C NMR (DMSO-d6):  (ppm) 150.43, 146.40, 
139.49, 132.96, 129.54, 129.32, 128.82, 128.57, 127.88, 127.36, 126.10, 
124.54, 119.23, 118.02, 112.52, 38.49, 20.09. 
 
5.1.1.2.2.14.  N-((3-(4-Chlorophenyl)-1-phenyl-1H-pyrazol-4-yl)methyl)-
4-methylaniline (4n) 
17
. Yield 76%; m.p. = 89 – 91 °C from CH3CN. The 
compound exhibited spectroscopic data identical to those previously reported 
17
. Anal. Calc. for C23H20ClN3: C 73.89, H 5.39, Cl 9.48, N 11.24; found C 
73.90, H 5.40, Cl 9.48, N 11.22. 
 
5.1.1.2.2.15.     N-((3-(4-(Trifluoromethyl)phenyl)-1-phenyl-1H-pyrazol-
4-yl)methyl)-4-methylaniline (4o). Yield 69%; m.p. = 98 – 100 °C from 
C6H12. Anal. Calc. for C24H20F3N3: C 70.75, H 4.95, F 13.99, N 10.31; found 
C 70.74, H 4.96, F 14.00, N 10.30. 
1
H-NMR δ (ppm) (CDCl3): 7.99 – 8.02 
(m, 3H), 7.77 (d, 2H, J = 7.6 Hz), 7.71 (d, 2H, J = 8.4 Hz), 7.50 (t, 2H, J = 7.6 
Hz), 7.35 (t, 1H, J = 7.6 Hz), 7.08 (d, 2H, J = 8.4 Hz), 6.66 (d, 2H, J = 8.4 
Hz), 4.38 (s, 2H), 2.31 (s, 3H). 
13
C NMR (DMSO-d6):  (ppm) 149.9, 146.3, 
139.7, 136.3, 131.0, 129.8, 129.6, 129.3 (q, JC-F = 31 Hz), 126.2, 126.2, 126.1, 
125.6, 124.1(q, JC-F = 3 Hz), 123.0 (q, JC-F = 270 Hz), 119.9, 117.2, 113.4, 
36.4, 21.3. 
 
5.1.1.2.2.16. 4-methyl-N-((1-phenyl-3-(p-tolyl)-1H-pyrazol-4-yl)methyl) 
aniline (4p) 
17
. Yield 68%; m.p. = 89 – 91 °C from CH3CN. The compound 
exhibited spectroscopic data identical to those previously reported 
17
. Anal. 
Calc. for C24H23N3: C 81.55, H 6.56, N 11.89; found C 81.52, H 6.58, N 11.89. 
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5.1.1.2.2.17. N-((3-(4-Bromophenyl)-1-phenyl-1H-pyrazol-4-yl)methyl)-
4-methylaniline (4q) 
17
. Yield 54%; m.p. = 89 – 92 °C from CH3CN. The 
compound exhibited spectroscopic data identical to those previously reported 
17
.  Anal. Calc. for C23H20BrN3: C 66.04, H 4.82, Br 19.10, N 10.04; found C 
66.03, H 4.83, Br 19.10, N 10.04. 
 
5.1.1.2.2.18.       4-(trifluoromethyl)-N-((1,3-diphenyl-1H-pyrazol-4-yl) 
methyl)aniline (4r).  Yield 67%; m.p.= 110 – 112 °C Crystallized EtOH. 
Anal. Calc. for C23H18F3N3: C 70.22, H 4.61, F 14.49, N 10.68; found C 
70.23, H 4.62, F 14.49, N 10.66. 
1
H-NMR δ (ppm) (CDCl3): 8.01 (s, 1H), 
7.75 – 7.78 (m, 4H), 7.39 – 7.50 (m, 7H), 7.33 (d, 1H, J = 7.2 Hz), 6.71 (d, 
2H, J = 8.4 Hz), 4.44 (s, 2H). 
13
C NMR (DMSO-d6):  (ppm) 151.38, 150.48, 
139.42, 132.78, 129.54, 129.01, 128.61, 127.98, 127.32, 126.19 (q, JC-F = 3 
Hz), 125.34 (q, JC-F = 268 Hz), 118.18, 118.09, 115.67 (q, JC-F = 32 Hz), 
111.60, 37.73, 15.05. 
 
5.1.1.2.2.19.  N-((3-(4-Chlorophenyl)-1-phenyl-1H-pyrazol-4-yl)methyl)-
4-(trifluoromethyl)aniline (4s). Yield 65%; m.p. = 100 – 103 °C from 
MeOH; Anal. Calc. for C23H17ClF3N3: C 64.57, H 4.00, Cl 8.29, F 13.32, N 
9.82; found C 64.59, H 4.01, Cl 8.27, F 13.32, N 9.80. 
1
H-NMR δ (ppm) 
(CDCl3): 7.97(s, 1H), 7.72 – 7.76 (m, 4H), 7.41 – 7.55 (m, 6H), 7.34 (t, 1H, J 
= 7.6 Hz), 6.69 (d, 2H, J = 8.4 Hz), 4.39 (s, 2H). 
13
C NMR (DMSO-d6):  
(ppm) 151.35, 149.24, 139.31, 132.70, 131.62, 129.57, 129.28, 128.94, 
128.68, 126.35, 126.18 (q, JC-F = 4 Hz), 126.53 (q, JC-F = 268 Hz), 118.27, 
118.16, 115.72 (q, JC-F = 32 Hz), 111.65, 37.66. 
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5.1.1.2.2.20.    4-(Trifluoromethyl)-N-((3-(4-(trifluoromethyl)phenyl)-1-
phenyl-1H-pyrazol-4-yl)methyl)aniline (4t). Yield 68%; m.p. = 97 – 100 °C 
from C6H12. Anal. Calc. for C24H17F6N3: C 62.47, H 3.71, F 24.71, N 9.11; 
found C 62.49, H 3.70, F 24.70, N 9.11. 
1
H-NMR δ (ppm) (CDCl3): 8.02 (s, 
1H), 7.93 (d, 2H, J = 8.0 Hz), 7.76 (d, 2H, J = 8.4 Hz), 7.71 (d, 2H, J = 8.0 
Hz), 7.46 – 7.53 (m, 4H), 7.36 (t, 1H, J = 7.6 Hz), 6.72 (d, 2H, J = 8.4 Hz), 
4.44 ( s, 2H). 
13
C NMR (DMSO-d6):  (ppm) 151.33, 148.87, 139.25, 136.75, 
129.57, 129.49, 128.19 (q, JC-F = 32 Hz), 127.77,  126.51, 126.16, (q, JC-F = 
4.7 Hz), 125.50 (q, JC-F = 4.7 Hz), 125.30 (q, JC-F = 267 Hz), 124.23 (q, JC-F = 
270 Hz), 118.76, 118.26, 115.83 (q, JC-F = 31 Hz), 111.68, 37.66. 
 
5.1.1.2.2.21. 4-(Trifluoromethyl)-N-((1-phenyl-3(-p-tolyl)-1H-pyrazol-4-
yl)methyl)aniline (4u). Yield 73%; m.p. = 128 – 130 °C from C6H12. Anal. 
Calc. for C24H20F3N3: C 70.75, H 4.95, F 13.99, N 10.31; found C 70.75, H 
4.96, F 13.98, N 10.31. 
1
H-NMR δ (ppm) (CDCl3): 7.97(s, 1H), 7.75 (d, 2H, 
J= 7.6 Hz), 7.67 (d, 2H, J= 8.0 Hz), 7.44 – 7.50 (m, 4H), 7.31 (t, 1H, J = 7.6 
Hz), 7.27 (d, 2H, J = 8.4 Hz), 6.69 (d, 2H, J = 8.4 Hz), 4.42 (s, 2H), 2.42 (s, 
3H). 
13
C NMR (DMSO-d6):  (ppm) 151.38, 150.52, 139.45, 137.32, 129.96, 
129.53, 129.17, 128.88, 127.22, 126.18 (q, JC-F = 3 Hz), 126.11, 125.34 (q, JC-
F = 270 Hz), 118.03, 118.00?, 115.62 (q, JC-F = 31 Hz), 111.57, 37.74, 20.76. 
 
5.1.1.2.2.22.  N-((3-(4-Bromophenyl)-1-phenyl-1H-pyrazol-4-yl)methyl)-
4-(trifluoromethyl)aniline (4v). Yield 56%; m.p. = 101 – 105 °C from 
EtOH. Anal. Calc. for  C23H17BrF3N3: C 58.49, H 3.63, Br 16.92, F 12.07, N 
8.90; found C 58.49, H 3.62, Br 16.92, F 12.08, N 8.90. 1H-NMR δ (ppm) 
(CDCl3): 8.02 (s, 1H), 7.74 (d, 2H, J = 7.6 Hz), 7.65 (d, 2H, J = 8.4 Hz), 7.58 
(d, 2H, J = 8.4 Hz), 7.45 – 7.51 (m, 4H), 7.34 (t, 1H, J = 7.2 Hz), 6.72 (d, 2H, J 
= 8.4 Hz), 4.41 (s, 2H). 
13
C NMR (DMSO-d6):  (ppm) 151.33, 149.27, 
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139.31, 131.98, 131.57, 129.55, 129.21, 126.34, 126.18 (q, JC-F = 3 Hz), 
125.32 (q, JC-F = 268 Hz), 121.33, 118.28, 118.15, 115.78 (q, JC-F = 32 Hz), 
111.65, 37.67.  
 
5.1.1.3. Biology 
5.1.1.3.1. Test compounds 
Compounds were dissolved in DMSO at 100 µM, and then diluted in 
culture medium. 
 
5.1.1.3.2. Cells and Viruses 
Cell lines were purchased from American Type Culture Collection 
(ATCC). The absence of mycoplasma contamination was checked 
periodically by the Hoechst staining method. Cell lines supporting the 
multiplication of RNA and DNA viruses were the following: CD4
+
 human T-
cells containing an integrated HTLV-1 genome (MT-4); Madin Darby Bovine 
Kidney (MDBK) [ATCC CCL22 (NBL-1) Bos Taurus], Baby Hamster 
Kidney (BHK-21) [ATCC CCL10 (C-13) Mesocricetus auratus] and Monkey 
kidney (Vero 76) [ATCCCRL 1587 Cercopithecus Aethiops]. Viruses were 
purchased from American Type Culture Collection (ATCC), with the 
exception of Yellow Fever Virus (YFV) and Human Immunodeficiency Virus 
type-1 (HIV-1). Viruses representative of positive-sense single stranded 
RNAs (ssRNA
+
) were: (i) Retroviridae: the IIIB laboratory strain of HIV-1, 
obtained from the supernatant of the persistently infected H9/IIIB cells (NIH 
1983); (ii) Flaviviridae: yellow fever virus (YFV) [strain 17-D vaccine 
(Stamaril Pasteur J07B01)] and bovine viral diarrhoea virus (BVDV) [strain 
NADL (ATCC VR-534)]; (iii) Picornaviridae: human enterovirus B 
[coxsackie type B5 (CV-B5), strain Faulkner, (ATCC VR-185)], and human 
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enterovirus C [poliovirus type-1 (Sb-1), Sabin strain Chat (ATCC VR-1562)]. 
Viruses representative of negative-sense, single-stranded RNAs (ssRNA
-
) 
were: (iv) Paramyxoviridae: human respiratory syncytial virus (RSV) [strain 
A2 (ATCC VR-1540)]; (v) Rhabdoviridae: vesicular stomatitis virus (VSV) 
[lab strain Indiana (ATCC VR 158)]. The virus representative of double-
stranded RNAs (dsRNA) Reoviridae was reovirus type-1 (Reo-1) [simian 
virus 12, strain 3651 (ATCC VR- 214)]. DNA virus representatives were: (vi) 
Poxviridae: vaccinia virus (VV) [strain Elstree (Lister Vaccine) (ATCC VR-
1549)]; and (vii) Herpesviridae: human herpesvirus 1 (HSV-1) [strain KOS 
(ATCC VR- 1493)].  
 
5.1.1.3.3. Cytotoxicity Assays 
Cytotoxicity assays were run in parallel with antiviral assays. 
Exponentially growing MT-4 cells were seeded at an initial density of 1x10
5
 
cells/mL in 96-well plates in RPMI-1640 medium, supplemented with 10% 
foetal bovine serum (FBS), 100 units/mL penicillin G and 100 mg/mL 
streptomycin. Cell cultures were then incubated at 37 °C in a humidified, 5% 
CO2 atmosphere, in the absence or presence of serial dilutions of test 
compounds. Cell viability was determined after 96 h at 37 °C by the 3-(4,5- 
dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide (MTT) method 
4
. 
MDBK and BHK cells were seeded in 96-well plates at an initial density of 
6x10
5 
and 1x10
6
 cells/mL, respectively, in Minimum Essential Medium with 
Earle‟s salts (MEM-E), L glutamine, 1 mM sodium pyruvate and 25 mg/L 
kanamycin, supplemented with 10% horse serum (MDBK) or 10% foetal 
bovine serum (FBS) (BHK). Cell cultures were then incubated at 37 °C in a 
humidified, 5% CO2 atmosphere in the absence or presence of serial dilutions 
of test compounds. Cell viability was determined after 72 hrs at 37 °C by the 
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MTT method. Vero76 cells were seeded in 96-well plates at an initial density 
of 5x10
5
 cells/mL, in Dulbecco‟s Modified Eagle Medium (D-MEM) with L-
glutamine and 25 mg/L kanamycin, supplemented with 10% FBS. Cell 
cultures were then incubated at 37 °C in a humidified, 5% CO2 atmosphere in 
the absence or presence of serial dilutions of test compounds. Cell viability 
was determined after 48-96 h at 37 °C by the by the MTT method. 
 
5.1.1.3.4. Antiviral assays  
Antiviral activity against HIV-1 was based on inhibition of virus-
induced cytopathogenicity in MT-4 cells acutely infected with a multiplicity 
of infection (m.o.i.) of 0.01. Briefly, 50 µL of RPMI containing 1x10
4
 MT-4 
cells were added to each well of flat bottom microtitre trays, containing 50 µL 
of RPMI without or with serial dilutions of test compounds. Then, 20 µL of a 
HIV-1 suspension containing 100 CCID50 were added. After 4-day of 
incubation at 37 °C, cell viability was determined by the MTT method. 
Antiviral activity against YFV and Reo-1 was based on inhibition of virus-
induced cytopathogenicity in BHK-21 cells acutely infected with a m.o.i. of 
0.01. Activity of compounds activity against BVDV was based on inhibition 
of virus-induced cytopathogenicity in MDBK cells acutely infected with a 
m.o.i. of 0.01. Briefly, BHK and MDBK cells were seeded in 96-well plates 
at a density of 5x10
4
 and 3x10
4
 cells/well, respectively, and were allowed to 
form confluent monolayers by incubating overnight in growth medium at 37 
°C in a humidified CO2 (5%) atmosphere. Cell monolayers were then infected 
with 50 µL of a proper virus dilution in maintenance medium [MEM-Earl 
with L-glutamine, 1 mM sodium pyruvate and 0.025 g/L kanamycin, 
supplemented with 0.5% inactivated FBS] to give an m.o.i of 0.01. After 2 
hrs, 50 µL of maintenance medium, without or with serial dilutions of test 
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compounds, were added. After a 3-/4-day incubation at 37 °C, cell viability 
was determined by the MTT method 
20
. 
Antiviral activity against CV-B5, Sb-1, VV, HSV-1, VSV and RSV 
was determined by plaque reduction assays in infected cell monolayers. To 
this end, Vero 76-cells were seeded in 24-well plates at a density of 2x10
5
 
cells/well and were allowed to form confluent monolayers by incubating 
overnight in growth medium [Dulbecco‟s Modified Eagle Medium (D-MEM) 
with L-glutamine and 4500 mg/L D-glucose and 0.025 g/L kanamycin, 
supplemented with 10% FBS] at 37 °C in a humidified CO2 (5%) atmosphere. 
Then, monolayers were infected for 2 h with 250 µL of proper virus dilutions 
to give 50 to 100 PFU/well. Following removal of unadsorbed virus, 500 µL 
of maintenance medium [D-MEM with L-glutamine and 4500 mg/L 
Dglucose, supplemented with 1% inactivated FBS] containing 0.75% 
methylecellulose, without or with serial dilutions of test compounds, were 
added. Cultures were incubated at 37 °C for 2 (Sb-1 and VSV), 3 (CVB-5, 
VV and HSV-1) or 5 days (RSV) and then fixed with PBS containing 50% 
ethanol and 0.8% crystal violet, washed and air-dried. Plaques were then 
counted. 
 
5.1.1.3.5. Linear regression analysis 
The extent of cell growth/viability and viral multiplication, at each drug 
concentration tested, were expressed as percentage of untreated controls. 
Concentrations resulting in 50% inhibition (CC50 or EC50) were determined 
by linear regression analysis. 
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5.1.2. Anti DENV-2 and WNV studies of N-((1,3-diphenyl-1H-
pyrazol-4-yl)methyl)anilines 
N-((1,3-diphenyl-1H-pyrazol-4-yl)methyl)anilines (4a, 4b, 4c, 4d, 4g, 
4h, 4i, 4k, 4l, 4m, 4n, 4o) able to interfere with YFV and/or BVDV 
replication were successively tested against two additional significant human 
pathogens such as DENV-2 and WNV, both belonging to the Flavivirus genus 
of the Flaviviridae family. Cytotoxicity and antiviral activity against DENV-2 
and YFV of the selected inhibitors were reported in Table 3. For comparison, 
Table 3 includes also previously obtained data on YFV and BVDV 
replication. 
Results showed that the antiviral activity of tested compounds extended 
to DENV-2 replication, while WNV replication was only marginally affected 
by few compounds (4g, 4i, 4n, 4o). When compared the antiviral activity 
against the selected viruses belonging to the Flaviviridae family, all the tested 
compounds exhibited the higher potency against DENV-2.  
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Table 3. Cytotoxicity and antiviral activity of N-((1,3-diphenyl-1H-pyrazol-4-yl)methyl) 
anilines 4a–v against ssRNA+ (BVDV, YFV, DENV-2, WNV) viruses.  
 
 
 
Compds R R1 
MDBK 
aCC50 
(µM) 
BVDV 
bEC50 
(µM) 
cSI 
CC50/
EC50 
BHK-21 
dCC50 
(µM) 
YFV 
eEC50 
(µM) 
cSI 
CC50/
EC50 
fDENV-2 
EC50 
(µM) 
cSI 
CC50/
EC50 
gWNV 
EC50 
(µM) 
4a CH3 H >100 >100 - >100 38.0±6.0 >2.6 30.0±4.0 >3.3 >100 
4b Br H >100 >100 - >100 20.0±4.0 >5.0 22.0±6.0 >4.5 >100 
4c H Br >100 31.0±0.5 >3.2 >100 32.0±4.0 >3.1 >100 - >100 
4d Cl Br >100 >100 - >100 28.0±5.0 >3.6 11.0±0.4 >9.1 >100 
4g Br Br >100 >100 - >100 54.0±6.0 >1.8 23.0±6.0 >4.3 80.0±8.5 
4h H Cl >100 29.0±1.5 >3.4 >100 29.0±3.5 >3.4 13.0±5.0 >7.7 >100 
4i Cl Cl >100 31.0±2.0 >3.2 73 >73 - 14.5±3.5 5.0 57.5±0.5 
4k CH3 Cl >100 >100 - >100 34.0±0.5 >2.9 12.1±3.0 >8.3 >100 
4l Br Cl >100 ≥100 - >100 43.0±0.5 >2.3 12.9±2.3 >7.7 >100 
4m H CH3 >100 53.0±3.0  >1.9 >100 65.0±5.0 >1.5 11.2±3.6 >8.9 >100 
4n Cl CH3 >100 55.0±5.0 >1.8 >100 >100 - 11.1±1.6 >9.0 39.0±1.0 
4o CF3 CH3 >100 54.0±4.0 >1.8 88 >88 - 14.3±0.7 6.1 59.0±1.1 
Ref. compounds          
NM 299    >100 46.0±3.3 >2.2    
Ribavirin 57.0±6.2  19.0±5.3 3.0       
NM 108    60   1.2 50 0.65 
Data represent mean values for three independent determinations. Variation among duplicate samples was less than 15%. 
aCompound concentration required to reduce the viability of mock-infected MDBK (Bovine normal kidney) cells by 50%, as determined 
by the MTT method. bCompound concentration required to achieve 50% protection of MDBK cells from the BVDV-induced 
cytopathogenicity, as determined by the MTT method. cSelectivity index (SI) was the ratio between CC50 and EC50. d Compound 
concentration required to reduce the viability of mock-infected BHK (Hamster normal kidney fibroblast) monolayers by 50%, as 
determined by the MTT method. eCompound concentration required to reduce the viability of mock-infected BHK cells from the YFV-
induced cytopathogenicity, as determined by the MTT method. fCompound concentration required to achieve 50% protection of BHK 
cells from DENV-2 induced cytopathogenicity, as determined by the MTT method.  gCompound concentration required to achieve 50% 
protection of BHK cells from WNV induced cytopathogenicity, as determined by the MTT method. 
 
5.1.2.1. Experimental 
5.1.2.1.1. Biology 
The cytotoxicity and antiviral assays were performed by Prof. Roberta 
Loddo, Department of Biomedical Sciences, Microbiology and Virology 
Section, University of Cagliari. 
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5.1.2.1.1.1. Test compounds 
Compounds were dissolved in DMSO at 100 µM, and then diluted in 
culture medium. 
 
5.1.2.1.1.2. Cells and Viruses 
Baby Hamster Kidney (BHK-21) [ATCC CCL10 (C-13) Mesocricetus 
auratus] was utilized to support the multiplication of Dengue virus type 
2 (DENV-2) and West Nile virus (WNV). Cell line was purchased from 
American Type Culture Collection (ATCC). The absence of mycoplasma 
contamination was checked periodically by the Hoechst staining method. 
DENV-2 and WNV utilized were clinical isolate. 
 
5.1.2.1.1.3. Cytotoxicity Assays 
BHK cells were seeded in 96-well plates at an initial density of 1x10
6
 
cells/mL in Minimum Essential Medium with Earle‟s salts (MEM-E), L 
glutamine, 1 mM sodium pyruvate and 25 mg/L kanamycin, supplemented 
with 10% horse serum (MDBK) or 10% foetal bovine serum (FBS) (BHK). 
Cell cultures were then incubated at 37 °C in a humidified, 5% CO2 
atmosphere in the absence or presence of serial dilutions of test compounds. 
Cell viability was determined after 72 hrs at 37 °C by the MTT method.  
 
5.1.2.1.1.4. Antiviral assays  
Antiviral activity against DENV-2 and WNV was based on inhibition 
of virus-induced cytopathogenicity in BHK-21 cells acutely infected with a 
m.o.i. of 0.01. Briefly, BHK cells were seeded in 96-well plates at a density of 
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5x10
4
 cells/well and were allowed to form confluent monolayers by 
incubating overnight in growth medium at 37 °C in a humidified CO2 (5%) 
atmosphere. Cell monolayers were then infected with 50 µL of a proper virus 
dilution in maintenance medium [MEM-Earl with L-glutamine, 1 mM sodium 
pyruvate and 0.025 g/L kanamycin, supplemented with 0.5% inactivated 
FBS] to give an m.o.i of 0.01. After 2 hrs, 50 µL of maintenance medium, 
without or with serial dilutions of test compounds, were added. After a 3-/4-
day incubation at 37 °C, cell viability was determined by the MTT method 
20
. 
 
5.1.2.1.1.5. Linear regression analysis 
The extent of cell growth/viability and viral multiplication, at each drug 
concentration tested, were expressed as percentage of untreated controls. 
Concentrations resulting in 50% inhibition (CC50 or EC50) were determined 
by linear regression analysis. 
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5.1.3.Design, synthesis, antiviral evaluation and SAR studies of 
new 1-(phenylsulfonyl) or 1-benzyl-substituted 1H-pyrazol 
-4-yl-methylanilines and (E)-1,3-diphenyl-1-styryl-1H-
pyrazoles 
In an effort to identify compounds more active against RSV and/or 
against viruses belonging to Flaviviridae family and to maintain the low 
cytotoxicity of the hit compounds, we initially planned to modify the 
substituent at position N1 of pyrazole ring. Two new series of compounds 
containing phenylsulfonyl group (11a-p, 12a-l) or a benzyl moiety (15a-l) 
were designed and synthesized (Figure 1). 
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The identification of 5-amino-1-(phenylsulfonyl)-1H-pyrazol-3-yl 
benzoate derivatives (SID) as allosteric inhibitors of West Nile Virus (WNV) 
NS2B-NS3 proteinase 
1
 suggested to combine the 1-phenylsulfonyl fragment 
of SID with the N-((3-phenyl-1H-pyrazol-4-yl)methyl)aniline core of 
compounds 4a-v in order to identify new promising Flaviviridae inhibitors 
(Figure 2).  
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To further investigate the impact on antiviral activity of the substituent 
at position N1 of the pyrazole ring, the phenyl ring was also replaced by a 
benzyl moiety (Figure 3). 
 
 
 
 
In order to verify the importance for the antiviral activity of the basic 
substituent at position 4 of pyrazole ring, we also prepared a new series of 4-
styryl analogues 18a-i of compounds 4a-v (Figure 4).  
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5.1.3.1. Results and discussion  
5.1.3.1.1. Chemistry 
As shown in Scheme 2, the compounds 11a-p and 12a-l were 
synthesized in five steps starting from the condensation of the suitable 
acetophenone with semicarbazide hydrochloride, in the presence of sodium 
acetate. The obtained semicarbazones 5a-d were treated with Vilsmeier-
Haack reagent (DMF-POCl3) to give the corresponding 3-phenyl-1H-
pyrazole-4-carbaldehydes (6a-d) which were converted into the respective 3-
phenyl-1-(phenylsulfonyl)-1H-pyrazole-4-carbaldehydes (7a-d and 8a-c) by 
treatment with the appropriate benzenesulfonyl chloride under basic 
condition. The subsequent condensation with the appropriate anilines 
provided the corresponding Schiff bases 9a-p and 10a-l which were finally 
converted into the desired N-((3-phenyl-1-(phenylsulfonyl)-1H-pyrazol-4-
yl)methyl)anilines (11a-p and 12a-l) by reduction with sodium borohydride.  
A similar synthetic procedure was utilized for the synthesis of the 1-
benzyl analogues 15a-l (Scheme 3). For this purpose 3-phenyl-1H-pyrazol-4-
carbaldehydes 6a-c were alkylated with benzyl bromide in the presence of 
sodium hydride to give the corresponding 1-benzyl-3-phenyl-1H-pyrazole-4-
carbaldehydes 13a-c.  
The subsequent condensation with the appropriate anilines, followed by 
reduction of intermediate Schiff bases (14a-l) were conducted in a similar 
manner as described for the 1-(phenylsulfonyl) analogues 11a-p and 12a-l 
and resulted in the designed N-((1-benzyl-3-phenyl-1H-pyrazol-4-
yl)methyl)aniline 15a-l.  
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(E)-1,3-Diphenyl-1-stiril-1H-pyrazoles 18a-i were synthetized accor-
ding to the three steps procedure shown in Scheme 4. Initially 1-phenyl-2-(1-
phenylethylidene)hydrazones 16a-c and the corresponding 1,3-diphenyl-1H-
pyrazole-4-carbaldehydes 17a-c were prepared following the procedure 
previously described 
2
. The subsequent Horner-Wadsworth-Emmons reaction 
of aldehydes 17a-c with commercially available diethyl benzylphosphonates, 
carried out using sodium hydride as base in dry THF, provided only the (E) 
isomers 18a-i. The trans configuration of the double bound was confirmed on the 
basis of the coupling constant values of the vinylic protons (Jα-β = 16.4 Hz). 
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5.1.3.1.2. Antiviral tests 
All the synthesized pyrazole derivatives (11a-p, 12a-l, 15a-l and 18a-i) 
were assayed for antiviral activity against a large panel of RNA and DNA 
viruses. Cytotoxicity and antiviral activity of the new compounds (11a-p, 
12a-l, 15a-l, and 18a-i) and reference inhibitors are reported in Tables 3 – 10. 
The majority of new N-((3-phenyl-1-(phenylsulfonyl)-1H-pyrazol-4-
yl)methyl)anilines 11a-p exhibited a better activity than the parent 
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compounds 4a-v against YFV (EC50 ranging from 2.7 M to 12.2 M), 
coupled with high selectivity (SI ranging from >8.20 to >37.04) due to the 
absence of cytotoxicity for BHK-21 cell line up to the highest concentration 
tested (100 M). All these derivatives showed better activity and selectivity 
than the reference drug 6-Azauridine (EC50 = 46.0 M, SI > 2.2).  Despite the 
presence of a p-methoxy substituent on the phenylsulfonyl group was required 
for a potent antiviral activity in SID compounds 
1
, the p-methoxy 
phenylsulfonyl analogues 12a-l were totally inactive or less potent YFV 
inhibitors with respect to corresponding 11a-p. On the contrary, the 
introduction of a p-methoxy substituent converted inactive or poor effective 
unsubstituted compounds 11a-p in the more potent anti-BVDV agents 12a-l. 
In particular, 12a showed the best anti-BVDV potency and selectivity (EC50 = 
5.0 M, SI >20). The 1-(phenylsulfonyl)analogues able to interfered with 
YFV and/or BVDV replication were also tested against DENV-2 and WNV. 
Surprisingly, the replacement of the phenyl ring at N1 position with a 
phenylsulfonyl group completely abolished the activity against these two 
Flavivirus.  
Similarly to the N-phenyl derivatives 4a-v, several N-phenylsulfonyl 
analogues 11a-p exhibited anti-RSV activity in the micromolar concentration 
(EC50 ranging from 9.0 M to 23.0 M) generally coupled with high 
selectivity (SI ranging from 5.3 to >11.1). SAR studies indicated that the para 
substitution at the 3-phenyl ring is necessary for RSV inhibitory activity, in 
contrast the introduction of the p-methoxy substituent on the phenylsulfonyl 
moiety abolished the activity (Table 4 and 6). 
When tested against Reo-1, CVB-5, Sb-1, VV, HSV-1 and HIV-1, the 
compounds were devoid of antiviral activity up to the highest concentration 
tested, with the exceptions of analogues 11n and 11o which showed moderate 
activity against CBV-5 and 11a that affected the HIV-1 replication (Table 5). 
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Table 4. Cytotoxicity and antiviral activity of N-((3-phenyl-1-(phenylsulfonyl)-1H-
pyrazol-4-yl)methyl)aniline 11a–p against ssRNA+ (BVDV, YFV, DENV-2, WNV) and 
ssRNA
- 
(RSV) viruses. 
 
 
 
 
Compds R R1 
MDBK 
aCC50 
(µM) 
BVDV 
bEC50 
(µM) 
BHK-21 
cCC50 
(µM) 
YFV 
dEC50 
(µM) 
eSI 
CC50/ 
EC50 
DENV-2 
fEC50 
(µM) 
WNV 
gEC50 
(µM) 
Vero76 
hCC50 
(µM) 
RSV 
iEC50 
(µM) 
eSI 
CC50/ 
EC50 
11a Br H >100 18.0±4.0 >100 3.0±1.0 >33.3 >100 >100 87.0 16.5±1.5 5.3 
11b Br Cl >100 >100 >100 3.5±1.5 >28.6 >100 >100 90.0 13.5±1.5 6.7 
11c Br Br >100 >100 >100 6.5±3.5 >15.4 >100 >100 90.0 15.0±3.0 6.0 
11d Br CH3 >100 >53.0 >100 5.5±2.5 >18.2 >100 >100 93.0 11.0±1.0 8.5 
11e Cl H >100 >100 >100 7.8±0.4 >12.8 >100 >100 >100 10.0±2.0 >10.0 
11f Cl Cl >100 42.5±2.5 >100 4.6±0.3 >21.7 >100 >100 >100 9.0±1.0 >11.1 
11g Cl Br >100 >100 >100 6.0±1.4 >16.7 >100 >100 >100 13.5±1.5 >7.4 
11h Cl CH3 >100 >100 >100 7.0±1.6 >14.3 >100 >100 >100 23.0±2.5 >4.4 
11i CH3 H >100 >100 >100 12.2±2.8 >8.2 >100 >100 >100 11.0±1.0 >9.1 
11j CH3 Cl >100 >100 >100 4.7±0.9 >21.3 >100 >100 >100 11.0±1.0 >9.1 
11k CH3 Br >100 >100 >100 2.7±1.3 >37.0 >100 >100 >100 13.0±1.0 >7.7 
11l CH3 CH3 >100 >100 >100 3.7±0.65 >27.0 >100 >100 >100 11.0±1.0 >9.1 
11m H H >100 >100 >100 >100 - - - >100 >100 - 
11n H Cl >100 >100 >100 7.1±0.35 >14.1 >100 >100 45.0 >45.0 - 
11o H Br >100 >100 >100 6.1±1.7 >16.4 >100 >100 44.0 >44.0 - 
11p H CH3 >100 >100 >100 >100 - - - ≥100 >100 - 
Ref. Compds.           
Ribavirin 55.0 16.0±2.0      55.0 37.5±2.5 1.5 
6-Azauridine   >100 46.0±1.5 >2.2   ≥100 1.8±0.25 ≥55.5 
NM108   60   1.2 0.65    
Data represent mean values for three independent determinations. Variation among duplicate samples was less than 15%. 
aCompound concentration required to reduce the viability of mock-infected MDBK (Bovine normal kidney) cells by 50%, as determined 
by the MTT method. bCompound concentration required to achieve 50% protection of MDBK cells from the BVDV-induced 
cytopathogenicity, as determined by the MTT method. cCompound concentration required to reduce the viability of mock-infected BHK 
(Hamster normal kidney fibroblast) monolayers by 50%, as determined by the MTT method. dCompound concentration required to 
reduce the viability of mock-infected BHK cells from the YFV-induced cytopathogenicity, as determined by the MTT method. e 
Selectivity index (SI) was the ratio between CC50 and EC50.  
fCompound concentration required to achieve 50% protection of BHK cells 
from DENV-2 induced cytopathogenicity, as determined by the MTT method. gCompound concentration required to achieve 50% 
protection of BHK cells from WNV induced cytopathogenicity, as determined by the MTT method. hCompound concentration required 
to reduce the viability of mock-infected VERO76 (monkey normal kidney) monolayers by 50%. iCompound concentration required to 
reduce the plaque number of RSV (Respiratory Syncytial Virus) by 50% in VERO 76 monolayers. 
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Table 5. Cytotoxicity and antiviral activity of N-((3-phenyl-1-(phenylsulfonyl)-1H-
pyrazol-4-yl)methyl)aniline 11a–p against ssRNA+ (HIV-1, CVB-5, Sb-1), ssRNA- 
(VDV), dsRNA (Reo-1) and DNA (VV, HSV-1) viruses. 
 
Compds R R1 
MT-4 
aCC50 
(µM) 
HIV-1 
bEC50 
(µM) 
BHK-21 
cCC50 
(µM) 
Reo-1 
dEC50 
(µM) 
Vero76 
eCC50 
(µM) 
CVB-5 Sb-1 VV HSV-1 VSV 
EC50 
f(µM) 
11a Br H >100 20 >100 >100 87.0 >87.0 >87.0 >87.0 >87.0 >87.0 
11b Br Cl >100 >100 >100 >100 90.0 >90.0 >90.0 >90.0 >90.0 >90.0 
11c Br Br >100 >100 >100 >100 90.0 >90.0 >90.0 >90.0 >90.0 >90.0 
11d Br CH3 >100 >100 >100 >100 93.0 >93.0 >93.0 >93.0 >93.0 >93.0 
11e Cl H >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 
11f Cl Cl >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 
11g Cl Br >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 
11h Cl CH3 >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 
11i CH3 H >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 
11j CH3 Cl >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 
11k CH3 Br >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 
11l CH3 CH3 >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 
11m H H >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 
11n H Cl >100 >100 >100 >100 45.0 20.0±5.0 >45.0 >45.0 >45.0 >45 .0 
11o H Br 20 >20 >100 >100 44.0 24.0±11.0 >44.0 >44.0 >44.0 >44.0 
11p H CH3 >100 >100 >100 >100 ≥100 >100 >100 >100 >100 >100 
Ref. Compds.           
EFV 39 0.002         
ACG     >100    2.9±0.1  
Pleconaril     70.0 0.0025±0.0005 2.0±0.1    
M 5255     20.0   2.0±0.1   
NM107   >100 7.5±1.5       
Data represent mean values for three independent determinations. Variation among duplicate samples was less than 15%. 
aCompound concentration required to reduce the viability of mock-infected MT-4 (cd4+ Human T-cells containing an integrated HTL V-
1 genome) cells by 50%, as determined by the MTT method. bCompound concentration required to achieve 50% protection of MT-4 
cells from the HIV-1 induced cytioathigenicity, as determined by the MTT method. cCompound concentration required to reduce the 
viability of mock-infected BHK (hamster normal kidney fibroblast) monolayers by 50%, as determined by the MTT method. 
dCompound concentration required to achieve 50% protection of BHK cells (kideney fibroblast) from the Reo (Reovirus 1), induced 
cytopathogenicity, as determined by the MTT method. eCompound concentration required to reduce the viability of mock-infected 
VERO76 (monkey normal kidney) monolayers by 50%. fCompound concentration required to reduce the plaque number of CVB-5 
(Coxsackievirus B5), Sb-1 (Poliovirus 1), VV (Vaccina virus), HSV-1 (Herpesvirus 1) and VSV ( Vescicular Stomatitis Virus) by 50% 
in VERO76 monolayers. 
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Table 6. Cytotoxicity and antiviral activity of N-((1-((4-methoxyphenyl)sulfonyl)-3-
phenyl-1H-pyrazol-4-yl)methyl)aniline 12a–l against ssRNA+ (BVDV, YFV, DENV-2, 
WNV) and ssRNA
- 
(RSV) viruses. 
 
 
 
Compds R R1 
MDBK 
aCC50 
(µM) 
BVDV 
bEC50 
(µM) 
cSI 
CC50/ 
EC50 
BHK-21 
dCC50 
(µM) 
YFV 
eEC50 
(µM) 
cSI 
CC50/
EC50 
DENV-2 
fEC50 
(µM) 
WNV 
gEC50 
(µM) 
Vero76 
hCC50 
(µM) 
RSV 
iEC50 
(µM) 
12a Br H >100 5.0±1.4 >20.0 >100 >100 - >100 >100 >100 >100 
12b Br Cl >100 21.0±4.2 >4.8 >100 21.0±4.0 >4.8 >100 >100 >100 >100 
12c Br Br >100 25.0±2.8 >4.0 >100 >100 - >100 >100 >100 >100 
12d Br CH3 >100 >100 - >100 17.5±6.4 >5.7 >100 100 >100 >100 
12e Cl H >100 >100 - >100 >100 - - - >100 >100 
12f Cl Cl >100 8.5±3.5 >11.8 >100 16.5±9.6 >6.1 >100 >100 >100 >100 
12g Cl Br >100 13.0±2.8 >7.7 >100 18.0±2.8 >5.5 >100 >100 >100 >100 
12h Cl CH3 >100 >100 - >100 >100 - - - >100 >100 
12i CH3 H >100 >100 - >100 >100 - - - >100 >100 
12j CH3 Cl >100 >100 - >100 >100 - - - >100 >100 
12k CH3 Br >100 18.5±7.8 >5.4 >100 >100 - >100 100 >100 >100 
12l CH3 CH3 >100 >100 - >100 >100 - - - >100 >100 
Ref. Compds.           
Ribavirin >100 16.0±2.0 >6.2        
6-Azauridine    >100 46.0±2.5 >2.2   9.3±1.6 1.1±0.4 
NM 108    60   1.2 0.65   
Data represent mean values for three independent determinations. Variation among duplicate samples was less than 15%. 
aCompound concentration required to reduce the viability of mock-infected MDBK (Bovine normal kidney) cells by 50%, as determined 
by the MTT method. bCompound concentration required to achieve 50% protection of MDBK cells from the BVDV-induced 
cytopathogenicity, as determined by the MTT method. cSelectivity index (SI) was the ratio between CC50 and EC50.   
dCompound concentration required to reduce the viability of mock-infected BHK (Hamster normal kidney fibroblast) monolayers by 
50%, as determined by the MTT method. eCompound concentration required to reduce the viability of mock-infected BHK cells from 
the YFV-induced cytopathogenicity, as determined by the MTT method. fCompound concentration required to achieve 50% protection 
of BHK cells from DENV-2 induced cytopathogenicity, as determined by the MTT method. gCompound concentration required to 
achieve 50% protection of BHK cells from WNV induced cytopathogenicity, as determined by the MTT method.  hCompound 
concentration required to reduce the viability of mock-infected VERO76 (monkey normal kidney) monolayers by 50%. iCompound 
concentration required to reduce the plaque number of RSV (Respiratory Syncytial Virus) by 50% in VERO76 monolayers. 
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Table 7. Cytotoxicity and antiviral activity of N-((1-((4-methoxyphenyl)sulfonyl)-3-
phenyl-1H-pyrazol-4-yl)methyl)aniline 12a–l against ssRNA+ (HIV-1, CVB-5, Sb-1), 
ssRNA
-
 (VDV), dsRNA (Reo-1) and DNA (VV, HSV-1) viruses.  
 
Compds R R1 
MT-4 
aCC50 
(µM) 
HIV-1 
bEC50 
(µM) 
BHK-21 
cCC50 
(µM) 
Reo-1 
dEC50 
(µM) 
Vero76 
eCC50 
(µM) 
CVB-5 Sb-1 VV HSV-1 VSV 
fEC50 
(µM) 
12a Br H >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 
12b Br Cl >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 
12c Br Br >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 
12d Br CH3 >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 
12e Cl H >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 
12f Cl Cl >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 
12g Cl Br >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 
12h Cl CH3 >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 
12i CH3 H >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 
12j CH3 Cl >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 
12k CH3 Br >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 
12l CH3 CH3 >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 
Ref. Compds.           
EFV 37 0.002         
ACG     >100    2.4±0.6  
Pleconaril     77.0±6.8 0.005±0.002 2.0±0.6    
M 5255     19.3±2.5   1.4±0.2   
NM 107   >100 6.0±2.1       
Data represent mean values for three independent determinations. Variation among duplicate samples was less than 15%. 
aCompound concentration required to reduce the viability of mock-infected MT-4 (cd4+ Human T-cells containing an integrated HTL V-
1 genome) cells by 50%, as determined by the MTT method. bCompound concentration required to achieve 50% protection of MT-4 
cells from the HIV-1 induced cytioathigenicity, as determined by the MTT method. cCompound concentration required to reduce the 
viability of mock-infected BHK (hamster normal kidney fibroblast) monolayers by 50%, as determined by the MTT method. 
dCompound concentration required to achieve 50% protection of BHK cells (kidney fibroblast) from the Reo (Reovirus 1), induced 
cytopathogenicity, as determined by the MTT method. eCompound concentration required to reduce the viability of mock.infected 
VERO76 (monkey normal kidney) monolayers by 50%. fCompound concentration required to reduce the plaque number of CVB-5 
(Coxsackievirus B5), Sb-1 (Poliovirus 1), VV (Vaccina virus), HSV-1 (Herpesvirus 1) and VSV ( Vescicular Stomatitis Virus) by 50% 
in VERO76 monolayers. 
 
The substitution of the phenyl with a benzyl moiety at position 
N1 of the pyrazole ring resulted in N-((1-benzyl-3-phenyl-1H-pyrazol-4-
yl)methyl)anilines 15a-l. Similarly to related N-phenylsulfonyl derivatives 
11a-p, most of the N-benzyl compounds exhibited  a potent inhibition of YFV 
replication (EC50 ranging from 9.8 M to 13.9 M) and no toxicity against 
BHK-21 cells up to the higher concentration tested (100 M), thus comparing 
favorably with the reference compound 6-Azauridine (EC50 = 46.0 M, SI > 
2.2) (Table 8).  With the exception of 15g, the benzyl derivatives 15a-l also 
affected the BVDV replication, however their potency was generally modest 
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(EC50 ranging from 15.6 M to 57.0 M). Differently to related N-
phenylsulfonyl derivatives 11a-p, the N-benzyl analogues 15a-l showed 
additional activity against DENV-2, although with a lesser degree of potency 
than the parent N-phenyl derivatives 4a-v.   
 
Table 8. Cytotoxicity and antiviral activity of N-((1-benzyl-3-phenyl-1H-pyrazol-4-
yl)methyl)aniline 15a–l against ssRNA+ (BVDV, YFV, DENV-2, WNV) and ssRNA- 
(RSV) viruses. 
 
 
 
Compds R R1 
MDBK 
aCC50 
(µM) 
BVDV 
bEC50 
(µM) 
cSI 
CC50/ 
EC50 
BHK-21 
dCC50 
(µM) 
YFV 
eEC50 
(µM) 
cSI 
CC50/ 
EC50 
DENV-2 
fEC50 
(µM) 
cSI 
CC50/ 
EC50 
WNV 
gEC50 
(µM) 
Vero76 
hCC50 
(µM) 
RSV 
iEC50 
(µM) 
15a Br H >100 29.1±2.9 >3.4 >100 11.6±0.5 >8.6 >100 - >100 17 >17 
15b Br Cl >100 19.2±3.2 >5.2 >100 9.8±0.5 >10.2 18.5±1.5 >5.4 >100 9.1 >9.1 
15c Br Br >100 46.3±1.3 >2.2 >100 10.6±1.4 >9.4 >100 - >100 25 11.1±1.0 
15d Br CH3 >100 27.5±1.5 >3.6 >100 10.0±1.6 10 28.0±1.0 >3.6 >100 16.4 >16.4 
15e Cl H >100 27.5±0.5 3.6 >100 13.9±1.7 >7.2 33.5±1.5 3.0 >100 34 >34 
15f Cl Cl >100 31.0±6.0 >3.2 >100 10.5±2.5 >9.5 18.0±1.0 >5.5 >100 8.2 >8.2 
15g Cl Br >100 >100 - >100 >100 - 21.0±2.0 >4.8 >100 >100 >100 
15h Cl CH3 >100 44.3±3.8 >2.3 >100 13.1±1.4 >7.6 22.5± 4.5 >4.4 >100 76 >76 
15i CH3 H >100 30.0±6.0 >3.3 >100 >100 - 37.0±0.0 >2.7 >100 15.1 >15.1 
15j CH3 Cl >100 15.6±1.4 >6.4 >100 10.4±1.4 >9.6 21.0±2.0 >4.8 >100 15 >15 
15k CH3 Br >100 57.0±5.0 >1.7 >100 12.4±1.6 >8.1 >100 - >100 >100 13.1±1.0 
15l CH3 CH3 >100 57.0±4.0 >6.4 >100 >100 - >100 - >100 >100 >100 
Ref. Compds.            
Ribavirin >100 13.6±1.7 >7.3          
6-Azauridine    >100 46±2.5 >2.2    9.3±1.6 1.1±0.4 
NM 108 >100 1.3±0.3 >76.9 68±6.0 2.0±0.2 34 1.9±0.1 >35.8 0.8±0.2   
Data represent mean values for three independent determinations. Variation among duplicate samples was less than 15%. 
aCompound concentration required to reduce the viability of mock-infected MDBK (Bovine normal kidney) cells by 50%, as determined 
by the MTT method. bCompound concentration required to achieve 50% protection of MDBK cells from the BVDV-induced 
cytopathogenicity, as determined by the MTT method. cSelectivity index (SI) was the ratio between CC50 and EC50.  
dCompound 
concentration required to reduce the viability of mock-infected BHK (Hamster normal kidney fibroblast) monolayers by 50%, as 
determined by the MTT method. eCompound concentration required to reduce the viability of mock-infected BHK cells from the YFV-
induced cytopathogenicity, as determined by the MTT method. fCompound concentration required to achieve 50% protection of BHK 
cells from DENV-2 induced cytopathogenicity, as determined by the MTT method. gCompound concentration required to achieve 50% 
protection of BHK cells from DENV-2 induced cytopathogenicity, as determined by the MTT method. hCompound concentration 
required to reduce the viability of mock-infected VERO76 (monkey normal kidney) monolayers by 50%. iCompound concentration 
required to reduce the plaque number of RSV (Respiratory Syncytial Virus) by 50% in VERO76 monolayers. 
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Only the 4-bromoaniline derivatives 15b and 15k showed anti-RSV 
activity and selectivity (EC50 = 11 M and 13 M; SI =2.3 and 7.7, 
respectively) while differently substituted N-benzyl derivatives are not able to 
inhibit the replication of RSV up to the corresponding EC50 for Vero76 cells 
(Table 8). It is interesting to note that the lack of cytotoxicity against Vero76 
cells was observed up to the highest concentration tested (100 µM), when the 
cultures were incubated with serial dilution of N-benzyl derivatives 15a-l at 
37 °C for 2 days and 3 days, whereas a remarkable increase of cytotoxicity 
was generally observed after incubation of Vero76 cells for 5 days, time 
necessary to observe the RSV-induced cytopathogenicity (Tables 8). 
N-benzyl derivatives were also generally inactive against WNV (Table 
8) and representative members of other virus families, only 15d, 15f and 15i 
were able to affect the CVB-5 replication at high concentrations and 15e, 15i 
and 15k exhibited a moderate activity against HIV-1 (Table 9). 
The new synthesized (E)-1,3-diphenyl-4-styryl-1H-pyrazoles (18a-i) 
were generally no toxic against host cell lines used to support the replication 
of selected viruses (Tables 10 and 11). On the other hand, this substitution 
completely abolished the anti-RSV activity. Concerning the activity against 
viruses belonging to Flaviviridae family, several styryl derivatives retained 
the ability to interfere with BVDV, YFV  and DENV-2 replication, however, 
their potency were generally moderate. In contrast, only analogs 18d and 18i 
showed a modest activity and selectivity against WNV (EC50 = 30.5 M and 
60.0 M, SI = 3.3 and 1.7, respectively). SAR studies indicate that the 
presence of a methyl group in R (18g-i) led to analogues active against 
BVDV, YFV and DENV-2, while the BVDV replication was inhibited also 
by analogues bearing a methyl group in R
1 
(18c and 18f). Exception to this 
rule was the 4-chlorophenyl analogue 18d that was endowed with activity 
against BVDV, YFV and WNV (Table 10). 
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Table 9. Cytotoxicity and antiviral activity of N-((1-benzyl-3-phenyl-1H-pyrazol-4-
yl)methyl)aniline 15a–l against ssRNA+ (HIV-1, CVB-5, Sb-1), ssRNA- (VDV), dsRNA 
(Reo-1) and DNA (VV, HSV-1) viruses. 
 
Compds R R1 
MT-4 
aCC50 
(µM) 
HIV-1 
bEC50 
(µM) 
BHK-21 
cCC50 
(µM) 
Reo-1 
dEC50 
(µM) 
Vero76 
eCC50 
(µM) 
CVB-5 Sb-1 VV HSV-1 VSV 
fEC50 
(µM) 
15a Br H >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 
15b Br Cl 97 >97 >100 >100 >100 >100 >100 >100 >100 >100 
15c Br Br >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 
15d Br CH3 >100 >100 >100 >100 >100 23.2±3.8 >100 >100 >100 >100 
15e Cl H 69 9.1±2.1 >100 >100 >100 >100 >100 >100 >100 >100 
15f Cl Cl 59 > 59 >100 >100 >100 50.7±1.3 >100 >100 >100 >100 
15g Cl Br 79 > 79 >100 >100 >100 >100 >100 >100 >100 >100 
15h Cl CH3 70 >70 >100 >100 >100 >100 >100 >100 >100 >100 
15i CH3 H >100 12.7±1.3 >100 >100 >100 32.3±3.7 >100 >100 >100 >100 
15j CH3 Cl >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 
15k CH3 Br >100 60.5±7.8 >100 >100 >100 >100 >100 >100 >100 >100 
15l CH3 CH3 >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 
Ref. Compds.         
EFV 38.0±2.0 0.002±0.0        
ACG     > 100    2.4±0.6  
Pleconaril     77.0±6.8 0.005±0.002     
M 5255     19.3±2.5   1.4±0.2   
NM 107   >100 6.0±2.1       
aCompound concentration required to reduce the viability of mock-infected MT-4 (cd4+ Human T-cells containing an integrated HTL V-
1 genome) cells by 50%, as determined by the MTT method. bCompound concentration required to achieve 50% protection of MT-4 
cells from the HIV-1 induced cytioathigenicity, as determined by the MTT method. cCompound concentration required to reduce the 
viability of mock-infected BHK (hamster normal kidney fibroblast) monolayers by 50%, as determined by the MTT method. 
dCompound concentration required to achieve 50% protection of BHK cells (kideney fibroblast) from the Reo (Reovirus 1), induced 
cytopathogenicity, as determined by the MTT method. eCompound concentration required to reduce the viability of mock-infected 
VERO76 (monkey normal kidney) monolayers by 50%. fCompound concentration required to reduce the plaque number of CVB-5 
(Coxsackievirus B5), Sb-1 (Poliovirus 1), VV (Vaccina virus), HSV-1 (Herpesvirus 1) and VSV ( Vescicular Stomatitis Virus) by 50% 
in VERO76 monolayers. 
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Table 10. Cytotoxicity and antiviral activity of (E)-1,3-diphenyl-4-styryl-1H-pyrazoles 
18a–i against ssRNA+ (BVDV, YFV, DENV-2, WNV) and ssRNA- (RSV) viruses. 
 
 
 
Compds R R1 
MDBK 
aCC50 
(µM) 
BVDV 
bEC50 
(µM) 
cSI 
CC50/
EC50 
BHK-21 
dCC50 
(µM) 
YFV 
eEC50 
(µM) 
cSI 
CC50/
EC50 
DENV-2 
fEC50 
(µM) 
cSI 
CC50/
EC50 
WNV 
gEC50 
(µM 
Vero76 
hCC50 
(µM) 
RSV 
iEC50 
(µM) 
18a Br H >100 >100 - >100 >100 - >100 - >100 36 >36 
18b Br Cl >100 >100 - >100 >100 - >100 - >100 >100 >100 
18c Br CH3 >100 59.0±3.0 >1.7 >100 >100 - >100 - >100 >100 >100 
18d Cl H >100 42.1±4.1 >2.4 >100 28.0±1.5 >3.6 >100 - 30.5±1.5 39 >39 
18e Cl Cl >100 >100 - >100 >100 - >100 - >100 60 >60 
18f Cl CH3 >100 50.5±2.5 >1.9 >100 >100 - >100 - >100 >100 >100 
18g CH3 H >100 61.0±7.0 >1.6 >100 38.0±1.0 >2.6 13.5±1.3 >7.4 >100 82 >100 
18h CH3 Cl >100 40.5±4.5 >2.5 >100 63.0±5.0 >1.6 50.0±3.0 >2.0 >100 >100 >100 
18i CH3 CH3 >100 32.5±0.5 >3.1 >100 48.0±5.0 >2.1 18.5±0.5 >5.4 60.0±2.0 >100 >100 
Ref. Compds            
Ribavirin >100 13.6±1.7 >7.3         
6-Azauridine    >100 46.0±2.5 >2.2    9.3±1.6 1.1±0.
4 
NM108 >100 1.3±0.3 >76.9 68.0±6.0 2.0±0.2 34 1.9±0.1 >35.8 0.8±0.2   
Data represent mean values for three independent determinations. Variation among duplicate samples was less than 15%. 
aCompound concentration required to reduce the viability of mock-infected MDBK (Bovine normal kidney) cells by 50%, as determined 
by the MTT method. bCompound concentration required to achieve 50% protection of MDBK cells from the BVDV-induced 
cytopathogenicity, as determined by the MTT method. cSelectivity index (SI) was the ratio between CC50 and EC50.  
dCompound 
concentration required to reduce the viability of mock-infected BHK (Hamster normal kidney fibroblast) monolayers by 50%, as 
determined by the MTT method. eCompound concentration required to reduce the viability of mock-infected BHK cells from the YFV-
induced cytopathogenicity, as determined by the MTT method. fCompound concentration required to achieve 50% protection of BHK 
cells from DENV-2 induced cytopathogenicity, as determined by the MTT method. gCompound concentration required to achieve 50% 
protection of BHK cells from DENV-2 induced cytopathogenicity, as determined by the MTT method. hCompound concentration 
required to reduce the viability of mock-infected VERO76 (monkey normal kidney) monolayers by 50%. iCompound concentration 
required to reduce the plaque number of RSV (Respiratory Syncytial Virus) by 50% in VERO76 monolayers. 
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Table 11. Cytotoxicity and antiviral activity of (E)-1,3-diphenyl-4-styryl-1H-pyrazoles 
18a–i against ssRNA+ (HIV-1, CVB-5, Sb-1), ssRNA- (VDV), dsRNA (Reo-1) and DNA 
(VV, HSV-1) viruses. 
 
Compds R R1 
MT-4 
aCC50 
(µM) 
HIV-1 
bEC50 
(µM) 
BHK-21 
cCC50 
(µM) 
Reo-1 
dEC50 
(µM) 
Vero76 
eCC50 
(µM) 
CVB-5 Sb-1 VV HSV-1 VSV 
fEC50 
(µM) 
18a Br H >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 
18b Br Cl >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 
18c Br CH3 >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 
18d Cl H >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 
18e Cl Cl >100 >100 >100 >100 60 >60 >60 >60 >60 >60 
18f Cl CH3 >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 
18g CH3 H >100 43.0±3.2 >100 >100 >100 >100 >100 >100 >100 >100 
18h CH3 Cl >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 
18i CH3 CH3 >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 
Ref. Compds.           
EFV 38.0±2.0 0.002±0.0         
ACG     >100    2.4±0.6
1 
 
Pleconaril     77.0±6.8 0.005±0.002 2.0±0.6    
M 5255     19.3±2.5   1.4±0.2   
NM107   >100 6.0±2.1       
aCompound concentration required to reduce the viability of mock-infected MT-4 (cd4+ Human T-cells containing an integrated HTL V-
1 genome) cells by 50%, as determined by the MTT method. bCompound concentration required to achieve 50% protection of MT-4 
cells from the HIV-1 induced cytioathigenicity, as determined by the MTT method. cCompound concentration required to reduce the 
viability of mock-infected BHK (hamster normal kidney fibroblast) monolayers by 50%, as determined by the MTT method. 
dCompound concentration required to achieve 50% protection of BHK cells (kidney fibroblast) from the Reo (Reovirus 1), induced 
cytopathogenicity, as determined by the MTT method. eCompound concentration required to reduce the viability of mock-infected 
VERO76 (monkey normal kidney) monolayers by 50%. fCompound concentration required to reduce the plaque number of CVB-5 
(Coxsackievirus B5), Sb-1 (Poliovirus 1), VV (Vaccina virus), HSV-1 (Herpesvirus 1) and VSV ( Vescicular Stomatitis Virus) by 50% 
in VERO76 monolayers. 
 
5.1.3.2. Experimental 
5.1.3.2.1. Chemistry 
Chemicals were purchased from Sigma-Aldrich and used without 
further purification. Melting points were determined on a Stuar Scientific 
SMP1 apparatus and are uncorrected. 
1
H NMR and 
13
C NMR spectra were 
recorded on a Bruker AM-400 spectrometer in CDCl3 or DMSO-d6, and 
chemical shifts were reported in ppm (). All compounds were routinely 
checked by thin-layer chromatography (TLC). TLC was performed on silica 
gel or aluminium oxide fluorescent coated plates (Fluka, DC-Alufolien 
Kieselgel or aluminum oxide F254). Compound purity was determined by 
elemental analysis and was confirmed to be > 95% for all the tested 
compounds. Analytical results are within ±0.40% of the theoretical values.  
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5.1.3.2.1.1. General procedure for the synthesis of the (E)-2-(1-
phenylethylidene)hydrazinecarboxamides (5a-d). 
A solution of semicarbazide hydrochloride (2.3 mmol) in water (43 ml) 
was added dropwise to a stirred solution of the appropriate acetophenone (2.2 
mmol) and sodium acetate (3 mmol) in ethanol (43 ml) at room temperature. 
After the addition, the mixture was refluxed for 6 h under magnetic stirring, 
cooled at room temperature and stirred 18 h. Afterwards the ethanol was 
removed under reduced pressure and the precipitate was collected by filtration 
and used for the next reaction without further purification. 
 
5.1.3.2.1.1.1. (E)-2-(1-(4-Bromophenyl)ethylidene)hydrazinecarboxamide 
(5a). Yield: 77%, m.p. = 198 – 201 °C. 1H NMR (DMSO-d6, 400 MHz): δ 
(ppm) 9.47 (s, 1H, NH), 7.81 (d, 2H, H2, H6, J2-3 = 8.0 Hz), 7.54 (d, 2H, H3, 
H5, J2-3 = 8.0 Hz), 6.58 (s, 2H, NH2), 2.18 (s, 3H, CH3). 
13
C NMR (DMSO-
d6, 100 MHz): δ (ppm) 157.23, 142.84, 137.44, 130.99, 127.99, 121.74, 
13.05. 
 
5.1.3.2.1.1.2. (E)- 2-(1(4-Chlorophenyl)ethylidene)hydrazinecarboxamide 
(5b). Yield: 74%, m.p. = 198 – 199 °C. 1H NMR (DMSO-d6, 400 MHz): δ 
(ppm) 9.45 (s, 1H, NH), 7.88 (d, 2H, H2, H6, J2-3 = 8.4 Hz), 7.40 (d, 2H, H3, 
H5, J2-3 = 8.4 Hz), 6.57 (s, 2H, NH2), 2.18 (s, 3H, CH3). 
13
C NMR (DMSO-d6, 
100 MHz): δ (ppm) 157.22, 142.73, 137.06, 133.01, 128.07, 127.70, 13.09. 
 
5.1.3.2.1.1.3. (E)-2(1(p-Tolyl)ethylidene)hydrazinecarboxamide (5c). 
Yield: 87%, m.p. = 199 – 200°C (lit. = 200 °C) 3. The compound exhibited 
spectroscopic data identical to those previously reported 
3
.  
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5.1.3.2.1.1.4.  (E)-2-(1-Phenylethylidene)hydrazinecarboxamide (5d). 
Yield: 83%, m.p. = 196 – 197 °C. 1H NMR (DMSO-d6, 400 MHz): δ (ppm) 
9.40 (s, 1H, NH), 7.84 (d, 2H, H2, H6, J2-3 = 6.4 Hz), 7.37 – 7.35 (m, 3H, H3, 
H4, H5), 6.53 (s, 2H, NH2), 2.19 (s, 3H, CH3). 
13
C NMR (DMSO-d6, 100 
MHz): δ (ppm) 157.29, 143.93, 138.17, 128.32, 128.08, 125.84, 13.21.   
 
5.1.3.2.1.2. General procedure for the synthesis of the 3-phenyl-1H-
pyrazol-4-carbaldeydes (6a-d). 
To a solution of the suitable (E)-2-(1-phenylethylidene) 
hydrazinecarboxamides 5a-d (12 mmol) in dry DMF (9 ml) cooled in ice 
bath, POCl3 (2 ml) was added dropwise. The mixture was stirred in ice bath 
for 30 min and then heated at 65 °C for 6 hours. After cooling and stirring at 
room temperature for 18 hours, the mixture was diluted with water and ice, 
neutralized with NaOH 2N and extracted with ethyl acetate. The organic layer 
was washed with brine, dried over anhydrous Na2SO4, filtered and evaporated 
to dryness. The residue was purified by crystallization from CHCl3/n-Hexane 
or from CHCl3/Pet. Intermediate 6c was purified by column chromatography 
on silica gel eluting with a mixture of AcOEt and n-Hexane 1:1.  
 
5.1.3.2.1.2.1. 3-(4-Bromophenyl)-1H-pyrazole-4-carbaldehyde (6a). 
Yield 97%, m.p. = 127 – 128 °C (lit. = 163 – 165 °C) 4 from CHCl3/n-
Hexane. 
1
H NMR (DMSO-d6, 400 MHz): δ (ppm) 13.80 (s, 1H, NH), 9.90 (s, 
1H, CHO), 8.49 (s, 1H, pyrazole-H5), 7.83 (d, 2H, H2, H6, J2-3 = 8.0 Hz), 
7.69 (d, 2H, H3, H5, J2-3 = 8.0 Hz). 
13
C NMR (DMSO-d6, 100 MHz): δ (ppm) 
184.57, 152.81, 138.86, 138.56, 131.41, 130.39, 122.36, 119.85.  
  
5.1.3.2.1.2.2. 3-(4-Chlorophenyl)-1H-pyrazole-4-carbaldehyde (6b). 
Yield: 99%, m.p. = 130 – 131 °C (lit. = 142 – 144 °C) 4 from AcOEt/n-
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Hexane. 
1
H NMR (DMSO-d6, 400 MHz): δ (ppm) 13.70 (s, 1H, NH), 9.91 (s, 
1H, CHO), 8.49 (s, 1H, pyrazole-H5), 7.90 (d, 2H, H2, H6, J2-3 = 8.0 Hz), 
7.56 (d, 2H, H3, H5, J2-3 = 8.0 Hz). 
13
C NMR (DMSO-d6, 100 MHz): δ (ppm) 
184.64, 140.60, 133.71, 130.18, 128.49, 128.54, 125.39, 119.88. 
 
5.1.3.2.1.2.3. 3-(p-Tolyl)-1H-pyrazole-4-carbaldehyde (6c). Yield: 60%, 
m.p. = 123 – 124 °C (lit. = 123 – 125 °C) 4 from AcOEt/n-Hexane. 1H NMR 
(CDCl3, 400 MHz): δ (ppm) 12.58 (s, 1H, NH), 9.94 (s, 1H, CHO), 8.05 (s, 
1H, pyrazole-H5), 7.53 (d, 2H, H2, H6, J2-3 = 7.6 Hz), 7.29 (d, 2H, H3, H5, J2-
3 = 7.6 Hz), 2.43 (s, 3H, CH3). 
13
C NMR (CDCl3, 100 MHz): δ (ppm) 185.22, 
150.08, 140.5, 138.80, 129.87, 128.69, 125.33, 120.03, 21.41. 
 
5.1.3.2.1.2.4. 3-Phenyl-1H-pyrazole-4-carbaldehyde (6d). Yield: 93%, 
m.p. = 129–130 °C (lit. = 145 °C) 4 from CHCl3/n-Hexane. 
1
H NMR (DMSO-
d6, 400 MHz): δ (ppm) 13.72 (s, 1H, NH), 9.91 (s, 1H, CHO), 8.60 (s, 1H, 
pyrazole-H5), 7.83 (d, 2H, H2, H6, J2-3 = 8.0 Hz), 7.56 – 7.50 (m, 3H, H3, H4, 
H5). 
13
C NMR (DMSO-d6, 100 MHz): δ (ppm) 184.71, 140.01, 133.08, 
130.10, 128.76, 127.08, 126.49, 110.48. 
 
5.1.3.2.1.3. General procedure for the synthesis of the 3-phenyl-1-
(phenylsulfonyl)-1H-pyrazol-4-carbaldehydes (7a-d) and the 1-((4-
methoxyphenyl)sulfonyl)-3-phenyl-1H-pyrazole-4-carbaldehyde (8a-c). 
NaH (6.8 mmol) was added to a stirred solution of the appropriate 3-
phenyl-1H-pyrazole-4-carbaldehyde 6a-d (6.8 mmol) in dry THF (100 ml). 
The mixture was stirred 30 min at room temperature, than the suitable 
benzenesulfonyl chloride (9.6 mmol) was added. After stirring for 24 h at 
room temperature, water was added to the mixture and THF was removed 
under reduced pressure. The obtained suspension was extracted with ethyl 
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acetate and the organic phase was washed with brine and dried over Na2SO4 
anhydrous, filtered and evaporated to dryness. The residue was purified by 
crystallization from suitable solvent. 
 
5.1.3.2.1.3.1.          3-(4-Bromophenyl)-1-(phenylsulfonyl)-1H-pyrazole-4-
carbaldehyde (7a). Yield: 85%, m.p. = 121 – 122 °C from AcOEt/Pet.Et. 1H 
NMR (CDCl3, 400 MHz): δ (ppm) 9.97 (s, 1H, CHO), 8.71 (s, 1H, pyrazole-
H5), 8.11 (d, 2H, H2, H6, J2-3 = 7.6 Hz), 7.25 (t, 1H, H4, J3-4 = 7.6 Hz), 7.66 – 
7.56 (m, 6H, H3, H5, H2', H6', H3', H5'). 
13
C NMR (CDCl3, 100 MHz): δ 
(ppm) 183.63, 155.33, 137.24, 135.84, 135.45, 131.84, 130.58, 129.73, 
129.02, 128.73, 124.56, 122.61.   
 
5.1.3.2.1.3.2.        3-(4-Clorophenyl)-1-(phenylsulphonyl)-1H-pyrazole-4-
carbaldehyde (7b). Yield: 60%, m.p. = 121 – 122 °C from EtOH/n-Hexane. 
1
H NMR (DMSO-d6, 400 MHz): δ (ppm) 9.95 (s, 1H, CHO), 9.41 (s, 1H, 
pyrazole-H5), 8.15 (d, 2H, H2, H6, J2-3 = 7.6 Hz), 7.87 (t, 1H, H4, J3-4 = 7.6 
Hz), 7.83 (d, 2H, H2', H6', J2'-3' = 8.4 Hz), 7.74 (t, 2H, H3, H5, J2-3 = J3-4 = 7.6 
Hz), 7.54 (d, 2H, H3', H5', J2'-3' = 8.4 Hz). 
13
C NMR (DMSO-d6, 100 MHz): δ 
(ppm) 184.65, 153.70, 140.92, 136.02, 135.10, 134.75, 130.52, 130.27, 
128.74, 128.55, 128.26, 122.62. 
 
5.1.3.2.1.3.3. 1-(Phenylsulfonyl)-3-(p-tolyl)-1H-pyrazole-4-carbaldehyde 
(7c). Yield: 90%, m.p. = 126 °C da AcOEt/Pet. Et. 
1
H NMR (CDCl3, 400 
MHz): δ (ppm) 9.98 (s, 1H, CHO), 8.69 (s, 1H, pyrazole-H5), 8.10 (d, 2H, 
H2, H6, J2-3 = 8.0 Hz), 7.69 (t, 1H, H4, J3-4 = 8.0 Hz), 7.61 – 7.56 (m, 4H, H2', 
H6', H3, H5), 7.24 (d, 2H, H3', H5', J2-3 = 8.0 Hz), 2,38 (s, 1H, CH3). 
13
C 
NMR (CDCl3, 100 MHz): δ (ppm) 184.47, 156.87, 140.18, 136.14, 136.07, 
135.27, 129.65, 129.41, 128.95, 128.67, 127.22, 122.65, 21.36. 
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5.1.3.2.1.3.4. 3-Phenyl-1-(phenylsulphonyl)-1H-pyrazole-4-carbaldehyde 
(7d). Yield: 50%, m.p. = 110 – 111 °C from EtOH/n-Hexane. 1H NMR 
(CDCl3, 400 MHz): δ (ppm) 9.92 (s, 1H, CHO), 8.71 (s, 1H, pyrazole-H5), 
8.11 (d, 2H, H2, H6, J2-3 = 8.0 Hz), 7.71 – 7.69 (m, 3H, H2', H6', H4), 7.59 (t, 
2H, H3, H5, J2-3 = 8.0 Hz), 7.46 – 7.44 (m, 3H, H3', H4', H5'). 
13
C NMR 
(CDCl3, 100 MHz): δ (ppm) 184.38, 156.81, 140.93, 136.16, 135.99, 135.34, 
130.07, 129.98, 129.68, 129.07, 128.70, 122.66.  
 
5.1.3.2.1.3.5.        3-(4-Bromophenyl)-1-((4-methoxyphenyl)sulfonyl)-1H-
pyrazole-4-carbaldehyde (8a). Yield: 62%, m.p. = 110 – 112 °C from 
AcOEt/n-Hexane. 
1
H NMR (DMSO-d6, 400 MHz): δ (ppm) 9.94 (s, 1H, 
CHO), 9.33 (s, 1H, pyrazole-H5), 8.07 (d, 2H, H2, H6, J2-3 = 8.0 Hz), 7.75 (d, 
2H, H2', H6', J2'-3' = 8.0 Hz ), 7.67 (d, 2H, H3', H5', J2'-3' = 8.0 Hz), 7.23 (d, 
2H, H3, H5, J2-3 = 8.0 Hz ), 3.87 (s, 1H, OCH3). 
13
C NMR (DMSO-d6, 100 
MHz): δ (ppm) 184.84, 164.93, 153.43, 140.27, 131.46, 130.96, 130.70, 
129.24, 125.86, 123.43, 122.32, 115.50, 56.09. 
 
5.1.3.2.1.3.6.         3-(4Chlorophenyl)-1-((4-methoxyphenyl)sulfonyl)-1H-
pyrazole-4-carbaldehyde (8b). Yield: 35%, m.p. = 114 – 115 °C from 
AcOEt/n-Hexane. 
1
H NMR (DMSO-d6, 400 MHz): δ (ppm) 9.93 (s, 1H, 
CHO), 9.34 (s, 1H, pyrazole-H5), 8.07 (d, 2H, H2, H6, J2-3= 8.0 Hz), 7.82 (d, 
2H, H2', H6', J2'-3' = 8.0 Hz ), 7.52 (d, 2H, H3', H5', J2'-3' = 8.0 Hz), 7.23 (d, 
2H, H3, H5, J2-3 = 8.0 Hz ), 3.87 (s, 1H, OCH3). 
13
C NMR (DMSO-d6, 100 
MHz): δ (ppm) 185.15, 165.42, 153.85, 140.94, 135.17, 131.46, 130.98, 
129.35, 129.01, 126.33, 122.81, 115.98, 56.58. 
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5.1.3.2.1.3.7.   1-((4-Methoxyphenyl)sulfonyl)-3-(p-tolyl)-1H-pyrazole-4-
carbaldehyde (8c). Yield: 68%, m.p. = 107 – 108 °C from AcOEt/n-Hexane. 
1
H NMR (DMSO-d6, 400 MHz): δ (ppm) 9.94 (s, 1H, CHO), 9.27 (s, 1H, 
pyrazole-H5), 8.07 (d, 2H, H2, H6, J2-3 = 8.0 Hz), 7.68 (d, 2H, H2', H6', J2'-3' = 
8.0 Hz ), 7.27 (d, 2H, H3', H5', J2'-3' = 8.0 Hz), 7.22 (d, 2H, H3, H5, J2-3 = 8.0 
Hz ), 3.86 (s, 1H, OCH3), 2.35 (s, 1H, -CH3). 
13
C NMR (DMSO-d6, 100 
MHz): δ (ppm) 185.24, 165.34, 155.25, 140.26, 140.04, 131.40, 129.52, 
129.11, 127.65, 126.52, 122.79, 115.94, 56.55, 21.36. 
 
5.1.3.2.1.4. General procedure for the synthesis of (E)-N-((3-phenyl-1-
(phenylsulfonyl)-1H-pyrazol-4-yl)methylene)aniline (9a-p) and (E)-N-((1-
((4-methoxyphenyl)sulfonyl)-3-phenyl-1H-pyrazol-4-yl)methylene)aniline 
(10a-l). 
The suitable aniline (1.09 mmol) was added to a solution of the 
appropriate 1-phenylsulfonyl-1H-pyrazol-4-carbaldehyde 7a-d or 8a-c (1.2 
mmol) in dry ethanol (30 ml) and glacial acetic acid (0.1 ml). The mixture 
was refluxed for 6 h under magnetic stirring. After cooling, water was added 
and ethanol was removed under reduced pressure. The obtained suspension 
was extracted with diethyl ether and the organic layer was washed with brine, 
dried on Na2SO4 anhydrous, filtered and evaporated to dryness. The residual 
oil was used for the next reaction without further purification. 
 
5.1.3.2.1.5. General procedure for the synthesis of N-[(3-phenil-1-
(phenylsulfonil)-1H-pyrazol-4-il)methyl]aniline (11a-p) and N-((1-((4-
methoxyphenyl)sulfonyl)-3-phenyl-1H-pyrazol-4-yl)methyl)aniline (12a-l). 
To a stirred solution of the crude 1-phenylsulphonyl-1H-pirazol-4-yl-
methyleneaniline 9a-p or 10a-l (1 mmol) in dry THF (17 ml), NaBH4 (10 
mmol) was added and the mixture was stirred at room temperature for 24 h. 
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After this period, water was added and THF was removed under reduced 
pressure. The suspension was extracted with ethyl acetate and the organic 
phase was washed with brine, dried under Na2SO4 anhydrous, filtered and 
evaporated to dryness. The residue obtained was purified by crystallization 
from suitable solvent.  
 
5.1.3.2.1.5.1.   N-((3-(4-Bromophenyl)-1-(phenylsulfonyl)-1H-pyrazol-4-
yl)methyl)aniline (11a). Yield: 36%; m.p. = 110 – 11 °C from AcOEt/n-
Hexane; Anal. Calc. for C22H18BrN3O2S: C 56.42, H 3.87, Br 17.06, N 8.97, S 
6.85; found C 56.61, H 3.88, Br 17.04, N 8.98, S 6.84. 
1
H NMR (CDCl3, 400 
MHz): δ (ppm) 8.10 (s, 1H, pyrazole-H5), 8.01 (d, 2H, H2, H6, J2-3 = 7.2 Hz), 
7.64 (t, 1H, H4, J3-4 = 7.2 Hz), 7.57 – 7.48 (m, 6H, H3, H5, H2', H6', H3', 
H5'), 7.18 (t, 2H, H3'', H5'', J2''-3'' = J3''-4'' = 7.6 Hz), 6.77 (t, 1H, H4'', J3''-4'' = 7.6 
Hz), 6.59 (d, 2H, H2'', H6'', J2''-3'' = 7.6 Hz), 4.23 (s, 2H, CH2). 
13
C NMR 
(CDCl3, 100 MHz): δ (ppm) 154.67, 147.24, 137.08, 134.57, 131.90, 131.86, 
130.41, 129.56, 129.42, 129.40, 128.19, 123.53, 120.83, 118.48, 113.19, 
39.12.  
 
5.1.3.2.1.5.2.     N-((3-(4-Bromophenyl)-1-(phenysulfonyl)-1H-pyrazol-4-
yl)methyl)-4-chloroaniline (11b). Yield: 52%; m.p. = 137 – 138 °C from 
AcOEt/n-Hexane; Anal. Calc. for C22H17BrClN3O2S: C 52.55, H 3.41, Br 
15.89, Cl 7.05, N 8.36, S 6.38; found C 52.66, H 3.40, Br 15.95, Cl 7.06, N 
8.33, S 6.40. 
1
H NMR (CDCl3, 400 MHz): δ (ppm) 8.07 (s, 1H, pyrazole-H5), 
8.01 (d, 2H, H2, H6, J2-3 = 8.0 Hz), 7.65 (t, 1H, H4, J3-4 = 8.0 Hz), 7.55 – 7.49 
(m, 6H, H3, H5, H2', H6', H3', H5'), 7.11 (d, 2H, H3'', H5'', J2''-3'' = 8.4 Hz), 
6.49 (d, 2H, H2'', H6'', J2''-3'' = 8.4 Hz), 4.20 (s, 2H, CH2). 
13
C NMR (CDCl3, 
100 MHz): δ (ppm) 154.61, 145.70, 136.99, 134.64, 131.94, 131.80, 130.31, 
129.50, 129.45, 129.23, 128.18, 123.61, 123.10, 120.40, 114.24, 39.16.  
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5.1.3.2.1.5.3.      4-Bromo-N-((3-(4-bromophenyl)-1-(phenylsulfonyl)-1H-
przl-4-yl)methyl)aniline (11c). Yield: 42%; m.p. = 150 –151 °C from 
AcOEt/n-Hexane; Anal. Calc. for C22H17Br2N3O2S: C 48.28, H 3.13, Br 
29.20, N 7.68, S 5.86; found C 48.39, H 3.14, Br 29.29, N 7.66, S 5.87. 
1
H 
NMR (CDCl3, 400 MHz): δ (ppm) 8.07 (s, 1H, pyrazole-H5), 8.01 (d, 2H, 
H2, H6, J2-3 = 8.0 Hz), 7.65 (t, 1H, H4, J3-4 = 8.0 Hz), 7.56 – 7.49 (m, 6H, H3, 
H5, H2', H6', H3', H5'), 7.24 (d, 2H, H3'', H5'', J2''-3'' = 8.4 Hz), 6.44 (d, 2H, 
H2'', H6'', J2''-3'' = 8.4 Hz), 4.20 (s, 2H, CH2). 
13
C NMR (CDCl3, 100 MHz): δ 
(ppm) 154.59, 146.10, 136.98, 134.64, 132.10, 131.94, 131.79, 130.28, 
129.48, 129.44, 128.17, 123.60, 120.32, 114.71, 110.14, 39.04  
 
5.1.3.2.1.5.4.    N-((3-(4-Bromophenyl)-1-(phenylsulfonyl)-1H-pyrazol-4-
yl)methyl)-4-methylaniline (11d). Yield: 37%; m.p. = 112 °C from 
AcOEt/n-Hexane; Anal. Calc. for C23H20BrN3O2S: C 57.27, H 4.18, Br 16.56, 
N 8.71, S 6.65; found C 57.08, H 4.19, Br 16.53, N 8.73, S 6.63. 
1
H NMR 
(CDCl3, 400 MHz): δ (ppm) 8.09 (s, 1H, pyrazole-H5), 8.01 (d, 2H, H2, H6, 
J2-3 = 8.0 Hz), 7.63 (t, 1H, 4H, J3-4 = 8.0 Hz), 7.57 – 7.48 (m, 6H, H3, H5, H2', 
H6', H3', H5'), 6.98 (d, 2H, H3'', H5'', J2''-3'' = 7.6 Hz), 6.51 (d, 2H, H2'', H6'', 
J2''-3'' = 7.6 Hz), 4.19 (s, 2H, CH2), 2.24 (s, 3H, CH3). 
13
C NMR (CDCl3, 100 
MHz): δ (ppm) 154.69, 144.99, 137.09, 134.54, 131.87, 131.84, 130.44, 
129.87, 129.57, 129.40, 128.17, 127.73, 123.48, 121.02, 113.36, 39.41, 20.41.  
 
5.1.3.2.1.5.5.   N-((3-(4-Chlorophenyl)-1-(phenylsulfonyl)-1H-pyrazol-4-
yl)methyl)aniline (11e). Yield: 21%, m.p. = 117 – 118 °C from n-Hexane; 
Anal. Calc. for C22H18ClN3O2S: C 62.33, H 4.28, Cl 8.36, N 9.91, S 7.56; 
found C 62.14, H 4.29, Cl 8.39, N 9.94, S 7.53. IR: 3316, 1375, 1886 cm-1. 
1
H NMR (CDCl3, 400 MHz): δ (ppm) 8.12 (s, 1H, pyrazole-H5), 8.02 (d, 2H, 
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H2, H6, J2-3 = 7.6 Hz), 7.64 (t, 1H, H4, J3-4 = 7.6 Hz), 7.60 (d, 2H, H2', H6', 
J2'-3' = 7.6 Hz), 7.53 (t, 2H, H3, H5, J2-3 = J3-4 = 7.6 Hz), 7.33 (d, 2H, H3', H5', 
J2'-3' = 7.6 Hz), 7.18 (t, 2H, H3'', H5'', J2''-3'' = J3''-4'' = 7.6 Hz), 6.78 (t, 1H, H4'', 
J3''-4'' = 7.6 Hz), 6.60 (d, 2H, H2'', H6'', J2''-3'' = 7.6 Hz), 4.24 (s, 2H, CH2). 
13
C 
NMR (CDCl3, 100 MHz): δ (ppm) 154.72, 16.96, 137.09, 135.22, 134.58, 
131.98, 129.87, 129.42, 129.40, 129.31, 128.92, 128.17, 120.50, 118.84, 
113.54, 39.30. 
 
5.1.3.2.1.5.6.       4-Cloro-N-((3-(4-chlorophenyl)-1-(phenylsulfonyl)-1H-
pyrazol-4-yl)methyl)aniline (11f). Yield: 21%, m.p. = 142 – 143 °C from n-
Hexane; Anal. Calc. for C22H17Cl2N3O2S: C 57.65, H 3.74, Cl 15.47, N 9.17, 
S 7.00; found C 57.83, H 3.75, Cl 15.50, N 9.19, S 6.88. 
1
H NMR (CDCl3, 
400 MHz): δ (ppm) 8.12 (s, 1H, pyrazole-H5), 8.02 (d, 2H, H2, H6, J2-3 = 8.0 
Hz), 7.66 (t, 1H, H4, J3-4 = 8.0 Hz), 7.58 – 7.53 (m, 4H, H2', H6', H3, H5), 
7.35 (d, 2H, H3', H5', J2'-3' = 6.8 Hz), 7.10 (d, 2H, H3'', H5'', J2''-3'' = 7.2 Hz), 
6.52 (d, 2H, H2'', H6'', J2''-3'' = 7.2 Hz), 4.20 (s, 2H, CH2). 
13
C NMR (CDCl3, 
100 MHz): δ (ppm) 154.67, 144.97, 136.93, 135.32, 134.66, 131.98, 129.74, 
129.46, 129.43, 129.25, 128.96, 128.18, 123.73, 119.92, 114.78, 39.44.  
 
5.1.3.2.1.5.7.     4-Bromo-N-((3-(4-chlorophenyl)-1-(phenylsulfonyl)-1H-
pyrazol-4-yl)methyl)aniline (11g). Yield: 28%, m.p. = 142–143 °C from n-
Hexane; Anal. Calc. for C22H17BrClN3O2S: C 52.55, H 3.41, Br 15.89, Cl 
7.05, N 8.36, S 6.38; found C 52.48, H 3.42, Br 15.96, Cl 7.04, N 8.38, S 
6.37. 
1
H NMR (CDCl3, 400 MHz): δ (ppm) 8.14 (s, 1H, pyrazole-H5), 8.02 
(d, 2H, H2, H6, J2-3  = 8.0 Hz), 7.67 (t, 1H, H4, J3-4 = 8.0 Hz), 7.57 – 7.54 (m, 
4H, H2', H6', H3, H5), 7.35 (d, 2H, H3'', H5'', J2''-3'' = 7.6 Hz), 7.24 (d, 2H, 
H3', H5', J2'-3' = 8.4 Hz), 6.48 (d, 2H, H2'', H6'', J2''-3'' = 7.6 Hz), 4.24 (s, 2H, 
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CH2). 
13
C NMR (CDCl3, 100 MHz): δ (ppm) 154.66, 145.40, 136.95, 135.33, 
134.66, 132.12, 132.01, 129.74, 129.46, 129.25, 128.96, 128.17, 119.89, 
115.28, 110.83, 39.35.  
 
5.1.3.2.1.5.8.   N-[(3-(4-Chlorophenyl)-1-(phenylsulfonyl)-1H-pyrazol-4-
yl)methyl]-4-methylanyline (11h). Yield 29%, m.p. = 100 – 101 °C from n-
Hexane; Anal. Calc. for C23H20ClN3O2S: C 63.08, H 4.60, Cl 8.10, N 9.59, S 
7.32; found C 63.30, H 4.62, Cl 8.06, N 9.62, S 7.30. 
1
H NMR (CDCl3, 400 
MHz): δ (ppm) 8.13 (s, 1H, pyrazole-H5), 8.02 (d, 2H, H2, H6, J2-3 = 8.0 Hz), 
7.66 – 7.60 (m, 3H, H4, H2, H6), 7.53 (t, 2H, H3, H5, J2-3 = J3-4 = 8.0 Hz), 
7.33 (d, 2H, H3', H5', J2'-3' = 8.0 Hz), 6.98 (d, 2H, H3", H5'', J2''-3'' = 7.6 Hz), 
6.53 (d, 2H, H2'', H6'', J2''-3'' = 7.6 Hz), 4.21 (s, 3H, CH3), 2.25 (s, 2H, CH2). 
13
C NMR (CDCl3, 100 MHz): δ (ppm) 154.72, 144.38, 137.04, 135.22, 
134.55, 131.98, 129.88, 129.41, 129.33, 128.90, 128.27, 128.17, 120.61, 
113.79, 39.65, 20.44.  
 
5.1.3.2.1.5.9. N-[(1-(Phenylsulfonyl)-3-(p-tolyl)-1H-pyrazol-4-yl)methyl] 
aniline (11i). Yield: 20%, m.p. = 128 – 129 °C from AcOEt/n-Hexane; Anal. 
Calc. for C23H21N3O2S: C 68.46, H 5.25, N 10.41, S 7.95; found C 68.66, H 
5.26, N 10.38, S 7.97.  
1
H NMR (CDCl3, 400 MHz): δ (ppm) 8.09 (s, 1H, 
pyrazole-H5), 7.99 (d, 2H, H2, H6, J2-3 = 8.0 Hz), 7.60 (t, 1H, H4, J3-4 = 8.0 
Hz), 7.54 – 7.47 (m, 4H, H3, H5, H2', H6'), 7.17 – 7.14 (m, 4H, H3', H5', 
H3'', H5''), 6.76 (t, 1H, H4'', J3''-4'' = 8.0 Hz), 6.58 (d, 2H, H2'', H6'', J2''-3'' = 8.0 
Hz), 4.25 (s, 2H, CH2), 2.34 (s, 3H, CH3). 
13
C NMR (CDCl3, 100 MHz): δ 
(ppm) 155.89, 146.92, 139.12, 137.25, 134.37, 131.72, 129.38, 129.33, 
128.55, 128.08, 127.90, 120.76, 118.57, 114.96, 113.49, 39.39, 21.29.  
 
106 
 
5.1.3.2.1.5.10.  4-Chloro-N-[(1-(phenylsulfonyl)-3-(p-tolyl)-1H-pyrazol-4-
yl)methyl]aniline (11j). Yield: 22%, m.p. = 115 °C from AcOEt/n-Hexane; 
Anal. Calc. for C23H20ClN3O2S: C 63.08, H 4.60, Cl 8.10, N 9.59, S 7.32; 
found C 62.89, H 4.61, Cl 8.07, N 9.57, S 7.29. 
1
H NMR (CDCl3, 400 MHz): 
δ (ppm) 8.05 (s, 1H, pyrazole-H5), 7.98 (d, 2H, H2, H6, J2-3 = 7.2 Hz), 7.61 (t, 
1H, H4, J3-4 = 7.2 Hz), 7.54 – 7.48 (m, 4H, H3, H5, H2', H6'), 7.17 (d, 2H, 
H3', H5', J2'-3' = 7.2 Hz), 7.07 (d, 2H, H3'', H5'', J2''-3'' = 8.0 Hz), 6.47 (d, 2H, 
H2'', H6'', J2''-3'' = 8.0 Hz), 4.25 (s, 2H, CH2) 2.34 (s, 3H, CH3) 
13
C NMR 
(CDCl3, 100 MHz): δ (ppm) 155.85, 145.52, 139.22, 137.15, 134.44, 131.66, 
129.41, 129.35, 129.13, 128.45, 128.06, 127.84, 123.05, 120.43, 114.47, 
39.36, 21.29.  
 
5.1.3.2.1.5.11.  4-Bromo-N-[(1-(phenylsulfonyl)-3-(p-tolyl)-1H-pyrazol-4-
yl)methyl]aniline (11k). Yield: 24%, m.p. = 110°C from AcOEt/n-Hexane; 
Anal. Calc. for C23H20BrN3O2S: C 57.27, H 4.18, Br 16.56, N 8.71, S 6.65; 
found C 57.41, H 4.19, Br 16.52, N 8.69, S 6.64. 
1
H NMR (CDCl3, 400 
MHz): δ ppm 8.03 (s, 1H, pyrazole-H5), 7.98 (d, 2H, H2, H6, J2-3 = 8.0 Hz), 
7.61 (t, 1H, H4, J3-4 = 8.0 Hz), 7.51 – 7.48 (m, 4H, H3, H5, H2', H6'), 7.21 – 
7.15 (m, 4H, H3', H5', H3'', H5''), 6.42 (d, 2H, H2'', H6'', J2''-3'' = 7.6 Hz), 4.20 
(s, 2H, CH2), 2.33 (s, 3H, CH3). 
13
C NMR (CDCl3, 100 MHz): δ (ppm) 
155.84, 146.00, 139.22, 137.14, 134.44, 131.99, 131.66, 129.41, 129.35, 
128.45, 128.05, 127.84, 120.41, 114.91, 110.05, 39.23, 21.29 
 
5.1.3.2.1.5.12.  4-Methyl-N-[(1-(phenysulfonyl)-3-(p-tolyl)-1H-pyrazol-4-
yl)methyl]aniline (11l). Yield: 41%, m.p. = 123 – 124 °C from AcOEt/n-
Hexane; Anal. Calc. for C24H23N3O2S: C 69.04, H 5.55, N 10.06, S 7.68; 
found C 68.81, H 5.57, N 10.25, S 7.65. 
1
H NMR (CDCl3, 400 MHz): δ 
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(ppm) 8.08 (s, 1H, pyrazole-H5), 8.00 (d, 2H, H2, H6, J2-3 = 7.2 Hz), 7.61 (t, 
1H, 4H, J3-4 = 7.2 Hz), 7.55 – 7.47 (m, 4H, H3, H5, H2', H6'), 7.17 (d, 2H, 
H3', H5', J2'-3' = 7.6 Hz), 6.97 (d, 2H, H3'', H5'', J2''-3'' = 8.0 Hz), 6.51 (d, 2H, 
H2'', H6'', J2''-3'' = 8.0 Hz), 4.2 (s, 2H, CH2), 2.34 (s, 3H, CH3-Ar), 2.24 (s, 3H, 
CH3-Ar''). 
13
C NMR (CDCl3, 100 MHz): δ (ppm) 155.90, 144.75, 139.09, 
137.29, 134.34, 131.68, 129.81, 129.36, 129.31, 128.61, 128.08, 127.91, 
127.78, 121.00, 113.61, 39.69, 21.29, 20.42. 
 
5.1.3.2.1.5.13.     N-[(3-Phenyl-1-(phenysulfonyl)-1H-pyrazol-4-yl)methyl] 
aniline (11m). Yield: 64%, m.p. = 139°C, from CHCl3/n-Hexane; Anal. Calc. 
for C22H19N3O2S: C 67.84, H 4.92, N 10.79, S 8.23; found C 68.02, H 4.93, N 
10.76, S 8.20. 
1
H NMR (CDCl3, 400 MHz): δ (ppm) 8.1 (s, 1H, pyrazole-H5), 
8.01 (d, 2H, H2, H6, J2-3 = 8.0 Hz), 7.66 – 7.61 (m, 3H, H4, H2', H6'), 7.52 (t, 
2H, H3, H5, J2-3 = J3-4 =8.0 Hz), 7.39 – 7.37 (m, 3H, H3', H4', H5'), 7.17 (t, 
2H, H3'', H5'', J2''-3'' = J3''-4'' = 7.6 Hz), 6.76 (t, 1H, H4'', J3''-4'' = 7.6 Hz), 6.58 (d, 
2H, H2'', H6'', J2''-3'' = 7.6 Hz), 4.27 (s, 2H, CH2). 
13
C NMR (CDCl3, 100 
MHz): δ (ppm) 155.77, 147.26, 137.17, 134.45, 131.66, 131.45, 129.36, 
129.34, 129.11, 128.70, 128.12, 128.01, 121.04, 118.32, 113.20, 39.20.   
 
5.1.3.2.1.5.14.  4-Chloro-N-[(3-phenyl-1-(phenylsulphonyl)-1H-pyrazol-4-
yl)methyl]aniline (11n). Yield: 14%, m.p. = 136 – 137 °C from CHCl3/n-
Hexane; Anal. Calc. for C22H18ClN3O2S: C 62.33, H 4.28, Cl 8.36, N 9.91, S 
7.56; found C 62.48, H 4.29, Cl 8.35, N 9.88, S 7.54. 
1
H NMR (CDCl3, 400 
MHz): δ (ppm) 8.09 (s, 1H, pyrazole-H5), 8.01 (d, 2H, H2, H6, J2-3 = 8.0 Hz), 
7.65 – 7.60 (m, 3H, H4, H2', H6'), 7.52 (t, 2H, H3, H5, J2-3 = J3-4 = 8.0 Hz), 
7.38 – 7.37 (m, 3H, H3', H4', H5'), 7.08 (d, 2H, H3'', H5'', J2''-3'' = 8.4 Hz), 6.49 
(d, 2H, H2'', H6'', J2''-3'' = 8.4 Hz), 4.25 (s, 1H, CH2). 
13
C NMR (CDCl3, 100 
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MHz): δ (ppm) 155.79, 145.29, 137.11, 134.52, 131.74, 131.33, 129.39, 
129.18, 129.16, 128.72, 128.12, 127.98, 123.33, 120.35, 114.62, 39.42.  
 
5.1.3.2.1.5.15.    4-Bromo-N-[(3-phenyl-1-(phenylsulfonyl)-1H-pyrazol-4-
yl)methyl]aniline (11o). Yield: 14%, m.p. = 122 °C from CHCl3/n-Hexane; 
Anal. Calc. for C22H18BrN3O2S: C 56.42, H 3.87, Br 17.06, N 8.97, S 6.85; 
found C 56.28, H 3.89, Br 17.08, N 8.95, S 6.84. 
1
H NMR (CDCl3, 400 
MHz): δ (ppm) 8.09 (s, 1H, pyrazole-H5), 8.01 (d, 2H, H2, H6, J2-3 = 7.6 Hz), 
7.66 – 7.59 (m, 3H, H4, H2', H6'), 7.53 (t, 2H, H3, H5, J2-3 = J3-5 = 7.6 Hz), 
7.37 – 7.35 (m, 3H, H3', H4', H5'), 7.22 (d, 2H, H3'', H5'', J2''-3'' = 7.6 Hz), 6.45 
(d, 2H, H2'', H6'', J2''-3'' = 7.6 Hz), 4.25 (s, 2H, CH2). 
13
C NMR (CDCl3, 100 
MHz): δ (ppm) 155.79, 145.67, 137.10, 134.53, 132.06, 131.75, 131.31, 
129.40, 129.20, 128.73, 128.13, 127.98, 120.25, 115.13, 110.46, 39.34.  
 
5.1.3.2.1.5.16.    4-Methyl-N-((3-phenyl-1-(phenylsulfonyl)-1H-pyrazol-4-
yl)methyl)aniline (11p). Yield: 62% m.p. = 199°C, from CHCl3/n-Hexane; 
Anal. Calc. for C23H21N3O2S: C 68.46, H 5.25, N 10.41, S 7.95; found C 
68.65, H 5.27, N 10.44, S 7.92.  IR: 3396, 1376, 1185 cm-1. 
1
H NMR 
(CDCl3, 400 MHz): δ (ppm) 8.12 (s, 1H, pyrazole-H5), 8.02 (d, 2H, H2, H6, 
J2-3 = 8.0 Hz), 7.64 – 7.61 (m, 3H, H4, H2', H6'), 7.52 (t, 2H, H3, H5, J2-3 = J3-
4 = 8.0 Hz), 7.38 – 7.36 (m, 3H, H3', H4', H5'), 6.97 (d, 2H, H3'', H5'', J2''-3'' = 
7.2 Hz), 6.52 (d, 2H, H2'', H6'', J2''-3'' = 7.2 Hz), 4.25 (s, 2H, CH2), 2.24 (s, 3H, 
CH3). 
13
C NMR (CDCl3, 100 MHz): δ (ppm) 155.86, 144.51, 137.25, 134.41, 
131.77, 131.47, 129.84, 129.34, 129.08, 128.67, 128.14, 128.05, 128.03, 
120.92, 113.77, 39.74, 20.42.   
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5.1.3.2.1.5.17.       N-((3-Bromophenyl)-1-((4-methoxphenyl)sulfonyl)-1H-
pyrazol-4-yl)methyl)aniline (12a). Yield: 41%, m.p. = 131 – 134 °C from 
CHCl3/n-Hexane; Anal. Calc. for C23H20BrN3O3S: C 55.43, H 4.04, Br 16.03, 
N 8.43, S 6.43; found C 55.58, H 4.05, Br 16.08, N 8.46, S 6.44.  
1
H NMR 
(CDCl3, 400 MHz): δ (ppm) 7.96 (s, 1H, pyrazole-H5), 7.58 (d, 2H, H2', H6', 
J2'-3' = 8.8 Hz), 7,57 (d, 2H, H2, H6, J2-3 = 8.4 Hz), 7.52(d, 2H, H3', H5', J2'-3' = 
8.8 Hz), 7.19 (t, 2H, H3'', H5'', J2''-3'' = J3''-4'' = 8.0 Hz), 6.98 (d, 2H, H3, H5, J2-3 
= 8.4 Hz), 6.78 (t, 1H, H4'', J3''-4'' = 8.0 Hz), 6.60 (d, 2H, H2'', H6'', J2''-3'' = 8.0 
Hz), 4.24 (s, 2H, CH2), 3.86 (s, 3H, OCH3). 
13
C NMR (CDCl3, 100 MHz): δ 
(ppm) 164.04, 146.70, 144.43, 131.37, 131.09, 130.15, 130.02, 129.05, 
128.89, 127.65, 122.89, 119.80, 117.97, 116.32, 114.15, 112.26, 55.28, 38.59. 
 
5.1.3.2.1.5.18.   N-((3-(4-bromophenyl)-1-((4-methoxphenyl)sulfonyl)-1H-
pyrazol-4-yl)methyl)-4-chloroaniline (12b). Yield: 50%, m.p. = 153 – 154 
°C from CHCl3/n-Hexane; Anal. Calc. for C23H19BrClN3O3S: C 51.84, H 
3.59, Br 15.00, Cl 6.65, N 7.89, S 6.02; found C 52.05, H 3.58, Br 15.03, Cl 
6.64, N 7.92, S 5.99. 
1
H NMR (CDCl3, 400 MHz): δ (ppm) 8.07 (s, 1H, 
pyrazole-H5), 7.95 (d, 2H, H2, H6, J2-3 = 8.8 Hz), 7.52 (m, 4H, H2', H6', H3', 
H5'), 7.12 (d, 2H, H3'', H5'', J2''-3'' =  8.8 Hz ), 6.98 (d, 2H, H3, H5, J2-3 = 8.8 
Hz), 6.50 (d, 2H, H2'', H6'', J2''-3'' = 8.8 Hz), 4.21 (s, 2H, CH2), 3.86 (s, 3H, 
OCH3). 
13
C NMR (CDCl3, 100 MHz): δ (ppm) 164.05, 153.77, 144.81, 
132.55, 131.39, 131.14, 130.14, 129.88, 128.99, 128.73, 127.52, 122.96, 
119.17, 114.17, 114.01, 55.30, 38.79. 
 
5.1.3.2.1.5.19.         4-Bromo-N-((3-(4-bromophenyl)-1-((4-methoxphenyl) 
sulfonyl)-1H-pyrazol-4-yl)methyl)aniline (12c). Yield: 63%, m.p. = 162 – 
164 °C from CHCl3/n-Hexane; Anal. Calc. for C23H19Br2N3O3S: C 47.85, H 
3.32, Br 27.68, N 7.28, S 5.55; found C 47.86, H 3.33, Br 27.67, N 7.28, S 
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5.55. 
1
H NMR (CDCl3, 400 MHz): δ (ppm) 8.06 (s, 1H, pyrazole-H5), 7.94 
(d, 2H, H2', H6', J2'-3' = 8.0 Hz), 7.52 (m, 4H, H2, H6, H3', H5'), 7.25 (d, 2H, 
H3'', H5'', J2''-3'' =  8.8 Hz), 6.98 (d, 2H, H3, H5, J2-3 = 8.8 Hz), 6.46 (d, 2H, 
H2'', H6'', J2''-3'' = 8.8 Hz), 4.20 (s, 2H, CH2), 3.86 (3H, -OCH3). 
13
C NMR 
(CDCl3, 100 MHz): δ (ppm) 164.03, 153.02, 145.57, 132.55, 131.58, 131.39, 
131.05, 130.13, 129.89, 128.97, 127.51, 122.96, 119.32, 114.22, 114.17, 
55.31, 38.53. 
 
5.1.3.2.1.5.20.   N-((3-(4-Bromophenyl)-1-((4-methoxphenyl)sulfonyl)-1H-
pyrazol-4-yl)methyl)-4-methylaniline (12d). Yield: 50%, m.p. = 164 – 166 
°C from CHCl3/n-Hexane; Anal. Calc. for C24H22BrN3O3S: C 56.25, H 4.33, 
Br 15.59, N 8.20, S 6.26; found C 56.39, H 4.34, Br 15.65, N 8.17, S 6.27. 
1
H 
NMR (CDCl3, 400 MHz): δ (ppm.06 (s, 1H, pyrazole-H5), 7.99 (d, 2H, H2', 
H6', J2'-3' = 8.8 Hz), 7.61 (d, 2H, H2, H6, J2-6 = 8.8 Hz), 7.53 (d, 2H, H3', H5', 
J2'-3' = 8.8 Hz), 7.03 - 6.99 (m, 4H, H3, H5, H3'', H5''), 6.55 (d, 2H, H2'', H6'', 
J2''-3'' = 8.0 Hz), 4.23 (s, 2H, CH2), 3.89 (s, 3H, OCH3), 2.28 (s, 1H, CH2). 
13
C 
NMR (CDCl3, 100 MHz): δ (ppm) 163.97, 153.85, 144.43, 131.34, 131.08, 
130.14, 129.36, 129.07, 127.67, 127.27, 122.86, 120.22, 119.98, 114.13, 
112.87, 55.28, 38.91, 30.43. 
 
5.1.3.2.1.5.21.   N-((3-(4-Chlorophenyl)-1-(4-methoxphenyl)sulfonyl)-1H-
pyrazol-4-yl)methyl)aniline (12e). Yield: 42%, m.p. = 143 – 145 °C from 
CHCl3/n-Hexane; Anal. Calc. for C23H20ClN3O3S: C 60.86, H 4.44, Cl 7.81, 
N 9.26, S 7.06; found C 61.04, H 4.45, Cl 7.78, N 9.29, S 7.04. 
1
H NMR 
(CDCl3, 400 MHz): δ (ppm) 8.09 (s, 1H, pyrazole-H5), 7.95 (d, 2H, H2', H6', 
J2'-3' = 8.0 Hz), 7.64 (d, 2H, H2, H6, J2-3 = 8.0 Hz), 7.35 (d, 2H, H3', H5', J2'-3' 
= 8.0 Hz), 7.19 (t, 2H, H3'', H5'' J2''-3'' = J3''-4'' = 8.0 Hz), 6.98 (d, 2H, H3, H5, 
J2-3 = 8.0 Hz), 6.77 (t, 1H, H4'', J3''-4'' = 8.0 Hz), 6.60 (d, 2H, H2'', H6'', J2''-3'' = 
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8.0 Hz), 4.24 (s, 2H, CH2), 3.85 (s, 3H, OCH3). 
13
C NMR (CDCl3, 100 MHz): 
δ (ppm) 163.98, 153.78, 146.73, 134.60, 131.09, 130.13, 129.56, 128.88, 
128.79, 128.40, 127.66, 119.83, 117.94, 114.15, 112.67, 55.28, 39.60. 
 
5.1.3.2.1.5.22.       4-Chloro-N-((3-(4-chlorophenyl)-1-((4-methoxyphenyl) 
sulfonyl)-1H-pyrazol-4-yl)methyl)aniline (12f). Yield: 36%, m.p. = 158 – 
159 °C from AcOEt/n-Hexane; Anal. Calc. for C23H19Cl2N3O3S: C 56.65, H 
3.92, Cl 14.52, N 8.60, S 6.57; found C 56.72, H 3.91, Cl 14.55, N 8.57, S 
6.56.  
1
H NMR (CDCl3, 400 MHz): δ (ppm) 8.08 (s, 1H, pyrazole-H5), 7.94 
(d, 2H, H2', H6', J2'-3' = 8.0 Hz), 7.59 (d, 2H, H2, H6 J2-3 = 7.2 Hz), 7.35 (d, 
2H, H3', H5', J2'-3' = 8.0 Hz), 7.12 (d, 2H, H3'', H5'', J2''-3'' = 8.0 Hz ), 6.98 (d, 
2H, H3, H5 J2-3 = 7.2 Hz), 6.51 (d, 2H, H2'', H6'', J2''-3'' = 8.0 Hz), 4.21 (s, 2H, 
CH2), 3.87 (s, 3H, OCH3). 
13
C NMR (CDCl3, 100 MHz): δ (ppm) 164.53, 
154.25, 145.47, 135.18, 133.05, 131.61, 130.64, 129.92, 128.95, 128.01, 
123.21, 119.77, 114.40, 114.39, 55.82, 39.22. 
 
5.1.3.2.1.5.23.       4-Bromo-N-((3-(4-chlorophenyl)-1-((4-methoxyphenyl) 
sulfonyl)-1H-pyrazol-4-yl)methyl)aniline (12g). Yield: 35%, m.p. = 169 – 
171 °C from AcOEt/n-Hexane; Anal. Calc. C23H19BrClN3O3S: C 51.84, H 
3.59, Br 15.00, Cl 6.65, N 7.89, S 6.02; found C 51.64, H 3.60, Br 14.96, Cl 
6.63, N 7.92, S 6.04. 
1
H NMR (CDCl3, 400 MHz): δ (ppm) 8.07 (s, 1H, 
pyrazole-H5), 7.95(d, 2H, H2', H6', J2'-3' = 8.0 Hz), 7.59 (d, 2H, H2, H6 J2-3 = 
7.2 Hz), 7.35 (d, 2H, H3', H5', J2'-3' = 8.0 Hz), 7.26 (m, 2H, H3'', H5''), 6.99 (d, 
2H, H3, H5, J2-3 = 7.2 Hz), 6.46 (d, 2H, H2'', H6'', J2''-3''= 8.0 Hz), 4.22 (s, 2H, 
CH2), 3.87 (s,3H, OCH3). 
13
C NMR (CDCl3, 100 MHz): δ (ppm) 164.55, 
154.22, 146.01, 135.19, 132.09, 131.59, 130.69, 129.92, 128.94, 129.23, 
128.94, 128.04, 119.80, 114.82, 114.68, 110.18, 55.82, 39.09. 
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5.1.3.2.1.5.24.  N-((3-(4-Chlorophenyl)-1-((4-methoxyphenyl)sulfonyl)-1H 
-pyrazol-4-yl)methyl)-4-methylaniline (12h). Yield: 35%, m.p. = 169 – 171 
°C from AcOEt/n-Hexane; Anal. Calc. for C24H22ClN3O3S: C 61.60, H 4.74, 
Cl 7.58, N 8.98, S 6.85; found C 61.75, H 4.75, Cl 7.61, N 9.01, S 6.83. 
1
H 
NMR (CDCl3, 400 MHz): δ (ppm) 8.12 (s, 1H, pyrazole-H5), 7.99 (d, 2H, 
H2', H6', J2'-3' = 8.0 Hz), 7.64 (d, 2H, H2, H6, J2-3 = 7.2 Hz ), 7.37 (d, 2H, H3', 
H5', J2'-3' = 8.0 Hz), 7.01 (m, 4H, H3, H5, H3'', H5''), 6.46 (d, 2H, H2'', H6'', 
J2''-3''= 8.0 Hz), 4.22 (s, 2H, CH2), 3.87 (s, 3H, OCH3), 2.28 (s, 3H, -CH3). 
13
C 
NMR (CDCl3, 100 MHz): δ (ppm) 164.47, 154.33, 144.82, 135.07, 131.61, 
130.63, 130.10, 129.87, 129.32, 128.88, 128.94, 128.23, 127.89, 120.42, 
114.63, 113.50, 55.78, 39.49, 20.42. 
 
5.1.3.2.1.5.25.  N-((1-((4-Methoxyphenyl)sulfonyl)-3-(p-tolyl)-1H-pyrazol-
4-yl)methyl)aniline (12i). Yield: 40%, m.p. = 154 – 155 °C from AcOEt/n-
Hexane; Anal. Calc. for C24H23 N3O3S: C 66.49, H 5.35, N 9.69, S 7.40; found 
C 66.68, H 5.37, N 9.66, S 7.32. 
1
H NMR (CDCl3, 400 MHz): δ (ppm) 7.97 
(s, 1H, pyrazole-H5), 7.95 (d, 2H, H2, H6, J2-3 = 8.0 Hz), 7.54 (d, 2H, H2', 
H6', J2'-3' = 8.0 Hz), 7.19 – 7.15 (m, 4H, H3', H5', H3'', H5''), 6.96 (d, 2H, H3, 
H5, J2-3 = 8.0), 6.77 (t, 1H, H4'' J3''-4''= 7.6 Hz), 6.60 (d, 2H, H2'', H6'', J2''-3'' = 
7.6 Hz), 4.27 (s, 2H, CH2), 3.85 (s, 3H, OCH3), 2.35 (s, 3H, CH3). 
13
C NMR 
(CDCl3, 100 MHz): δ (ppm) 163.81, 154.99, 146.88, 138.52, 130.83, 130.05, 
128.87, 128.83, 128.21, 127.93, 127.39, 120.04, 117.70, 114.06, 112.62, 
55.25, 38.70, 20.80. 
 
5.1.3.2.1.5.26.  4-Chloro-N-((1-(4-methoxyphenyl)sulfonyl)-3-(p-tolyl)-1H-
pyrazol-4-yl)methyl)aniline (12j). Yield: 56%, m.p. = 157 – 158 °C from 
AcOEt/n-Hexane; Anal. Calc. for C24H22ClN3O3S: C 61.60, H 4.74, Cl 7.58, 
N 8.98, S 6.85; found C 61.78, H 4.75, Cl 7.56, N 8.95, S 6.87. 
1
H NMR 
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(CDCl3, 400 MHz): δ (ppm) 8.03 (s, 1H, pyrazole-H5), 7.93 (d, 2H, H2, H6, 
J2-3 = 7.2 Hz), 7.52 (d, 2H, H2', H6', J2'-3' = 8.0 Hz), 7.18 (d, 2H, H3, H5, J2-3 = 
8.0 Hz), 7.09 (d, 2H, H3'', H5'', J2''-3'' = 8.0 Hz ), 6.95 (d, 2H, H3, H5, J2-3 = 7.2 
Hz), 6.48 (d, 2H, H2'', H6'', J2''-3'' = 8.0 Hz), 4.22 (s, 2H, CH2), 3.85 (s, 3H, 
OCH3), 2.36 (s, 3H, CH3) . 
13
C NMR (CDCl3, 100 MHz): δ (ppm) 164.37, 
155.44, 145.82, 139.10, 131.31, 130.60, 129.39, 129.13, 128.63, 128.33, 
127.84, 122.77, 120.11, 114.58, 114.24, 55.77, 39.25, 21.31. 
 
5.1.3.2.1.5.27.  4-Bromo-N-((1-(4-methoxyphenyl)sulfonyl)-3-(p-tolyl)-1H-
pyrazol-4-yl)methyl)aniline (12k). Yield: 33%, m.p. = 151 – 153 °C from 
AcOEt/n-Hexane; Anal. Calc. for C24H22BrN3O3S: C 56.25, H 4.33, Br 15.59, 
N 8.20, S 6.26; found C 56.08, H 4.34, Br 15.63, N 8.23, S 6.23. 
1
H NMR 
(CDCl3, 400 MHz): δ (ppm) 8.07 (s, 1H, pyrazole-H5), 7.96 (d, 2H, H2, H6, 
J2-3 = 8.8 Hz), 7.54 (d, 2H, H2', H6',  J2'-3' = 8.0 Hz), 7.28 – 7.20 (m, 4H, H3', 
H5', H3'', H5''), 7.01 (d, 2H, H3, H5, J2-3 = 8.8 Hz ), 6.47(d, 2H, H2'', H6'', J2''-
3'' = 8.8 Hz), 4.26 (s, 2H, CH2), 3.88 (s, 3H, OCH3), 2.38 (s, 3H, -CH3) . 
13
C 
NMR (CDCl3, 100 MHz): δ (ppm) 164.36, 155.45, 146.26, 139.13, 132.01, 
131.34, 130.54, 129.41, 128.57, 128.24, 127.83, 120.06, 114.68, 114.59, 
109.76, 55.80, 39.11, 21.35. 
 
5.1.3.2.1.5.28.  N-((1-((4-Methoxyphenyl)sulfonyl)-3-(p-tolyl)-1H-pyrazol-
4-yl)methyl)-4-methylaniline (12l). Yield: 25%, m.p. = 145 – 146 °C from 
CHCl3/n-Hexane; Anal. Calc. for C25H25N3O3S: C 67.09, H 5.63, N 9.39, S 
7.16; found C 66.90, H 5.64, N 9.40, S 7.15. 
1
H NMR (CDCl3, 400 MHz): δ 
(ppm) 8.07 (s, 1H, pyrazole-H5), 7.95 (d, 2H, H2, H6, J2-3 = 8.8 Hz), 7.56 (d, 
2H, H2', H6',  J2'-3' = 8.0 Hz), 7.18 (d, 2H, H3', H5', J2'-3' 8.0 Hz ), 6.99 – 6.95 
(m, 4H, H3, H5, H3'', H5''), 6.53(d, 2H, H2'', H6'', J2''-3'' = 8.8 Hz), 4.24 (s, 2H, 
CH2), 3.85 (s, 3H, OCH3), 2.35 (s, 3H, CH3), 2.25 (s, 3H, CH3). 
13
C NMR 
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(CDCl3, 100 MHz): δ (ppm) 163.80, 155.02, 144.41, 138.46, 130.85, 130.04, 
129.30, 128.84, 128.26, 128.01, 127.40, 127.38, 120.09, 114.04, 113.00, 
55.23, 39.13, 20.80, 19.91. 
 
5.1.3.2.1.6. General procedure for the synthesis of the 1-benzyl-3-
phenyl-1H-pyrazole-4-carbaldehydes (13a-c). 
NaH (4 mmol) was added to a stirred solution of the appropriate 3-
phenyl-1H-pyrazole-4-carbaldehyde 6a-c (4 mmol) in dry THF (90 ml). The 
mixture was stirred for 30 min at room temperature, than benzyl bromide (5 
mmol) was added. After stirring for 24 h at room temperature, water was 
added to the mixture and THF was removed under reduced pressure. The 
suspension obtained was extracted with ethyl acetate and the organic phase 
was washed with brine and dried on Na2SO4 anhydrous, filtered and 
evaporated to dryness. The residue was purified by column chromatography 
on silica gel eluting with a mixture of AcOEt and n-Hexane (1:3). 
 
5.1.3.2.1.6.1. 1-Benzyl-3-(4-bromophenyl)-1H-pyrazole-4-carbaldehyde 
(13a). Yield: 78%, m.p. = 83 – 84 °C from n-Hexane. 1H NMR (CDCl3, 400 
MHz): δ (ppm) 9.87 (s, 1H, CHO), 7.92 (s, 1H, pyrazole-H5), 7.67 (d, 2H, 
H2', H6', J2'-3' = 8.4 Hz), 7.57 (d, 2H, H3', H5', J2'-3' = 8.4 Hz), 7.38 – 7.36 (m, 
3H, H3, H4, H5), 7.30 (d, 2H, H2, H6, J2-3 = 7.6 Hz), 5.32 (s, 2H, CH2). 
13
C 
NMR (CDCl3, 100 MHz): δ (ppm) 183.78, 151.94, 134.38, 134.01, 131.28, 
130.06, 129.90, 128.65, 128.34, 127.85, 122.91, 120.81, 56.25. 
 
5.1.3.2.1.6.2. 1-Benzyl-3-(4-chlorophenyl)-1H-pyrazole-4-carbaldehyde 
(13b). Yield: 52%, m.p. = 95 – 96 °C from n-Hexane. 1H NMR (CDCl3, 400 
MHz): δ (ppm) 9.77 (s, 1H, CHO), 7.82 (s, 1H, pyrazole-H5), 7.63 (d, 2H, 
H3', H5', J2'-3' = 8.4 Hz), 7.32 – 26 (m, 5H, H3, H4, H5, H2', H6'), 7.19 (d, 2H, 
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H2, H6, J2-3 = 7.6 Hz), 5.22 (s, 2H, CH2). 
13
C NMR (CDCl3, 100 MHz): δ 
(ppm) 183.77, 151.90, 134.60, 134.37, 134.05, 130.86, 129.63, 128.64, 
128.32, 127.84, 126.59, 120.82, 56.23. 
 
5.1.3.2.1.6.3. 1-Benzyl-3-(p-tolyl)-1H-pyrazole-4-carbaldehyde (13c). 
Yield: 64%, m.p. = 100 – 101 °C from n-Hexane. 1H NMR (DMSO, 400 
MHz): δ (ppm) 9.86 (s, 1H, CHO), 8.65 (s, 1H, pyrazole-H5), 7.71 (d, 2H, 
H2', H6', J2'-3' = 8.0 Hz), 7.38 – 7.36 (m, 6H, H3, H4, H5, H3', H5'), 7.25 (d, 
2H, H2, H6, J2-3 = 8.0 Hz ), 5.35 (s, 2H, CH2). 
13
C NMR (DMSO-d6, 100 
MHz): δ (ppm) 184.45, 152.00, 138.21, 137.21, 136.25, 128.99, 128.78, 
128.65, 128.35, 127.97, 127.92, 120.93, 55.26, 20.81. 
 
5.1.3.2.1.7. General procedure for the synthesis of N-((1-benzyl-3-
phenyl-1H-pyrazol-4-yl)methylene)aniline (14a-l). 
The suitable aniline (2.4 mmol) was added to a solution of the 
appropriate 1-benzyl-3-phenyl-1H-pyrazole-4-carbaldehyde 13a-c (2.3 mmol) 
in dry ethanol (40 ml) and glacial acetic acid (0.1 ml). The mixture was 
refluxed for 6 h under magnetic stirring. After cooling, water was added and 
the ethanol was removed under reduced pressure. The obtained suspension 
was extracted with ethyl acetate and the organic layer was washed with brine, 
dried on Na2SO4 anhydrous, filtered and evaporated to dryness. The residual 
oil was used for the next reaction without further purification. 
 
5.1.3.2.1.8. General procedure for the synthesis of the N-((1-benzyl-3-
phenyl-1H-pyrazol-4-yl)methyl)aniline (15a-l ). 
To a stirred solution of the crude 1-benzyl-3-phenyl-1H-pyrazol-4-yl-
methyleneaniline 14a-l (2.4 mmol) in dry THF (67 ml) at room temperature, 
NaBH4 (2.4 mmol) was added and the mixture was stirred at room 
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temperature for 24 h. After this period, water was added and THF was 
removed under reduced pressure. The suspension was extract with ethyl 
acetate and the organic phase was washed with brine, dried under Na2SO4 
anhydrous, filtered and evaporated to dryness. The residue obtained was 
purified by column chromatography on silica gel eluting with a mixture of 
AcOEt and n-Hexane (1:3).   
 
5.1.3.2.1.8.1. N-((1-Benzyl-3-(4-bromophenyl)-1H-pyrazol-4-yl)methyl) 
aniline (15a). Yield: 23%, m.p. = 102 – 103 °C from n-Hexane; Anal. Calc. 
for C23H20BrN3: C 66.04, H 4.82, Br 19.10, N 10.04; found C 66.35, H 4.82, 
Br 19.04, N 10.08. 
1
H NMR (CDCl3, 400 MHz): δ (ppm) 7.60 (d, 2H, H2', 
H6', J2'-3' = 8.6 Hz), 7.49 (d, 2H, H3', H5', J2'-3' = 8.6 Hz), 7.38 – 7.31 (m, 4H, 
pyrazole-H5, H3, H4, H5), 7.26 – 7.23 (m, 2H, H2, H6), 7.18 (t, 2H, H3'', 
H5'', J2''-3'' = J3''-4''  = 8.0 Hz), 6.74 (t, 1H, H4'', J3''-4'' = 8.0 Hz), 6.68 (d, 2H, 
H2'', H6'', J2''-3'' = 8.0 Hz),  5.29 (s, 2H, CH2Ar), 4.21 (s, 2H, CH2NH). 
13
C 
NMR (CDCl3, 100 MHz): δ (ppm) 148.82, 147.62, 136.20, 132.30, 131.77, 
130.66, 129.33, 129.13, 128.91, 128.24, 127.89, 121.83, 118.09, 116.90, 
113.16, 56.28, 39.23. 
 
5.1.3.2.1.8.2. N-((1-Benzyl-3-(4-bromophenyl)-1H-pyrazol-4-yl)methyl)-
4-chloroaniline (15b). Yield: 34%, m.p. = 131 – 132 °C from n-Hexane; 
Anal. Calc. for C23H19BrClN3: C 61.01, H 4.23, Br 17.65, Cl 7.83, N 9.28; 
found C 60.85, H 4.24, Br 17.69, Cl 7.85, N 9.30. 
1
H NMR (CDCl3, 400 
MHz): δ (ppm) 7.57 (d, 2H, H3', H5', J2'-3' = 8.5 Hz), 7.50 (d, 2H, H2', H6', J2'-
3' = 8.5 Hz), 7,36 – 7.32 (m, 4H, pyrazole-H5, H3, H4, H5), 7.26 – 7.25 (m, 
2H, H2, H6), 7.11 (d, 2H, H3'', H5'', J2''-3'' = 8.8 Hz), 6.51 (d, 2H, H2'', H6'', 
J2''-3'' = 8.8 Hz ), 5.29 (s, 2H, CH2Ar), 4.18 (s, 2H, CH2NH). 13C NMR (CDCl3, 
100 MHz): δ (ppm) 148.79, 146.08, 136.11, 132.19, 131.80, 130.59, 129.14, 
129.07, 128.93, 128.29, 127.90, 122.65, 121.90, 116.47, 114.18, 56.31, 39.28. 
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5.1.3.2.1.8.3. N-((1-Benzyl-3-(4-bromophenyl)-1H-pyrazol-4-yl)methyl)-
4-bromoaniline (15c). Yield: 16%, m.p. = 143 – 144 °C from n-Hexane; 
Anal. Calc. for C23H19Br2N3: C 55.56, H 3.83, Br 32.14, N 8.45; found C 
55.77, H 3.82, Br 32.01, N 8.47. 
1
H NMR (CDCl3, 400 MHz): δ (ppm) 7.55 
(d, 2H, H2', H6', J2'-3' =  8.0 Hz), 7.50 (d, 2H, H3', H5', J2'-3' =  8.0 Hz), 7.39 – 
7.32 (m 4H, pyrazole-H5, H3, H4, H5),  7.27 – 7.23 (m, 4H, H2, H6, H3'', 
H5'' ), 6.49 (d, 2H, H2'', H6'', J2''-3'' =  8.0 Hz),  5.30 (s, 2H, CH2Ar), 4.19 (s, 
2H, CH2NH). 
13
C NMR (CDCl3, 100 MHz): δ (ppm) 148.78, 146.46, 136.11, 
132.19, 132.01, 131.81, 130.61, 129.07, 128.93, 128.29, 127.90, 121.91, 
116.40, 114.70, 109.74, 56.31, 39.19. 
 
5.1.3.2.1.8.4. N-((1-Benzyl-3-(4-bromophenyl)-1H-pyrazol-4-yl)methyl)-
4-methylaniline (15d). Yield: 10%, m.p. = 109 – 110 °C from n-Hexane; 
Anal. Calc. for C24H22BrN3: C 66.67, H 5.13, Br 18.48, N 9.72; found C 
66.89, H 5.13, Br 18.41, N 9.75. 
1
H NMR (CDCl3, 400 MHz): δ (ppm) 7.59 
(d, 2H, H2', H6', J2'-3' = 8.4 Hz), 7,49 (d, 2H, H3', H5', J2'-3' = 8.4 Hz), 7.41 (s, 
1H, pyrazole-H5), 7.37 – 7.31 (m, 3H, H3, H4, H5), 7.26 (d, 2H, H2, H6, J2-3 
= 7.2 Hz), 6.99 (d, 2H, H3'', H5'', J2''-3'' = 8.0 Hz), 6.56 (d, 2H, H2'', H6'', J2''-3'' 
=8.0 Hz), 5.29 (s, 2H, CH2Ar), 4.20 (s, 2H, CH2NH), 2.25 (s, 1H, CH3). 
13
C 
NMR (CDCl3, 100 MHz): δ (ppm) 148.85, 14.16, 136.22, 132.31, 131.75, 
130.69, 129.81, 129.15, 128.89, 128.22, 127.87, 127.54, 121.79, 116.93, 
113.49, 56.26, 39.64, 20.46. 
 
5.1.3.2.1.8.5. N-((1-Benzyl-3-(4-chlorophenyl)-1H-pyrazol-4-yl)methyl) 
aniline (15e). Yield: 16%, m.p. = 115 – 116 °C from n-Hexane; Anal. Calc. 
for C23H20ClN3: C 73.89, H 5.39, Cl 9.48, N 11.24; found C 74.10, H 5.41, Cl 
9.45, N 11.20. 
1
H NMR (CDCl3, 400 MHz): δ (ppm) 7.67 (d, 2H, H2', H6', J2'-
3' =  8.4 Hz), 7.38 – 7.31 (m, 6H, pyrazole-H5, H3, H4, H5, H3', H5'), 7.26 – 
7.24 (m, 2H, H2, H6), 7.18 (t, 2H, H3'', H5'', J2''-3'' = J3''-4''  = 8.0 Hz), 6.74 (t, 
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H, H4'', J3''-4'' = 8.0 Hz), 6.62 (d, 2H, H2'', H6'', J2''-3'' = 8.0 Hz), 5.29 (s, 2H, 
CH2Ar), 4.21 (s, 2H, CH2NH). 
13
C NMR (CDCl3, 100 MHz): δ (ppm) 148.82, 
147.65, 136.22, 133.60, 131.84, 130.65, 129.34, 128.91, 128.83, 128.40, 
128.24, 127.89, 118.06, 116.87, 113.14, 56.27, 39.22. 
 
5.1.3.2.1.8.6. N-((1-Benzyl-3-(4-chlorophenyl)-1H-pyrazol-4-yl)methyl)-
4-chloroaniline (15f). Yield: 59%, m.p. = 140 – 141 °C from n-Hexane; 
Anal. Calc. for C23H19Cl2N3: C 67.65, H 4.69, Cl 17.37, N 10.29; found C 
67.86, H 4.70, Cl 17.43, N 10.33. 
1
H NMR (CDCl3, 400 MHz): δ (ppm) 7.61 
(d, 2H, , H3', H5', J2'-3' = 8.44 Hz), 7,40 – 732 (m 6H, pyrazole-H5, H3, H4, 
H5, H2', H6'),  7.27 – 725 (m, 2H, H2, H6), 7.11 (d, 2H, H3'', H5'', J2''-3'' = 8.7 
Hz), 6.54 (d, 2H, H2'', H6'', J2''-3'' = 8.7 Hz ), 5.30 (s, 2H, CH2Ar), 4.20 (s, 2H, 
CH2NH). 
13
C NMR (CDCl3, 100 MHz): δ (ppm) 148.78, 146.09, 136.14, 
133.68, 131.76, 130.58, 129.14, 128.93, 128.86, 128.78, 128.29, 127.89, 
122.66, 116.45, 114.20, 56.29, 39.30. 
 
5.1.3.2.1.8.7. N-((1-Benzyl-3-(4-chlorophenyl)-1H-pyrazol-4-yl)methyl)-
4-bromoaniline (15g). Yield: 63%, m.p. = 133 – 134 °C from n-Hexane; 
Anal. Calc. for C23H19BrClN3: C 61.01, H 4.23, Br 17.65, Cl 7.83, N 9.28; 
found C 61.20, H 4.22, Br 17.59, Cl 7.86, N 9.31. 
1
H NMR (CDCl3, 400 
MHz): δ (ppm) 7.62 (d, 2H, H3', H5', J2'-3' = 8.3 Hz), 7.37 – 7.34 (m 6H, 
pyrazole-H5, H3, H4, H5, H2', H6'), 7.26 – 7.23 (m, 4H, H2, H6, H3'', H5'' ), 
6.48 (d, 2H, H2'', H6'', J2''-3'' = 8.7 Hz), 5.29 (s, 2H, CH2Ar), 4.18 (s, 2H, 
CH2NH). 
13
C NMR (CDCl3, 100 MHz): δ (ppm) 148.78, 146.30, 136.08, 
133.55, 131.98, 130.56, 128.88, 128.82, 128.74, 128.24, 127.85, 116.25, 
114.76, 109.82, 56.25, 39.22 
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5.1.3.2.1.8.8. N-((1-Benzyl-3-(4-chlorophenyl)-1H-pyrazol-4-yl)methyl)-
4-methylaniline (15h). Yield: 27%, m.p. = 106 – 107 °C from n-Hexane; 
Anal. Calc. for C24H22ClN3: C 74.31, H 5.72, Cl 9.14, N 10.83; found C 
74.02, H 5.74, Cl 9.17, N 10.80. 
1
H NMR (CDCl3, 400 MHz): δ (ppm) 7.66 
(d, 2H, H3', H5', J2'-3' = 8.4 Hz), 7.38 – 7.31 (m, 6H, pyrazole-H5, H3, H4, 
H5, H2', H6'), 7.25 (d, 2H, H2, H6, J2-3 = 7.8 Hz),  7.01 (d, 2H, H3'', H5'', J2''-
3'' = 8.2 Hz ), 6.55 (d, 2H, H2'', H6'', J2''-3'' = 8.2 Hz), 5.29 (s, 2H, CH2Ar), 4.19 
(s, 2H, CH2NH). 
13
C NMR (CDCl3, 100 MHz): δ (ppm) 148.78, 145.25, 
136.21, 133.52, 131.83, 130.61, 129.76, 128.85, 128.79, 128.77, 128.18, 
127.83, 127.39, 116.95, 113.37, 56.20, 39.55, 20.42. 
 
5.1.3.2.1.8.9. N-((1-Benzyl-3-(p-tolyl)-1H-pyrazol-4-yl)methyl)aniline (15i). 
Yield: 14%, m.p. = 106 – 107 °C from n-Hexane; Anal. Calc. for C24H23N3: C 
81.55, H 6.56, N 11.89; found C 81.36, H 6.55, N 11.87. 
1
H NMR (CDCl3, 
400 MHz): δ (ppm) 7.60 (d, 2H, H2', H6', J2'-3' = 8.0 Hz), 7.35 – 7.29 (m, 4H, 
pyrazole-H5, H3, H4, H5),  7.26 – 7.22 (m, 2H, H2, H6), 7.20 – 7.14 (m, 4H, 
H3', H5', H3'', H5''), 6.71 (t, 1H, H4'', J3''-4'' = 8.0 Hz), 6.60 (d, 2H, H2'', H6'', 
J2''-3'' = 8.0 Hz), 5.28 (s, 2H, CH2Ar), 4.23 (s, 2H, CH2NH), 2.35 (s, 1H, CH3). 
13
C NMR (CDCl3, 100 MHz): δ (ppm) 149.92, 147.94, 137.46, 136.50, 
130.51, 130.31, 129.38, 129.28, 128.85, 128.12, 128.87, 127.49, 117.74, 
116.81, 113.06, 56.15, 39.26, 21.29. 
 
5.1.3.2.1.8.10.  N-((1-Benzyl-3-(p-tolyl)-1H-pyrazol-4-yl)methyl)-4-chloro 
aniline (15j). Yield: 17%, m.p. = 91 – 92 °C from n-Hexane; Anal. Calc. for 
C24H22ClN3: C 74.31, H 5.72, Cl 9.14, N 10.83; found C 74.59, H 5.73, Cl 
9.16, N 10.86. 
1
H NMR (CDCl3, 400 MHz): δ (ppm) 7.54 (d, 2H, H2', H6', J2'-
3' = 8.0 Hz), 7.37 – 7.31 (m, 4H, pyrazole-H5, H3, H4, H5), 7.26 - 725 (m, 
2H, H2, H6), 7.19 (d, 2H, H3', H5', J2'-3' = 8.0 Hz), 7.09 (d, 2H, H3'', H5'', J2''-3'' 
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= 8.8 Hz ), 6.53 (d, 2H, H2'', H6'', J2''-3'' = 8.8 Hz),  5.30 (s, 2H, CH2Ar), 4.22 
(s, 2H, CH2NH), 2.36 (s, 1H, CH3). 
13
C NMR (CDCl3, 100 MHz): δ (ppm) 
149.96, 146.12, 137.55, 136.39, 130.37, 130.26, 129.39, 129.07, 128.86, 
128.16, 127.87, 127.45, 122.55, 116.22, 114.29, 56.18, 39.44, 21.27. 
 
5.1.3.2.1.8.11.  N-((1-Benzyl-3-(p-tolyl)-1H-pyrazol-4-yl)methyl)-4-bromo 
aniline (15k). Yield: 26%, m.p. = 94–95 °C from n-Hexane; Anal. Calc. for 
C24H22BrN3: C 66.67, H 5.13, Br 18.48, N 9.72; found C 66.51, H 5.1, Br 
18.42, N 9.69 
1
H NMR (CDCl3, 400 MHz): δ (ppm) 7.55 (d, 2H, H2', H6', J2'-
3' =  8.0 Hz), 7.34 – 7.30 (m, 4H, pyrazole-H5, H3, H4, H5),  7.26 – 7.18 (m, 
6H, H2, H6, H3', H5', H3'', H5'' ), 6.48 (d, 2H, H2'', H6'', J2''-3'' =  8.8 Hz),  
5.29 (s, 2H, CH2Ar), 4.20 (s, 2H, CH2NH), 2.35 (s, 1H, CH3). 
13
C NMR 
(CDCl3, 100 MHz): δ (ppm) 149.93, 146.60, 137.56, 136.39, 131.94, 130.36, 
130.25, 129.39, 128.86, 128.16, 127.87, 127.43, 116.20, 114.72, 109.51, 
56.18, 39.30, 21.27. 
 
5.1.3.2.1.8.12.  N-((1-Benzyl-3-(p-tolyl)-1H-pyrazol-4-yl)methyl)-4-methyl 
aniline (15l). Yield: 15%, m.p. = 104 – 105 °C from n-Hexane; Anal. Calc. 
for C25H25N3: C 81.71, H 6.86, N 11.43; found C 81.95, H 6.84, N 11.47. 
1
H 
NMR (CDCl3, 400 MHz): δ (ppm) 7.60 (d, 2H, , H2', H6', J2'-3' = 8.0 Hz), 7.35 
– 7.29 (m, 4H, pyrazole-H5, H3, H4, H5),  7.25 – 7.22 (m, 2H, H2, H6), 7.18 
(d, 2H, H3', H5', J2'-3' = 8.0 Hz), 6.97 (d, 2H, H3'', H5'', J2''-3'' = 8.4 Hz ), 6.53 
(d, 2H, H2'', H6'', J2''-3'' = 8.4 Hz),  5.28 (s, 2H, CH2Ar), 4.21 (s, 2H, CH2NH), 
2.35 (s, 1H, CH3), 2.23 (s, 1H, CH3). 
13
C NMR (CDCl3, 100 MHz): δ (ppm) 
149.91, 145.64, 137.41, 136.54, 130.55, 130.30, 129.76, 129.37, 128.83, 
128.09, 128.86, 127.49, 127.05, 116.96, 113.30, 56.14, 39.64, 21.29, 20.46. 
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5.1.3.2.1.9. General procedure for the synthesis of the (E)-1,3-
diphenyl-4-styryl-1H-pyrazole (18a-i). 
A solution of the appropriate diethyl benzyphosphonate (1.9 mmol) in 
dry THF (10 ml) was added dropwise to a stirred suspension of sodium 
hydride (1.9 mmol) in dry THF (5 ml). The mixture was stirred for 10 min at 
room temperature, then a solution of the appropriate 1,3-diphenyl-1H-
pyrazole-4-carbaldehyde 17a-c (1.8 mmol) in dry THF (5 ml) was added 
dropwise. After stirring for 24 hours at room temperature, water was added to 
the mixture and THF was removed under reduced pressure. The solid 
collected by filtration was washed with water, and purified by column 
chromatography on silica gel eluting with a mixture of ethyl acetate and n-
Hexane 1:3.  
 
5.1.3.2.1.9.1. (E)-3-(4-Bromophenyl)-1-phenyl-4-styryl-1H-pyrazole (18a). 
Yield: 13%, m.p. = 139 – 140 °C from n-Hexane; Anal. Calc. for C23H17BrN2: 
C 68.84, H 4.27, Br 19.91, N 6.98; found C 68.99, H 4.28, Br 19.84, N 7.00. 
1
H NMR (CDCl3, 400 MHz): δ (ppm) 8.17 (s, 1H, pyrazole-H5), 7.77 (d, 2H, 
H2', H6', J2'-3' = 8.0 Hz), 7.64 – 7.59 (m, 4H, H3, H5, H3', H5'), 7.49 – 7.43 
(m, 4H, H2, H6, H2'', H6''), 7.37 – 7.29 (m, 3H, H4, H3'', H5''), 7.27 – 7.24 
(m, 1H, H4''), 7.04 (d, 1H, Hα, Jα-β = 16.4 Hz), 6.95 (d, 1H, Hβ, Jα-β = 16.4 
Hz). 
13
C NMR (CDCl3, 100 MHz): δ (ppm) 150.63, 139.76, 137.31, 132.14, 
131.81, 130.07, 129.53, 129.44, 128.77, 127.59, 126.77, 126.23, 124.68, 
122.39, 120.27, 119.11, 118.28. 
 
5.1.3.2.1.9.2.     (E)-3-(4-Bromophenyl)-4-(4-chlorostyryl)-1-phenyl-1H-
pyrazole (18b). Yield: 15%, m.p. = 175 – 176 °C from n-Hexane; Anal. Calc. 
for C23H16BrClN2: C 63.40, H 3.70, Br 18.34, Cl 8.14, N 6.43; found C 63.21, 
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H 3.71, Br 18.41, Cl 8.11, N 6.44. 
1
H NMR (CDCl3, 400 MHz): δ (ppm) 8.15 
(s, 1H, pyrazole-H5), 7.77 (d, 2H, H2, H6, J2-3 = 7.6 Hz), 7.60 (s, 4H, H2', 
H6', H2'', H6''), 7.47 (t, 2H, H3, H5, J2-3 = 7.6 Hz), 7.35 – 7.29 (m, 5H, H4, 
H3', H5', H3'', H5''), 6.99 (d, 1H, Hα, Jα-β = 16.4 Hz), 6.88 (d, 1H, Hβ, Jα-β = 
16.4 Hz). 
13
C NMR (CDCl3, 100 MHz): δ (ppm) 150.66, 139.68, 135.80, 
133.09, 132.02, 131.80, 130.04, 129.50, 128.88, 128.02, 127.32, 126.82, 
124.69, 122.44, 119.94, 119.09, 118.70. 
 
5.1.3.2.1.9.3.     (E)-3-(4-Bromophenyl)-4-(4-methylstyryl)-1-phenyl-1H-
pyrazole (18c). Yield: 10%, m.p. = 149 – 150 °C from n-Hexane; Anal. Calc. 
for C24H19BrN2: C 69.41, H 4.61, Br 19.24, N 6.74; found C 69.61, H 4.62, Br 
19.31, N 6.76. 
1
H NMR (CDCl3, 400 MHz): δ (ppm) 8.14 (s, 1H, pyrazole-
H5), 7.76 (d, 2H, H2', H6', J2'-3' = 7.6 Hz), 7.64 – 7.58 (m, 4H, H2, H6, H3', 
H5'), 7.46 (t, 2H, H3, H5, J2-3 = 7.6 Hz), 7.34 – 7.28 (m, 3H, H4, H2'', H6''),  
7.15 (d, 2H, H3'', H5'', J2''-3'' = 8.0 Hz), 6.68 (d, 1H, Hα, Jα-β = 16.4 Hz), 6.91 
(d, 1H, Hβ, Jα-β = 16.4 Hz), 2.35 (s, 3H, CH3). 
13
C NMR (CDCl3, 100 MHz): δ 
(ppm) 150.49, 139.78, 137.48, 134.51, 121.19, 131.74, 130.02, 129.47, 
129.44, 129.42, 126.67, 126.11, 124.54, 122.29, 120.41, 119.05, 117.25, 
21.24. 
 
5.1.3.2.1.9.4. (E)-3-(4-Chlorophenyl)-1-phenyl-4-styryl-1H-pyrazole (18d). 
Yield: 13%, m.p. = 124 – 125 °C from n-Hexane; Anal. Calc. for C23H17ClN2: 
C 77.41, H 4.80, Cl 9.94, N 7.85; found C 77.12, H 4.81, Cl 9.97, N 7.83. 
1
H 
NMR (CDCl3, 400 MHz): δ (ppm) 8.16 (s, 1H, pyrazole-H5), 7.77 (d, 2H, 
H2', H6', J2'-3' = 7.8 Hz), 7.69 (d, 2H, H2, H6, J2-3 = 8.4 Hz), 7.49 – 7.43 (m, 
6H, H3, H5, H3', H5', H2'', H6''), 7.36 – 7.29 (m, 3H, H4, H3'', H5''), 7.27 – 
7.24 (m, 1H, H4''), 7.04 (d, 1H, Hα, Jα-β = 16.4 Hz), 6.95 (d, 1H, Hβ, Jα-β = 
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16.4 Hz). 
13
C NMR (CDCl3, 100 MHz): δ (ppm) 150.62, 139.78, 137.33, 
134.16, 131.69, 129.78, 129.52, 129.41, 128.86, 128.77, 127.58, 126.75, 
126.22, 124.66, 120.27, 119.11, 118.31. 
 
5.1.3.2.1.9.5.     (E)-3-(4-Chlorophenyl)-4-(4-chlorostyryl)-1-phenyl-1H-
pyrazole (18e). Yield: 23%, m.p. = 169 – 170 °C from n-Hexane; Anal. Calc. 
for C23H16Cl2N2: C 70.60, H 4.12, Cl 18.12, N 7.16; found C 70.88, H 4.12, 
Cl 18.19, N 7.18. 
1
H NMR (CDCl3, 400 MHz): δ (ppm) 8.17 (s, 1H, pyrazole-
H5), 7.77 (d, 2H, H2, H6, J2-3 = 8.0 Hz), 7.67 (d, 2H, H2', H6', J2'-3' = 8.8 Hz), 
7.5 – 7.44 (m, 4H, H3, H5, H2'', H6''), 7.37 – 7.29(m, 5H, H4, H3', H5', H3'', 
H5''), 7.01 (d, 1H, Hα, Jα-β = 16.4 Hz), 6.90 (d, 1H, Hβ, Jα-β = 16.4 Hz). 
13
C 
NMR (CDCl3, 100 MHz): δ (ppm) 150.66, 139.68, 135.80, 134.21, 133.07, 
131.55, 129.74, 129.51, 128.87, 128.85, 127.98, 127.32, 126.81, 124.67, 
119.94, 119.08, 118.89.   
 
5.1.3.2.1.9.6.     (E)-3-(4-Chlorophenyl)-4-(4-methylstyryl)-1-phenyl-1H-
pyrazole (18f). Yield: 15%, m.p. = 119 – 120 °C from n-Hexane; Anal. Calc. 
for C24H19ClN2: C 77.72, H 5.16, Cl 9.56, N 7.55; found C 77.50, H 5.18, Cl 
9.59, N 7.57. 
1
H NMR (CDCl3, 400 MHz): δ (ppm) 8.15 (s, 1H, pyrazole-
H5), 7.77 (d, 2H, H2, H6, J2-3 = 8.8 Hz), 7.69 (d, 2H, H2', H6', J2'-3' = 8.6 Hz), 
7.5. – 7.43 (m, 4H, H3, H5, H2'', H6''), 7.35 – 7.29 (m, 3H, H4, H3', H5'), 
7.15(d, 2H, H3'', H5'', J2''-3'' = 7.8 Hz), 6.99 (d, 1H, Hα, Jα-β = 16.4 Hz), 6.92 
(d, 1H, Hβ, Jα-β = 16.4 Hz), 2.36 (s, 3H, CH3). 
13
C NMR (CDCl3, 100 MHz): δ 
(ppm) 150.51, 139.80, 137.48, 135.55, 134.08, 131.74, 129.74, 129.49, 
129.44, 129.40, 128.81, 126.67, 126.12, 124.53, 120.43, 119.07, 117.30, 
21.24.   
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5.1.3.2.1.9.7. (E)-1-Phenyl-4-styryl-3-(p-tolyl)-1H-pyrazole (18g). Yield: 
30%, m.p. = 142-144 °C from n-Hexane; Anal. Calc. for C24H20N2: C 85.68, H 
5.99, N 8.33; found C 86.01, H 6.01, N 8.30. 
1
H NMR (CDCl3, 400 MHz): δ 
(ppm) 8.17 (s, 1H, pyrazole-H5), 7.78 (d, 2H, H2', H6', J2'-3' = 8.0 Hz), 7.64 (d, 
2H, H2, H6, J2-3 = 8.0 Hz), 7.48 – 7.43 (m, 4H, H3, H5, H2'', H6''), 7.35 – 7.21 
(m, 6H, H4, H3', H5', H4'', H2'', H6''),7.10 (d, 1H, Hα, Jα-β = 16.4 Hz), 6.95 (d, 
1H, Hβ, Jα-β = 16.4 Hz), 2.42 (s, 3H, CH3). 
13
C NMR (CDCl3, 100 MHz): δ 
(ppm) 151.15, 139.82, 138.00, 137.70, 130.42, 130.04, 129.81, 129.30, 129.26, 
128.47, 127.82, 126.85, 126.49, 126.43, 120.08, 118.80, 118.73, 21.35. 
 
5.1.3.2.1.9.8. (E)-4-(4-Chlorostyryl)-1-phenyl-3-(p-tolyl)-1H-pyrazole (18h). 
Yield: 33%, m.p. = 99 – 100 °C from n-Hexane; Anal. Calc. for C24H19ClN2: 
C 77.72, H 5.16, Cl 9.56, N 7.55; found C 77.41, H 5.17, Cl 9.59, N 7.53. 
1
H 
NMR (CDCl3, 400 MHz): δ (ppm) 8.14 (s, 1H, pyrazole-H5), 7.76 (d, 2H, 
H2'', H6'', J2''-3'' = 7.8 Hz), 7.61 (d, 2H, H2', H6', J2'-3' = 7.8 Hz), 7.45 (t, 2H, 
H3, H5 J3-4 = 7.7 Hz), 7.34 – 7.27 (m, 7H, H2, H6, H4, H3', H5', H3'', H5''),  
7.05 (d, 1H, Hα, Jα-β = 16.4 Hz), 6.87 (d, 1H, Hβ, Jα-β = 16.4 Hz), 2.41 (s, 3H, 
CH3). 
13
C NMR (CDCl3, 100 MHz): δ (ppm) 151.22, 139.78, 138.03, 136.65, 
132.06, 130.34, 130.04, 129.81, 129.21, 128.49, 128.15, 127.92, 126.90, 
126.57, 119.89, 119.73, 118.75, 21.34. 
 
5.1.3.2.1.9.9. (E)-4-(4-Methylstyryl)-1-phenyl-3-(p-tolyl)-1H-pyrazole (18i). 
Yield: 40%, m.p. = 140 – 141 °C from n-Hexane; Anal. Calc. for C25H22N2: C 
85.68, H 6.33, N 7.99; found C 86.01, H 6.34, N 7.96. 
1
H NMR (CDCl3, 400 
MHz): δ (ppm) 8.14 (s, 1H, pyrazole-H5), 7.77 (d, 2H, H2, H6, J2-3 = 7.6 Hz), 
7.64 (d, 2H, H2', H6', J2'-3' = 8.0 Hz), 7.45 (t, 2H, H3, H5 J3-4 = 7.6 Hz), 7.33 
(d, 2H, H2'', H6'', J2''-3'' = 8.0 Hz), 7.29 – 7.26 (m, 3H, H4, H3', H5'), 7.13 (d, 
2H, H3'', H5'', J2''-3'' = 8.0 Hz),  7.00 (d, 1H, Hα, Jα-β = 16.4 Hz), 6.92 (d, 1H, 
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Hβ, Jα-β = 16.4 Hz), 2.41 (s, 3H, CH3), 2.34 (s, 3H, CH3). 
13
C NMR (CDCl3, 
100 MHz): δ (ppm) 151.77, 139.87, 137.90, 137.21, 134.76, 130.26, 129.40, 
129.37, 129.29, 128.71, 128.42, 126.41, 126.08, 124.22, 120.29, 119.01, 
117.87, 21.33, 21.22. 
 
5.1.3.2.2. Biology 
The cytotoxicity and antiviral assays were performed by Prof. Roberta 
Loddo, Department of Biomedical Sciences, Microbiology and Virology 
Section, University of Cagliari.  
The new compounds were evaluated following the experimental 
protocol previously described in chapter 5.1.1.3. and 5.1.2.1.   
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5.1.4. Conclusions and perspectives  
The initial hits identified by the antiviral screening of a library of our 
compounds, have been structurally modified in order to enhance their anti-
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flavivirus or anti-pestivirus potency. Results of the SAR studies on the novel 
series of 1,3,4-trisubstituted-1H-pyrazoles (11a–p, 12a-l, 15a–l and 18a–i) 
designed and synthesized, allowed the selection of  N-((3-phenyl-1-
(phenylsulfonyl)-1H-pyrazol-4-yl)methyl)anilines (11a–p) as a new 
generation of hits for the development of potent and selective inhibitors of 
YFV replication. Time of addition studies are in progress in order to 
determine the possible step(s) of YFV replication cycle which are inhibited by 
compound 11k, selected for its high potency and low cytotoxicity. The 
identification of the molecular target for these compounds is necessary to 
address a further systematic optimization process.   
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5.2. Pyrazoline-based antiviral agents  
 
5.2.1. Design, synthesis and antiviral evaluation of new 1,3,5-
trisubstituted 4,5-dihydropyrazoles   
Pursuing our research on anti-Flaviridae compounds, we devoted our 
attention to pyrazoline analogues of previously described pyrazole 
derivatives. The first series of pyrazolines synthesized and tested (4a-i) 
retained the N-phenylsulfonyl and the 3-phenyl substituent present in 
previously studied pyrazole analogues, while a phenyl ring was introduced at 
C5 pyrazoline ring position (Figure 1). 
 
 
Unfortunately, these pyrazoline derivatives (4a-i) were inactive against 
all the viruses tested. 
In a second series of compounds, the phenylsulfonyl moiety at the N1 
position of the pyrazoline ring was replaced by a phenyl moiety bearing a 
sulfonamide group at the para position (5a-j, 6a-j, 7a-j). Either electron-
donor or withdrawing groups were introduced at the ortho, meta or para 
position of the 5-phenyl substituent while the phenyl ring at the 3 position 
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was unsubstituted or bore a bulky substituent such as a phenoxy or a 
benzyloxy at the para position (Figure 2). 
Encouraged by the potent anti-YFV activity of several 1-3,5-triphenyl-
pyrazolines, we also explored the replacement of the phenyl ring at the 3-
position of the pyrazoline ring with a styryl moiety. The sulfonamide group at 
the para position of the N1-phenyl ring was retained (9k-o) or replaced with a 
methyl substituent (9f-j). For comparison, the unsubstituted analogues (9a-e) 
were also synthesized. For easy of synthesis, the same substituent was 
introduced at the para position of 3-styryl and 5-phenyl moieties (Figure 2). 
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5.2.1.1. Results and discussion 
5.2.1.1.1. Chemistry 
   The 1,3,5-trisubstituted 4,5-dihydropyrazoles (4a-i, 5a-j, 6a-j and 7a-j) 
were synthesized according to Scheme 1. Chalcones 1a-l, 2a-j and 3a-j were 
obtained by Claisen-Schmidt condensation between substituted benzaldehyde 
and suitable acetophenone in basic alcoholic medium. The subsequent 
reaction between the appropriate chalcone and commercially available 
benzenesulfonylhydrazide or synthesized 4-hydrazinylbenzenesulfonamide in 
ethanol provided compounds 4a-i and 5a-j, 6a-j, 7a-j, respectively. The 
reaction proceeds via hydrazone formation and successive cyclization to 
pyrazolines. The formation of the pyrazoline derivatives was confirmed in 
1
H 
NMR spectra by the disappearance of signals for olefinic protons (between 
7.20 – 8.20 ppm) and the presence of three double doublets for the two 
methylene protons in position 4 (~ 4 ppm and ~ 3.9 ppm) and for the proton 
in position 5 (~ 5 ppm). 
As depicted in Scheme 2, (E)-1,5-diphenyl-3-styryl-4,5-dihydro-1H-
pyrazoles (9a-o) were synthesized in two steps starting from the cross-aldol 
condensation of the suitable benzaldehyde and acetone (2:1) in basic ethanolic 
solution. The obtained 1,5-diphenylpenta-1,4-dien-3-ones (8a-e) were 
subsequently refluxed with substituted phenylhydrazine in acidic ethanolic 
solution in order to obtain the target pyrazolines (9a-o).  
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5.2.1.1.2. Antiviral tests 
Cytotoxicity and antiviral activity of the new compounds (4a-i, 5 a-j, 6 
a-j, 7a-j and 9a-o) and reference inhibitors are reported in Tables 1-5. Each 
compound was evaluated in cell based assays for its cytotoxicity and antiviral 
activity against the panel of RNA and DNA viruses reported in chapter 
5.1.1.2. All the derivatives able to interfere with YFV and/or BVDV 
replication were tested against two additional significant human pathogens 
such as DENV-2 and WNV. 
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Data listed in Table 1 showed that compounds 4a-i were devoid of 
antiviral activity up to the highest concentration tested, corresponding to the 
CC50 for the specific host cells. The only exception was represented by 
derivatives 4e (R = H, R‟ = 4-Cl) that was able to interfere with YFV 
replication at high concentrations (CC50 = 63.5 M). 
As far as the antiviral activity reported in table 2, the majority of the 
new 1-3,5-triphenyl-pyrazolines (5a-j, 6a-j, 7a-j) interfered with YFV 
replication in the low micromolar concentrations (EC50s ranging from 1.8 to 
2.2 M) providing almost a 10-fold improvement in potency compared to the 
reference inhibitor 6-azauridine (EC50 = 20 M). However, the unsubstituted 
(5a-j) and the phenoxy (6a-j) analogues were generally endowed with 
significant cytotoxicity against BHK-21 cells resulting in compounds with 
modest selectivity indexes. On the contrary, the benzyloxy derivatives (7a-j) 
showed lower cytotoxicity and higher selectivity indexes, as a consequence. 
In particular, 7a (R = H) and the fluoro substituted derivatives 7b and 7d 
coupled high potency and selectivity. In addition, the majority of the 
benzyloxy derivatives (7a-j) inhibited also the BVDV replication, generally 
showing higher activity and selectivity than the reference compound ribavirin 
(EC50 = 19 M, SI = 3.2). 
All the analogues were inactive against the other two members of the 
Flavivirus genus (WNV and DENV-2) utilized in the antiviral tests (Table 2). 
When tested against HIV-1, Reo-1, Sb-1, VV, HSV-1, and VSV, all the 
compounds were devoid of antiviral activity up to the highest concentration 
tested, while five phenoxy derivatives (6a-e) and three benzyloxy analogues 
(7c, 7i, 7j) inhibited CVB-5 with EC50s ranging from 3.5 µM to 13.0 µM 
(Table 3). 
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Table 1. Cytotoxicity and antiviral activity of 3,5-diphenyl-1-(phenylsulfonyl)-4,5-
dihydro-1H-pyrazoles 4a-i against ssRNA
+
 (BVDV, YFV, CVB-5, Sb-1), ssRNA
- 
(VSV, 
RSV), dsRNA (Reo-1) and DNA (VV, HSV-1) viruses. 
 
 
Compds R R1 
MDBK 
aCC50 
(µM) 
BVDV 
bEC50 
(µM) 
BHK-21 
cCC50 
(µM) 
YFV 
dEC50 
(µM) 
Reo-1 
dEC50 
(µM) 
Vero76 
eCC50 
(µM) 
CVB-5 Sb-1 VV HSV-1 VSV RSV 
fEC50 
(µM) 
4a H H 67 >67 >100 >100 >100 95 >95 >95 >95 >95 >95 >95 
4b H 3-CH3 44 >44 95 >95 >95 32 >32 >32 >32 >32 >32 >32 
4c H 4-CH3 >100 >100 >100 >100 >100 90 >90 >90 >90 >90 >90 >90 
4d H 4-F 53 >53 >100 >100 >100 36 >36 >36 >36 >36 >36 >36 
4e H 4-Cl 66 >66 >100 63.5±3.5 >100 70 >70 >70 >70 >70 >70 >70 
4f H 3-Br >100 >100 >100 >100 >100 80 >80 >80 >80 >80 >80 >80 
4g H 4-Br >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 
4h OPh 3-CH3 >100 ≥100 54 >54 >54 ≥100 >100 >100 >100 >100 >100 >100 
4i OPh 4-CH3 >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 
Ref. compd.  
Ribavirin >100 16.0±2.0    >100      37.5±2.5 
6-Azauridine   >100 41.0±1.5  ≥100      1.8±0.25 
NM 107   >100  7.5±1.5        
ACG      >100    2.9±0.1   
Pleconaril      70 
0.0025 
±0.0005 
2.0±0.1     
NM 5255      20   2.0±0.1    
Data represent mean values for three independent determinations. Variation among duplicate samples was less than 15%. 
aCompound concentration required to reduce the viability of mock-infected MDBK (Bovine normal kidney) cells by 50%, as determined 
by the MTT method. bCompound concentration required to achieve 50% protection of MDBK cells from the BVDV-induced 
cytopathogenicity, as determined by the MTT method. cCompound concentration required to reduce the viability of mock-infected BHK 
(Hamster normal kidney fibroblast) monolayers by 50%, as determined by the MTT method. dCompound concentration required to 
reduce the viability of mock-infected BHK cells from the YFV and Reo-1 induced cytopathogenicity, as determined by the MTT 
method. eCompound concentration required to reduce the viability of mock-infected VERO76 (monkey normal kidney) monolayers by 
50%. fCompound concentration required to reduce the plaque number of CVB-5 (Coxsackievirus B5), Sb-1 (Poliovirus 1), VV (Vaccina 
virus), HSV-1 (Herpesvirus 1), VSV ( Vescicular Stomatitis Virus) and RSV (Respiratory Syncytial Virus) by 50% in VERO76 
monolayers.  
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Table 2. Cytotoxicity and antiviral activity of 4-(3,5- diphenyl-4,5-dihydro-1H-pyrazol-1-yl) 
benzenesulfonamides (5a-j, 6a-j, 7a-j) against ssRNA
+
 (BVDV, YFV, DENV-2, WNV) viruses. 
 
Compds R R1 
MDBK      
aCC50 
(µM) 
BVDV            
bEC50 
(µM) 
eSI 
CC50/EC50 
BHK-21  
dCC50 
(µM) 
YFV         
eEC50 
(µM) 
eSI    
CC50/EC50 
DENV-2        
fEC50 
(µM) 
WNV         
gEC50 
(µM) 
5a H H 16 >16 - 15 >10  - - - 
5b H 2-F 19 >19 - 21 >22 - - - 
5c H 3-F 20 >20 - 15 ≥12 - - - 
5d H 4-F 18 >18 - 12 2.6±0.4 4.6 >12 >12 
5e H 2-Cl 9 >9 - 13 2.4±0.4 5.4 >13 >13 
5f H 3-Cl 2 >2 - 8 2.5±0.1 3.2 >8 >8 
5g H 4-Cl 11 >11 - 32 >32 - - - 
5h H 2-CH3 18 >18 - 14 2.2±0.2 6.4 >14 >14 
5i H 3-CH3 23 >23 - 25 >25 - - - 
5j H 4-CH3 32 >32 - 7 2.2±0.2 3.2 >7 >7 
6a OPh H 5 >5 - 11 2.1±0.1 5.2 >11 >11 
6b OPh 2-F 36 >36 - 32 1.9±0.1 16.8 >32 >32 
6c OPh 3-F 12 >12 - 11 1.8±0.2 6.1 >11 >11 
6d OPh 4-F 6 >6 - 8 1.8±0.2 4.4 >8 >8 
6e OPh 2-Cl 5 >5 - 8 1.8±0.2 4.4 >8 >8 
6f OPh 3-Cl 6 >6 - 9 2.2±0.2 4.1 >9 >9 
6g OPh 4-Cl 19 >19 - 7 1.9±0.1 3.7 >7 >7 
6h OPh 2-CH3 16 >16 - 7 2.2±0.2 3.2 >7 >7 
6i OPh 3-CH3 6 >6 - 8 1.8±0.1 4.4 >8 >8 
6j OPh 4-CH3 21 >21  - 8 1.8±0.1 4.4 >8 >8 
7a OBn H 72 >72 - 84 2.2±0.2 38.2 >84 >84 
7b OBn 2-F >100 52.0±10.0 >1.9 92 1.8±0.2 51.1 >92 >92 
7c OBn 3-F 17 10.0±1.0  1.7 9 2.0±0.05 4.5 >9 >9 
7d OBn 4-F >100 >100 - 69 1.9±0.1 36.3 >69 >69 
7e OBn 2-Cl 55 7.5±3.5 7.3 12 1.9±0.1 6.3 >12 >12 
7f OBn 3-Cl 38 5.5±0.5 6.9 47 2.0±0.05 23.5 >47 >47 
7g OBn 4-Cl 19 4.5±1.5 4.2 16 1.9±0.1  8.4 >16 >16 
7h OBn 2-CH3 >100 >100 - 20 1.8±0.2 11.1 >20 >20 
7i OBn 3-CH3 53 12.5±4.5 4.2 8 1.8±0.2 4.4 >8 >8 
7j OBn 4-CH3 78 2.5±0.5 31.2 32 1.8±0.2 17.8 >32 >32 
Ref. Compds.    
Ribavirin 61 19 3.2      
6-Azauridine    >100 20 >5   
NM 108    47 108 0.7   
Data represent mean values for three independent determinations. Variation among duplicate samples was less than 15%. 
aCompound concentration required to reduce the viability of mock-infected MDBK (Bovine normal kidney) cells by 50%, as determined 
by the MTT method. bCompound concentration required to achieve 50% protection of MDBK cells from the BVDV-induced 
cytopathogenicity, as determined by the MTT method. cSelectivity index (SI) was the ratio between CC50 and EC50.   
dCompound 
concentration required to reduce the viability of mock-infected BHK (Hamster normal kidney fibroblast) monolayers by 50%, as 
determined by the MTT method. eCompound concentration required to reduce the viability of mock-infected BHK cells from the YFV-
induced cytopathogenicity, as determined by the MTT method. .  fCompound concentration required to achieve 50% protection of BHK 
cells from DENV-2 induced cytopathogenicity, as determined by the MTT method. gCompound concentration required to achieve 50% 
protection of BHK cells from WNV induced cytopathogenicity, as determined by the MTT method. 
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Table 3. Cytotoxicity and antiviral activity of 4-(3,5- diphenyl-4,5-dihydro-1H-pyrazol-1-
yl)benzenesulfonamides (5a-j, 6a-j, 7a-j) against ssRNA
+
 (HIV-1, CVB-5, Sb-1), ssRNA
-
 
(VSV, RSV), dsRNA (Reo-1) and DNA (VV, HSV-1) viruses.  
 
Compds R R1 
MT-4 
aCC50   
(µM) 
HIV-1 
bEC50 
(µM) 
BHK-21 
cCC50   
(µM) 
Reo-1 
dEC50 
(µM) 
Vero76 
eCC50 
(µM) 
CVB-5 
fEC50 
(µM) 
gSI 
CC50/
EC50 
Sb-1 VV HSV-1 VSV RSV 
hEC50  
(µM) 
5a H H 42 >42 15 >15 22 > 22 - >22 >22  >22 >22 >22 
5b H 2-F 42 >42 21 >21 28 > 28 - >28 >28 >28 >28 >28 
5c H 3-F 43 13 15 >15 24 > 24 - >24 >24 >24 >24 >24 
5d H 4-F 45 >45 12 >12 23 > 23 - >23 >23 >23 >23 >23 
5e H 2-Cl 44 >44 13 >13 26 > 26 - >26 >26 >26 >26 >26 
5f H 3-Cl 41 8.5 8 >8 21 > 21 - >21 >21 >21 >21 >21 
5g H 4-Cl 36 >36 32 >32 21 > 21 - >21 >21 >21 >21 >21 
5h H 2-CH3 43 >43 14 >14 24 > 24 - >24 >24 >24 >24 >24 
5i H 3-CH3 37 >37 25 >25 25 > 25 - >25 >25 >25 >25 >25 
5j H 4-CH3 40 >40 7 >7 20 > 20 - >20 >20 >20 >20 >20 
6a OPh H 41 12 11 >11 90/35 3.5±0.5  25.7 >90 >90 >90 >90 >35 
6b OPh 2-F 36 >36 32 >32 97 7.0±1.0 13.8 >97 >97 >97 >97 >97 
6c OPh 3-F 25 >25 11 >11 24 4.2±0.2 5.7 >24 >24 >24 >24 >24 
6d OPh 4-F 33 >33 8 >8 26 6.0±1.0 4.3 >26 >26 >26 >26 >26 
6e OPh 2-Cl 40 >40 8 >8 27 10.5±0.5 2.6 >27 >27 >27 >27 >27 
6f OPh 3-Cl 8 >8 9 >9 88 > 88 - >88 >88 >88 >88 >88 
6g OPh 4-Cl 9 >9 7 >7 88 > 88 - >88 >88 >88 >88 >88 
6h OPh 2-CH3 30 13 7 >7 90/14 > 90 - >90 >90 >90 >90 >14 
6i OPh 3-CH3 35 >35 8 >8 81/14 > 81 - >81 >81 >81 >81 >14 
6j OPh 4-CH3 7.2 >7.2 8 >8 86/20 > 86  - >86 >86 >86 >86 >20 
7a OBn H >100 >100 84 >84 > 100 > 100 - >100 >100 >100 >100 >100 
7b OBn 2-F 39 >39 92 >92 > 100 > 100 - >100 >100 >100 >100 >100 
7c OBn 3-F 65 >65 9 >9 95/25 8.5±2.5   11.2 >95 >95 >95 >95 >25 
7d OBn 4-F >100 >100 69 >69 90 > 90 - >90 >90 >90 >90 >90 
7e OBn 2-Cl 26 >26 12 >12 92 > 92 - >92 >92 >92 >92 >92 
7f OBn 3-Cl 33 13 47 >47 85 > 85 - >85 >85 >85 >85 >85 
7g OBn 4-Cl 70 >70 16 >16 82 > 82 - >82 >82 >82 >82 >82 
7h OBn 2-CH3 ≥100 >100 20 >20 100 > 100 - >100 >100 >100 >100 >100 
7i OBn 3-CH3 44 >44 8 >8 100 8.0±2.0 12.5 >100 >100 >100 >100 >100 
7j OBn 4-CH3 35 >35 32 >32 100 13.0±4.5  7.7 >100 >100 >100 >100 >100 
Ref. Compds.  
EFV 37 0.002          
Ribavirin     >100       30 
6-Azauridine   >100 19 17       2 
ACG     >100     1.6   
Pleconaril     80 0.02 4000 2.5     
NM 5255     8    1.3    
Data represent mean values for three independent determinations. Variation among duplicate samples was less than 15%. 
aCompound concentration required to reduce the viability of mock-infected MT-4 (cd4+ Human T-cells containing an integrated HTL V-
1 genome) cells by 50%, as determined by the MTT method. bCompound concentration required to achieve 50% protection of MT-4 
cells from the HIV-1 induced cytioathigenicity, as determined by the MTT method. cCompound concentration required to reduce the 
viability of mock-infected BHK (hamster normal kidney fibroblast) monolayers by 50%, as determined by the MTT method. 
dCompound concentration required to achieve 50% protection of BHK cells (kidney fibroblast) from the Reo (Reovirus 1), induced 
cytopathogenicity, as determined by the MTT method. eCompound concentration required to reduce the viability of mock-infected 
VERO76 (monkey normal kidney) monolayers by 50%. fCompound concentration required to reduce the plaque number of CVB-5 
(Coxsackievirus B5) by 50% in VERO76 monolayers. gSelectivity index (SI) was the ratio between CC50 and EC50. 
hCompound 
concentration required to reduce the plaque number of Sb-1 (Poliovirus 1), VV (Vaccina virus), HSV-1 (Herpesvirus 1), VSV 
(Vescicular Stomatitis Virus) and RSV (Respiratory Syncytial Virus) by 50% in VERO76 monolayers. 
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Concerning the activity against Flaviviridae of pyrazolines 9a-o, the 
results reported in Table 4 showed that the replacement of the phenyl ring 
at the 3-position of the pyrazoline ring with a styryl moiety results in 
compounds devoid of efficacy or exhibiting a specific activity against YFV. 
The only exception to this general rule was represented by compound 9o that 
in addition to be a potent and selective anti-YFV inhibitor (EC50 = 1.05 µM 
and SI = 17.1) was also able to interfere with the replication of BVDV and 
DENV-2, although with a lower potency (EC50 = 10.0 µM and 6.9 µM, 
respectively). SAR studies reveal that the sulfonamide group at the para 
position of the N1-phenyl ring (9k-o) was necessary for an anti-YFV potency 
in a low micromolar range (EC50s ranging from 1.05 µM to 2.2 µM). The 
replacement of the sulfonamide group with a methyl substituent in the same 
position suppressed the anti-YFV activity (9f, 9g, 9j) or led to analogues 
about 10-fold less potent than corresponding benzenesulfonamides (9h, 9i) 
(EC50 = 20.0 µM and 12.0 µM, respectively). Moreover, the lack of 
substituent at the para position completely abolished the anti-YFV activity. It 
is interesting to note that all the analogues able to interfere with YFV 
replication, exhibited improved potency and sometimes better selectivity than 
the reference inhibitor 6-Azauridine (EC50 = 41.0 µM and SI = >2.4). 
Unfortunately, the presence of the sulfonamide group seems to increase the 
cytotoxicity against all the cell lines utilized. In addition, when tested against 
viruses representative of the other virus families, the benzenesulfonamides 
9k, 9l and 9n affected the HIV-1 replication (Table 5). 
  
137 
 
Table 4. Cytotoxicity and antiviral activity of (E)-1,5-diphenyl-3-styryl-4,5-dihydro-1H-
pyrazoles 9a-o against ssRNA
+
 (BVDV, YFV, DENV-2, WNV) viruses. 
 
 
 
Compds R R1 
MDBK     
aCC50  
(µM) 
BVDV      
bEC50  
(µM) 
BHK-21       
cCC50  
(µM) 
YFV         
dEC50  
(µM) 
eSI     
CC50/E
C50 
DENV-2         
fEC50  
(µM) 
WNV         
gEC50  
(µM) 
9a H H >100 >100 >100 >100 - - - 
9b Cl H >100 >100 >100 >100 - - - 
9c F H >100 >100 >100 >100 - - - 
9d CH3 H >100 >100 >100 >100 - - - 
9e OCH3 H >100 >100 >100 >100 - - - 
9f H CH3 >100 >100 >100 >100 - - - 
9g Cl CH3 >100 >100 >100 >100 - - - 
9h F CH3 >100 >100 >100 20.0±6.0 >5 >100 >100 
9i CH3 CH3 >100 >100 >100 12.0±3.5 >8.3 >100 >100 
9j OCH3 CH3 >100 >100 >100 >100 - - - 
9k H SO2NH2 38 >38 10 2.2±0.65 4.5 >10 >10 
9l Cl SO2NH2 40 >40 8.5 1.1±0.1 7.7 >8.5 >8.5 
9m F SO2NH2 45 >45 7.5 1.75±0.25 4.3 >7.5 >7.5 
9n CH3 SO2NH2 8 >8 8.5 1.05±0.05 8.09 >8.5 >8.5 
9o OCH3 SO2NH2 >100 10.0±1.0 18 1.05±0.05 17.1 6.9±1.0 >18 
Ref. Compds.    
Ribavirin >100 16.0±2.0      
6-Azauridine   >100 41.0±1.5 >2.4   
NM 108   60   1.2 0.65 
Data represent mean values for three independent determinations. Variation among duplicate samples was less than 15%. 
aCompound concentration required to reduce the viability of mock-infected MDBK (Bovine normal kidney) cells by 50%, as determined 
by the MTT method. bCompound concentration required to achieve 50% protection of MDBK cells from the BVDV-induced 
cytopathogenicity, as determined by the MTT method. cCompound concentration required to reduce the viability of mock-infected BHK 
(Hamster normal kidney fibroblast) monolayers by 50%, as determined by the MTT method. dCompound concentration required to 
reduce the viability of mock-infected BHK cells from the YFV-induced cytopathogenicity, as determined by the MTT method. 
eSelectivity index (SI) was the ratio between CC50 and EC50.  
fCompound concentration required to achieve 50% protection of BHK cells 
from DENV-2 induced cytopathogenicity, as determined by the MTT method. gCompound concentration required to achieve 50% 
protection of BHK cells from WNV induced cytopathogenicity, as determined by the MTT method 
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Table 5. Cytotoxicity and antiviral activity of (E)-1,5-diphenyl-3-styryl-4,5-dihydro-1H-
pyrazoles 9a-o against ssRNA
+
 (HIV-1, CVB-5, Sb-1), ssRNA
-
 (VSV, RSV), dsRNA 
(Reo-1) and DNA (VV, HSV-1) viruses.  
 
Compds R R1 
MT-4 
aCC50   
(µM) 
HIV-1 
bEC50 
(µM) 
BHK-21 
cCC50   
(µM) 
Reo-1 
dEC50 
(µM) 
Vero76 
eCC50 
(µM) 
CVB-5 Sb-1 VV HSV-1 VSV RSV 
fEC50  
(µM) 
9a H H >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 
9b Cl H >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 
9c F H >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 
9d CH3 H >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 
9e OCH3 H >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 
9f H CH3 >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 
9g Cl CH3 >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 
9h F CH3 >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 
9i CH3 CH3 >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 
9j OCH3 CH3 >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 
9k H SO2NH2 35 17 10 >10 65/11 >65 >65 >65 >65 >65 >11 
9l Cl SO2NH2 34 14 8.5 >8 70/12 >60 >70 >70 >70 >70 >12 
9m F SO2NH2 37 >37 7.5 >7 60/6 10.5±0.5 >60 >60 >60 >60 >6 
9n CH3 SO2NH2 42 11 8.5 >8 60/7 >60 >60 >60 >60 >60 >7 
9o OCH3 SO2NH2 14 >14 18 >18 ≥100 >100 >100 >100 >100 >100 11.1±1.0 
Ref. Compds.  
EFV 39 0.002          
Ribavirin           37.5±2.5 
6-Azauridine   >100 9.5±1.5       1.8±0.25 
ACG     >100    2.9±0.1   
Pleconaril     70 
0.0025 
±0.0005 
2.0±0.1     
NM 5255     20   2.0±0.1    
Data represent mean values for three independent determinations. Variation among duplicate samples was less than 15%. 
aCompound concentration required to reduce the viability of mock-infected MT-4 (cd4+ Human T-cells containing an integrated HTL V-
1 genome) cells by 50%, as determined by the MTT method. bCompound concentration required to achieve 50% protection of MT-4 
cells from the HIV-1 induced cytioathigenicity, as determined by the MTT method. c Compound concentration required to reduce the 
viability of mock-infected BHK (hamster normal kidney fibroblast) monolayers by 50%, as determined by the MTT method. 
dCompound concentration required to achieve 50% protection of BHK cells (kidney fibroblast) from the Reo (Reovirus 1), induced 
cytopathogenicity, as determined by the MTT method. eCompound concentration required to reduce the viability of mock-infected 
VERO76 (monkey normal kidney) monolayers by 50%. fCompound concentration required to reduce the plaque number of CVB-5 
(Coxsackievirus B5), Sb-1 (Poliovirus 1), VV (Vaccina virus), HSV-1 (Herpesvirus 1), VSV ( Vescicular Stomatitis Virus) and RSV 
(Respiratory Syncytial Virus) by 50% in VERO76 monolayers. 
 
5.2.1.1.3. Time of addition studies 
1,3,5-Triphenyl-pyrazolines 7a and 7b were selected for time of 
addition experiments because of their potencies against YFV (EC50 = 2.2 M 
and 1.8 M, respectively) and high selectivity indexes (SI = 38.2 and 51.1, 
respectively). Time of addition experiments were performed to determine the 
possible step(s) in YFV replication cycle that is inhibited by inhibitors. For 
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this purpose, the selected compounds, 7a and 7b, were added at different time 
intervals after infection of BHK-21 cell cultures with YFV. A concentration 
of 20 M, approximately 10 times the EC50 against YFV, was utilized for 
both derivatives. For comparison, the same test was performed using the 
reference inhibitor 6-Azauridine, at a concentration of 90 M. 6-Azauridine is 
a nucleoside analog inhibitor of the Orotidine 5‟-phosphate decarboxylase 
(OMP-decarboxylase). This enzyme is essential in the biosynthesis of the 
pyrimidine nucleotides, as it converts the Orotidine monophosphate (OMP) in 
Uridine monophosphate (UMP) 
1
. Data represented in Figures 1-4 indicate 
that both pyrazolines 7a and 7b exhibit maximal inhibition when added in the 
pretreatment and during infection. A similar behavior was observed for the 
reference inhibitors, at higher concentrations. The comparison of the curves 
obtained for our compounds and for the reference inhibitor could suggest a 
similar mechanism of action, however, further investigations are necessary for 
the identification of the mechanism of action. 
 
Figure 1. Effect of time of addition on antiviral activity of derivative 7a (Blue). The same 
test was performed using the reference compound 6-Azauridine (Black) for comparison. In 
red we observe the untreated control. 
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Figure 2. Effect of time of addition on antiviral activity of derivative 7a (Green). The 
same test was performed using the reference compound 6-Azauridine (Blue) for 
comparison. In red we observe the untreated control. 
 
 
 
Figure 3. Effect of time of addition on antiviral activity of derivative 7b (Blue). The same 
test was performed using the reference compound 6-Azauridine (Black) for comparison. In 
red we observe the untreated control. 
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Figure 4. Effect of time of addition on antiviral activity of derivative 7b (Green). The 
same test was performed using the reference compound 6-Azauridine (Blue) for 
comparison. In red we observe the untreated control. 
 
 
 
5.2.1.2. Experimental 
5.2.1.2.1. Chemistry 
Chemicals were purchased from Sigma-Aldrich and used without 
further purification. 4-Benzyloxyacetophenone and 4-hydrazinylbenzene 
sulfonamide were synthetized according to the procedures previously 
reported 
2, 3
. Melting points were determined on a Stuar Scientific SMP1 
apparatus and are uncorrected. 
1
H NMR and 
13
C NMR spectra were recorded 
on a Bruker AM-400 spectrometer in CDCl3 or DMSO-d6, and chemical shifts 
were reported in ppm (). All compounds were routinely checked by thin-
layer chromatography (TLC). TLC was performed on silica gel or aluminium 
oxide fluorescent coated plates (Fluka, DC-Alufolien Kieselgel or aluminum 
oxide F254). Compound purity was determined by elemental analysis and was 
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confirmed to be > 95% for all the tested compounds. Analytical results are 
within ±0.40% of the theoretical values. 
 
5.2.1.2.1.1. General procedure for the synthesis of chalcones 1a-l, 2a-j 
and 3a-j. 
Barium hydroxide octahydrate (10 mmol) was added to a solution of 
the suitable acetophenone (10 mmol) and substituted benzaldehyde (12 mmol) 
in ethanol (150 ml). The reaction mixture was stirred overnight at 30°C; then 
water was added and the mixture was acidified with 2N HCl, until 
precipitation was observed. The precipitate was collected by filtration, 
washed with water and crystallized. Spectroscopic data of chalcones 1a-l, 2a-j 
and 3a-j are identical to those previously reported 
4-10
.  
 
5.2.1.2.1.2. General procedure for the synthesis of the 3,5-Diphenyl-1-
(phenylsulfonyl)-4,5-dihydro-1H-pyrazoles (4a-i).  
A solution of the suitable chalcone (3 mmol) and benzenesulfonyl 
hydrazide (3 mmol) in ethanol (60 ml) was refluxed and stirred for 6h. 
Subsequently the stirring was carried on at room temperature for 18 hours. 
Afterward, the mixture was poured into crushed ice and the precipitate was 
collected by filtration, washed with water and dried. The crude solid was 
purified by crystallization from suitable solvent (4b-g) or by column 
chromatography on silica gel eluting with a mixture of AcOEt and n-Hexane 
1:3 (4a, 4h, 4i). 
 
5.2.1.2.1.2.1.   3,5-Diphenyl-1-(phenylsulfonyl)-4,5-dihydro-1H-pyrazole 
(4a). Yield: 20%, m.p. = 205 – 206 °C (lit. = 205 – 206 °C) 11 from AcOEt/n-
Hexane; Anal. Calc. for C21H18N2O2S: C 69.59, H 5.01, N 7.73, S 8.85; found 
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C 69.83, H 5.03, N 7.76, S 8.82. 
1
H NMR (DMSO-d6, 400 MHz): δ (ppm) 7.96 
(d, 2H, H2, H6, J = 7.6), 7.70 – 7.52 (m, 8H, H3, H4, H5, H2''- H6''), 7.24 – 
6.98 (m, 5H, H2'- H6'), 5.08 (dd, 1H, CH, J = 10.0 Hz, J = 3.2 Hz), 4.04 (dd, 
1H, CH2, Jgem = 18.0 Hz, J = 3.2 Hz), 3.91 (dd, 1H, CH2, Jgem = 18.0 Hz, J = 
10.0 Hz). 
13
C NMR (DMSO-d6, 100 MHz): δ (ppm) 154.7, 144.4, 143.5,136.4, 
131.9, 131.0, 130.0, 128.8, 128.5, 128.2, 127.3, 126.9, 126.7, 49.5, 39.0. 
 
5.2.1.2.1.2.2.     3-Phenyl-1-(phenylsulfonyl)-5-(m-tolyl)-4,5-dihydro-1H-
pyrazole (4b). Yield: 20%, m.p. = 147 – 148 °C from EtOH; Anal. Calc. for 
C22H20N2O2S: C 70.19, H 5.35, N 7.44, S 8.52; found C 70.47, H 5.37, N 
7.47, S 8.50. 
1
H NMR (CDCl3, 400 MHz): δ (ppm) 7.95 (d, 2H, H2, H6, J = 
7.6 Hz), 7.59 – 7.55 (m, 4H, H3, H4, H5, H5''), 7.48 – 7.37 (m, 4H, H3', H5', 
H4'', H6''), 7.10 – 6.96 (m, 4H, H2', H4', H6', H2''), 4.90 (dd, 1H, CH, J = 
10.0 Hz, J = 3.2 Hz), 4.10 (dd, 1H, CH2, Jgem = 18.0 Hz, J = 3.2 Hz), 3.92 (dd, 
1H, CH2, Jgem = 18.0 Hz, J = 10.0 Hz). 
13
C NMR (CDCl3, 100 MHz): δ (ppm) 
151.9, 138.6, 138.1, 137.1, 136.2, 133.6, 132.3, 130.6, 129.6, 129.1, 128.7, 
128.7, 128.3, 128.2, 126.8, 66.5, 36.11, 21.2. 
 
5.2.1.2.1.2.3.       3-Phenyl-1-(phenylsulfonyl)-5-(p-tolyl)-4,5-dihydro-1H-
pyrazole (4c). Yield: 18%, m.p. = 160 – 161 °C from EtOH/n-Hexane; Anal. 
Calc. for C22H20N2O2S: C 70.19, H 5.35, N 7.44, S 8.52; found C 69.98, H 
5.36, N 7.46, S 8.55. 
1
H NMR (DMSO-d6, 400 MHz): δ (ppm) 7.96 (d, 2H, 
H3, H6), 7.70 – 7.49 (m, 8H, H3, H4, H5, H2'-H6'), 7.14 (d, 2H, H3', H5'), 
7.04 (d, 2H, H2', H6'), 5.03 (dd, 1H, CH, J = 10.0 Hz, J = 3.2 Hz), 4.01 (dd, 
1H, CH2, Jgem = 18.0 Hz, J = 3.2 Hz), 3.87 (dd, 1H, CH2, Jgem = 18.0 Hz, J = 
10.0 Hz). 
13
C NMR (DMSO-d6, 100 MHz): δ (ppm) 151.7, 144.4, 137.9, 
136.8, 135.9, 133.9, 133.6, 129.8, 129.2, 129.0, 128.7, 128.7, 128.1, 65.2, 
36.7, 20.6. 
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5.2.1.2.1.2.4. 5-(4-Fluorophenyl)-3-phenyl-1-(phenylsulfonyl)-4,5-dihydro-
1H-pyrazole (4d). Yield: 17%, m.p. = 155 – 156 °C from EtOH; Anal. Calc. 
for C21H17FN2O2S: C 66.30, H 4.50, F 4.99,  N 7.36, S 8.43; found C 66.31, H 
4.51, F 4.96, N 7.35, S 8.43. 
1
H NMR (DMSO-d6, 400 MHz): δ (ppm) 7.93 
(d, 2H, H2', H6', J = 8.4 Hz), 7.60 – 7.56 (m, 4H, H3', H5', H2 H6), 7.49 – 
7.39 (m, 5H, H4', H3, H4, H5), 7.17 (t, 2H, H2'', H6'', J2''-3''  = 8.4 Hz, J2''-F= 
6.0 Hz), 6.90 (t, 2H, H3'', H5'', J2''-3'' = J3”-F= 8.4 Hz), 4.90 (dd, 1H, CH, J = 
10.0 Hz, J = 3.2 Hz), 4.11 (dd, 1H, CH2, Jgem = 18.0 Hz, J = 3.2 Hz), 3.89 (dd, 
1H, CH2, Jgem = 18.0 Hz, J = 10.0 Hz). 
13
C NMR (DMSO-d6, 100 MHz): δ 
(ppm) 170.1 (d), 161.0, 145.4, 136.6, 136.0 (d), 135.9, 134.1, 133.7, 132.0 
(d), 129.1, 128.7, 128.1, 115.0 (d), 64.6, 36.7. 
 
5.2.1.2.1.2.5. 5-(4-Chlorophenyl)-3-phenyl-1-(phenylsulfonyl)-4,5-dihydro-
1H-pyrazole (4e). Yield: 20%, m.p. = 157 – 158 °C from EtOH/n-Hexane; 
Anal. Calc. for C21H17ClN2O2S: C 63.55, H 4.32, Cl 8.93, N 7.06, S 8.08; 
found C 63.80, H 4.33, Cl 8.90, N 7.07, S 8.11. 
1
H NMR (DMSO-d6, 400 
MHz): δ (ppm) 7.97 (d, 2H, H2, H6), 7.69 – 7.52 (m, 8H, H3, H4, H5, H2'-
H6'), 7.32 (m, 4H, H2'', H3'', H5'', H6''), 5.15 (dd, 1H, CH, J = 10.0 Hz, J = 
3.2 Hz), 4.07 (dd, 1H, CH2, Jgem = 18.0 Hz, J = 3.2 Hz), 3.93 (dd, 1H, CH2, 
Jgem = 18.0 Hz, J = 10.0 Hz). 
13
C NMR (DMSO-d6, 100 MHz): δ (ppm) 166.2, 
136.6, 135.8, 134.1, 133.6, 133.3, 131.7, 131.5, 129.1, 128.7, 128.1, 124.8, 
114.8, 64.7, 36.6. 
 
5.2.1.2.1.2.6. 5-(3-Bromophenyl)-3-phenyl-1-(phenylsulfonyl)-4,5-dihydro-
1H-pyrazole (4f). Yield: 17%, m.p. = 156 – 157 °C from EtOH/n-Hexane; 
Anal. Calc. for C21H17BrN2O2S: C 57.15, H 3.88, Br, 18.10, N 6.35, S 7.27; 
found C 56.96, H 3.89, Br, 18.04, N 6.36, S 7.29. 
1
H NMR (DMSO-d6, 400 
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MHz): δ (ppm) 7.98 (d, 2H, H2, H6), 7.70 – 7.21 (m, 12H, H3, H4, H5, H2'- 
H6', H2'', H4'', H5'', H6''), 5.16 (dd, 1H, CH, J = 10.0 Hz, J = 3.2 Hz), 4.11 
(dd, 1H, CH2, Jgem = 18.0 Hz, J = 3.2 Hz), 3.93(dd, 1H, CH2, Jgem = 18.0 Hz, J 
= 10.0 Hz). 
13
C NMR (DMSO-d6, 100 MHz): δ (ppm) 161.9, 136.5, 135.8, 
135.1, 134.1, 133.6, 132.8, 131.4, 130.1, 129.1, 128.9, 128.8, 128.7, 128.1, 
121.2, 64.82, 36.5. 
 
5.2.1.2.1.2.7. 5-(4-Bromophenyl)-3-phenyl-1-(phenylsulfonyl)-4,5-dihydro-
1H-pyrazole (4g). Yield: 20%, m.p. = 159 – 160 °C from EtOH/n-Hexane; 
Anal. Calc. for C21H17BrN2O2S: C 57.15, H 3.88, Br, 18.10, N 6.35, S 7.27; 
found C 57.35, H 3.90, Br, 18.15, N 6.34, S 7.25. 
1
H NMR (DMSO-d6, 400 
MHz): δ (ppm) 7.96 (d, 2H, H3'', H5'', J = 7.6 Hz), 7.73 – 7.63 (m, 8H, H2- 
H6, H4', H2'', H6''), 7.45 (d, 2H, H3', H5', J = 8.0 Hz), 7.24 (d, 2H, H2', H6', J 
= 8.4 Hz), 5.13 (dd, 1H, CH, J = 10.0 Hz, J = 3.2 Hz), 4.06 (dd, 1H, CH2, Jgem 
= 18.0 Hz, J = 3.2 Hz), 3.91 (dd, 1H, CH2, Jgem = 18.0 Hz, J = 10.0 Hz). 
13
C 
NMR (DMSO-d6, 100 MHz): δ (ppm) 162.9, 137.1, 136.3, 134.6, 134.1, 
132.5, 132.4, 131.5, 129.6, 129.2, 128.6, 115.1, 114.9, 65.2, 37.1. 
 
5.2.1.2.1.2.8.      3-(4-Phenoxyphenyl)-1-(phenylsulfonyl)-5-(m-tolyl)-4,5-
dihydro-1H-pyrazole (4h). Yield: 11%, m.p. = 142 – 143 °C from AcOEt/n-
Hexane; Anal. Calc. for C28H24N2O3S: C 71.77, H 5.16, N 5.98, S 6.84; found 
C 72.00, H 5.17, N 5.96, S 6.82. 
1
H NMR (DMSO-d6, 400 MHz): δ (ppm) 
8.01 (d, 2H, H2, H6, J = 7.2 Hz), 7.69 (t, 1H, H5'', J = 6.8 Hz), 7.64 (d, 2H, H3, 
H5, J = 7.6 Hz), 7.55 – 7.45 (m, 4H, H3, H5, H3', H5'), 7.26 (t, 1H, H4', J = 7.2 
Hz), 7.31 – 7.02 (m, 8H, H2', H6', H2'', H4'', H6'', H2''', H4''', H6'''), 5.0 (dd, 
1H, CH,  J = 10.0 Hz, J = 3.2 Hz), 4.0 (dd, 1H, CH2, Jgem = 18.0 Hz, J = 3.2 
Hz), 3.84 (dd, 1H, CH2, Jgem = 18.0 Hz, J = 10.0 Hz), 2.18 (s, 1H, CH3). 
13
C 
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NMR (DMSO-d6, 100 MHz): δ (ppm) 161.5, 154.7, 137.1, 136.7, 133.8, 132.1, 
130.7, 130.6, 130.5, 130.3, 126.1, 128.9, 128.6, 127.9, 126.9, 124.8, 119.9, 
117.0, 65.5, 36.3, 20.7. 
 
5.2.1.2.1.2.9.       3-(4-Phenoxyphenyl)-1-(phenylsulfonyl)-5-(p-tolyl)-4,5-
dihydro-1H-pyrazole (4i). Yield: 12%, m.p. = 164 – 165 °C from AcOEt/n-
Hexane; Anal. Calc. for C28H24N2O3S: C 71.77, H 5.16, N 5.98, S 6.84; found 
C 71.52, H 5.16, N 6.00, S 6.86. 
1
H NMR (DMSO-d6, 400 MHz): δ (ppm) 
7.97 (d, 2H, H2, H6, J = 7.2 Hz), 7.65 – 7.60 (m, 3H, H2', H6', H4'), 7.53 – 
7.47 (m, 4H, H3, H5, H3''', H5''') 7.25 – 7.02 (m, 9H,  H3', H5', H2'', H3'', 
H5'', H6'', H2''', H4''', H6'''), 5.0 (dd, 1H, CH, J = 10.0 Hz, J = 3.2 Hz), 3.98 
(dd, 1H, CH2, Jgem = 18.0 Hz, J = 3.2 Hz), 3.81 (dd, 1H, CH2, Jgem = 18.0 Hz, 
J = 10.0 Hz), 2.23 (s, 3H, CH3). 
13
C NMR (DMSO-d6, 100 MHz): δ (ppm) 
166.3, 161.6, 154.7, 150.9, 137.8, 136.8, 133.9, 130.7, 130.3, 129.7, 129.2, 
128.9, 128.6, 124.8, 119.9, 117.0, 65.1, 36.3, 20.6. 
 
5.2.1.2.1.3. General procedure for the synthesis of 4-(3,5- diphenyl-4,5-
dihydro-1H-pyrazol-1-yl)benzenesulfonamides (5a-j, 6a-j, 7a-j).  
A solution of the appropriate chalcone 1a-j, 2a-j and 3a-j (10 mmol) 
and 4-hydrazinylbenzenesulfonamide 
3
 (20 mmol) in dry ethanol (70 ml) and 
potassium hydroxide (20 mmol) was refluxed for 24h with stirring. After 
cooling, the mixture was poured into crushed ice. The precipitate was filtered, 
washed with water and dried. The crude solid was purified by crystallization 
from suitable solvent.  
 
5.2.1.2.1.3.1. 4-(3,5-Diphenyl-4,5-dihydro-1H-pyrazol-1-yl)benzene 
sulfnamide (5a). Yield: 69%, m.p. = 212 – 214 °C from EtOH; Anal. Calc. 
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for C21H19N3O2S: C 66.82, H 5.07, N 11.13, S 8.49; found C 67.03, H 5.09, N 
11.09, S 8.52. 
1
H NMR (DMSO-d6, 400 MHz):  (ppm) 7.85 – 7.07 (m, 16H, 
H2-H6, H2', H3', H5', H6', H2''-H6'', NH2), 5.69 (dd, 1H, CH), 4.02(dd, 1H, 
CH2), 3.24 (dd, 1H, CH2). 
13
C NMR (DMSO-d6, 100 MHz): δ (ppm) 151.7, 
147.0, 143.5, 136.4, 131.0, 130.2, 129.3, 128.8, 128.5, 128.2, 126.9, 126.7, 
113.8, 60.4, 40.0. 
 
5.2.1.2.1.3.2. 4-(5-(2-Fluorophenyl)-3-phenyl-4,5-dihydro-1H-pyrazol-1-
yl)benzenesulfonamide (5b). Yield: 27%, m.p. = 260 – 262 °C from MeOH; 
Anal. Calc. for C21H18FN3O2S: C 63.78, H 4.59, F 4.80, N 10.63, S 8.11; 
found C 64.03, H 4.60, F 4.80, N 10.59, S 8.08. 
1
H NMR (DMSO-d6, 400 
MHz):  (ppm) 7.84 – 7.11 (m, 15H, H2-H6, H2', H3', H5', H6', H2', H3', H5', 
H6', H3''-H6'', NH2), 5.86 (dd, 1H, CH), 4.06 (dd, 1H, CH2), 3.35 (dd, 1H, 
CH2). 
13
C NMR (DMSO-d6, 100 MHz): δ (ppm) 159.4 (d), 151.7, 146.5, 
136.2, 131.01, 130.3, 129.0,128.8, 128.5 (d), 128.3 (d), 128.0, 124.0, 115.3 
(d), 113.8, 108.8 (d), 53.6, 40.1.  
 
5.2.1.2.1.3.3. 4-(5-(3-fluorophenyl)-3-phenyl-4,5-dihydro-1H-pyrazol-1-
yl)benzenesulfonamide (5c). Yield: 20%, m.p. = 158 – 160 °C from C6H6; 
Anal. Calc. for C21H18FN3O2S: C 63.78, H 4.59, F 4.80, N 10.63, S 8.11; 
found C 64.01, H 4.60, F 4.79, N 10.59, S 8.10. 
1
H NMR (DMSO-d6, 400 
MHz):  (ppm) 7.85 – 7.09 (m, 15H, H2-H6, H2', H3', H5', H6', H2', H3', H5', 
H6', H2'', H4'', H5'', H6'', NH2), 5.72 (dd, 1H, CH), 4.02 (dd, 1H, CH2), 3.27 
(dd, 1H, CH2). 
13
C NMR (DMSO-d6, 100 MHz): δ (ppm) 162.7 (d), 151.7, 
147.2, 145.1 (d), 136.4, 131.0, 130.5 (d), 130.0, 129.3, 128.8, 128.2, 122.5, 
114.2 (d), 113.7 (d), 113.0, 60.4, 40.0. 
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5.2.1.2.1.3.4. 4-(5-(4-Fluorophenyl)-3-phenyl-4,5-dihydro-1H-pyrazol-1-
yl)benzenesulfonamide (5d). Yield: 77%, m.p. = 213 – 218 °C from MeOH; 
Anal. Calc. for C21H18FN3O2S: C 63.78, H 4.59, F 4.80, N 10.63, S 8.11; 
found C 63.56, H 4.58, F 4.81, N 10.59, S 8.14. 
1
H NMR (DMSO-d6, 400 
MHz):  (ppm) 7.85 – 7.08 (m, 15H, H2-H6, H2', H3', H5', H6', H2', H3', H5', 
H6', H2'', H3'', H5'', H6'', NH2), 5.71 (dd, 1H, CH), 4.01 (dd, 1H, CH2), 3.24 
(dd, 1H, CH2). 
13
C NMR (DMSO-d6, 100 MHz): δ (ppm) 160.9 (d), 151.7, 
143.7, 139.1 (d), 136.4, 131.0, 129.5, 128.8,  128.5(d), 128.0, 120.8, 116.7, 
115.3 (d), 60.8, 40.3. 
 
5.2.1.2.1.3.5. 4-(5-(2-chlorophenyl)-3-phenyl-4,5-dihydro-1H-pyrazol-1-
yl)benzenesulfonamide (5e). Yield: 22%, m.p. = 228 – 231 °C from MeOH; 
Anal. Calc. for C21H18ClN3O2S: C 61.23, H 4.40, Cl 8.61, N 10.20, S 7.78; 
found C 61.02, H 4.41, Cl 8.59, N 10.17, S 7.81. 
1
H NMR (DMSO-d6, 400 
MHz):  (ppm) 7.85 – 7.04 (m, 15H, H2-H6, H2', H3', H5', H6', H2', H3', H5', 
H6', H3''-H6'', NH2), 5.87 (dd, 1H, CH), 4.13(dd, 1H, CH2), 3.22 (dd, 1H, 
CH2). 
13
C NMR (DMSO-d6, 100 MHz): δ (ppm) 151.7, 143.8, 142.8, 136.2, 
132.2, 131.4, 129.5, 128.8, 128.5, 128.3, 128.1, 127.8, 126.6, 120.8, 116.7, 
55.3, 39.5.   
 
5.2.1.2.1.3.6. 4-(5-(3-chlorophenyl)-3-phenyl-4,5-dihydro-1H-pyrazol-1-
yl)benzenesulfonamide (5f). Yield: 32%, m.p. = 120 – 123 °C from C6H6; 
Anal. Calc. for C21H18ClN3O2S: C 61.23, H 4.40, Cl 8.61, N 10.20, S 7.78; 
found C 61.42, H 4.41, Cl 8.63, N 10.14, S 7.76 
1
H NMR (DMSO-d6, 400 
MHz):  (ppm) 7.80 – 7.11 (m, 13H, H2-H6, H2', H3', H5', H6', H2', H3', H5', 
H6', H2'', H4'', H5'', H6''), 5.37 (dd, 1H, CH), 4.92 (s, broad, 2H, NH2), 3.95 
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(dd, 1H, CH2), 3.24 (dd, 1H, CH2). 
13
C NMR (DMSO-d6, 100 MHz): δ (ppm) 
152.2, 144.9, 143.8, 136.4, 134.1, 131.1, 129.9, 129.5, 128.8, 128.2, 126.8, 
126.7, 125.0, 120.9, 116.5, 59.9, 40.0.  
 
5.2.1.2.1.3.7.  4-(5-(4-chlorophenyl)-3-phenyl-4,5-dihydro-1H-pyrazol-1-
yl)benzenesulfonamide (5g). Yield: 37%, m.p. = 203 – 205 °C from C6H6; 
Anal. Calc. for C21H18ClN3O2S: C 61.23, H 4.40, Cl 8.61, N 10.20, S 7.78; 
found C 61.45, H 4.39, Cl 8.64, N 10.16, S 7.80. 
1
H NMR (DMSO-d6, 400 
MHz):  (ppm) 7.84 – 7.08 (m, 15H, H2-H6, H2', H3', H5', H6', H2', H3', H5', 
H6', H2'', H3'', H5'', H6'', NH2), 5.72 (dd, 1H, CH), 4.02 (dd, 1H, CH2), 3.24 
(dd, 1H, CH2). 
13
C NMR (DMSO-d6, 100 MHz): δ (ppm) 151.7, 143.8, 141.6, 
136.4, 132.3, 131.0, 129.5, 128.8, 128.6, 128.2, 127.2, 120.8, 116.7, 60.4, 40.2.  
 
5.2.1.2.1.3.8. 4-(3-Phenyl-5-(o-tolyl)-4,5-dihydro-1H-pyrazol-1-yl)benzene 
sulfonamide (5h). Yield: 23%, m.p. = 204 – 206 °C from C6H6; Anal. Calc. 
for C22H21N3O2S: C 67.50, H 5.41, N 10.73, S 8.19; found C 67.25, H 5.39, N 
10.69, S 8.21. 
1
H NMR (DMSO-d6, 400 MHz):  (ppm) 7.78 – 7.02 (m, 15H, 
H2-H6, H2', H3', H5', H6', H2', H3', H5', H6', H3''-H6'', NH2), 5.56 – 5.52 
(dd, 1H, CH), 3.98 – 3.90 (dd, 1H, CH2), 3.17 – 3.11 (dd, 1H, CH2), 2.24 (s, 
3H, CH3). 
13
C NMR (DMSO-d6, 100 MHz): δ (ppm) 152.1, 143.6, 141.8, 
136.4, 134.7, 131.0, 130.2, 129.5, 128.8, 128.2, 126.6, 125.5, 123.1, 120.8, 
116.8, 57.9, 40.3, 19.6.  
 
5.2.1.2.1.3.9. 4-(3-Phenyl-5-(m-tolyl)-4,5-dihydro-1H-pyrazol-1-yl)benzene 
sulfonamide (5i). Yield: 27%, m.p. = 200 – 203 °C from C6H6; Anal. Calc. 
for C22H21N3O2S: C 67.50, H 5.41, N 10.73, S 8.19; found C 67.73, H 5.40, N 
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10.68, S 8.16.  
1
H NMR (DMSO-d6, 400 MHz):  (ppm) 8.24 – 6.89 (m, 15H, 
H2-H6, H2', H3', H5', H6', H2', H3', H5', H6', H2'', H4'', H5'', H6'', NH2), 5.75 
(dd, 1H, CH); 4.07(dd, 1H, CH2), 3.12 (dd, 1H, CH2), 2.49 (s, 3H, CH3). 
13
C 
NMR (DMSO-d6, 100 MHz): δ (ppm) 151.7, 143.8, 141.8, 136.4, 134.7, 
131.0, 130.2, 129.5, 128.8, 128.2, 126.6, 125.5, 123.1, 120.8, 116.7, 57.7, 
40.4, 21.6.  
 
5.2.1.2.1.3.10. 4-(3-Phenyl-5-(p-tolyl)-4,5-dihydro-1H-pyrazol-1-yl)benzene 
sulfonamide (5j). Yield: 27%, m.p. = 219 – 223 °C from C6H6; Anal. Calc. 
for C22H21N3O2S: C 67.50, H 5.41, N 10.73, S 8.19; found C 67.26, H 5.40, N 
10.76, S 8.22. 
1
H NMR (DMSO-d6, 400 MHz):  (ppm) 7.84 – 7.07 (m, 15H, 
H2-H6, H2', H3', H5', H6', H2', H3', H5', H6', H2'', H3'', H5'', H6'', NH2), 5.63 
(dd, 1H, CH), 3.99 (dd, 1H, CH2), 3.2 (dd, 1H, CH2), 2.29 (s, 3H, CH3). 
13
C 
NMR (DMSO-d6, 100 MHz): δ (ppm) 151.7, 143.4, 140.5, 136.4, 136.2, 
131.1, 129.5, 128.8, 128.6, 128.2, 125.3, 120.7, 116.4, 60.4, 40.1, 22.2. 
 
5.2.1.2.1.3.11.  4-(3-(4-phenoxyphenyl)-5-phenyl-4,5-dihydro-1H-pyrazol-
1-yl)benzenesulfonamide (6a). Yield: 36%, m.p. = 175 – 178 °C from EtOH; 
Anal. Calc. for C27H23N3O3S: C 69.06, H 4.94, N 8.95, S 6.83; found C 68.80, 
H 4.96, N 8.92, S 6.78. 
1
H NMR (DMSO-d6, 400 MHz):  (ppm) 7.86 – 7.07 
(m, 20H, H2, H3, H5, H6, H2', H3', H5', H6', H2''-H6'', H2'''-H6''', NH2), 5.67 
(dd, 1H, CH), 4.0 (dd, 1H, CH2), 3.22 (dd, 1H, CH2). 
13
C NMR (DMSO-d6, 
100 MHz): δ (ppm) 159.3, 157.0, 151.7, 147.0, 143.8, 143.5, 130.0, 129.8, 
129.5, 128.5, 128.2, 126.9, 126.6, 121.8, 118.9, 117.6, 113.8, 60.4, 40.1.  
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5.2.1.2.1.3.12.     4-(5-(2-fluorophenyl)-3-(4-phenoxyphenyl)-4,5-dihydro-
1H-pyrazol-1-yl)benzenesulfonamide (6b). Yield: 25%, m.p. = 208 – 212 
°C from C6H6; Anal. Calc. for C27H22FN3O3S: C 66.51, H 4.55, F 3.90, N 
8.62, S 6.58; found C 66.75, H 4.56, F 3.90, N 8.59, S 6.60. 
1
H NMR 
(DMSO-d6, 400 MHz):  (ppm) 7.87 – 7.11 (m, 19H, H2, H3, H5, H6, H2', 
H3', H5', H6', H3''-6'', H2'''-H6''', NH2), 5.85 (dd, 1H, CH), 4.05 (dd, 1H, 
CH2), 2.50 (dd, 1H, CH2). 
13
C NMR (DMSO-d6, 100 MHz): δ (ppm) 159.5(d), 
159.3, 157.1, 151.6, 143.8, 129.8, 129.5, 128.5 (d), 128.3 (d), 127.4, 124.1, 
121.8, 120.8, 118.9, 117.6, 116.7, 115.3 (d), 113.6, 108.8 (d), 53.6. 40.0.  
 
5.2.1.2.1.3.13.     4-(5-(3-fluorophenyl)-3-(4-phenoxyphenyl)-4,5-dihydro-
1H-pyrazol-1-yl)benzenesulfonamide (6c). Yield: 54%, m.p. = 180 – 182 °C 
from EtOH; Anal. Calc. for C27H22FN3O3S: C 66.51, H 4.55, F 3.90, N 8.62, S 
6.58; found C 66.76, H 4.55, F 3.89, N 8.60, S 6.59. 
1
H NMR (DMSO-d6, 400 
MHz):  (ppm) 7.86 – 7.12 (m, 19H, H2, H3, H5, H6, H2', H3', H5', H6', H2'', 
H4'', H5'', H6'', H2'''-H6''', NH2), 5.71(dd, 1H, CH), 4.01(dd, 1H, CH2), 3.26 
(dd, 1H, CH2). 
13
C NMR (DMSO-d6, 100 MHz): δ (ppm) 162.7 (d), 159.3, 
157.0, 151.7, 147.0, 151.7, 145.0 (d), 143.8, 130.4, 130.2 (d), 128.4, 127.4, 
122.5, 121.8, 118.9, 117.6, 113.9 (d), 113.7, 113.5 (d), 60.4, 40.2.  
 
5.2.1.2.1.3.14.     4-(5-(4-fluorophenyl)-3-(4-phenoxyphenyl)-4,5-dihydro-
1H-pyrazol-1-yl)benzenesulfonamide (6d). Yield: 56%, m.p. = 184 – 187 
°C from MeOH; Anal. Calc. for C27H22FN3O3S: C 66.51, H 4.55, F 3.90, N 
8.62, S 6.58; found C 66.26, H 4.56, F 3.89, N 8.65, S 6.57. 
1
H NMR 
(DMSO-d6, 400 MHz):  (ppm) 7.86 – 7.08 (m, 19H, H2, H3, H5, H6, H2', 
H3', H5', H6', H2'', H3'', H5'', H6'', H2'''-H6''', NH2), 5.70 (dd, 1H, CH), 3.99 
(dd, 1H, CH2), 3.21(dd, 1H, CH2). 
13
C NMR (DMSO-d6, 100 MHz): δ (ppm) 
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160.9 (d), 159.3, 157.2, 151.7, 147.0, 143.8, 139.2 (d), 130.1, 129.4, 128.5 
(d), 128.3, 127.4, 121.8, 120.8, 117.7, 115.3 (d), 113.8, 60.4, 39.9.  
 
5.2.1.2.1.3.15.     4-(5-(2-chlorophenyl)-3-(4-phenoxyphenyl)-4,5-dihydro-
1H-pyrazol-1-yl)benzenesulfonamide (6e). Yield: 27% m.p. = 131 – 135 °C 
from MeOH; Anal. Calc. for C27H22ClN3O3S: C 64.34, H 4.40, Cl 7.03, N 
8.34, S 6.36; found C 64.12, H 4.41, Cl 7.06, N 8.37, S 6.38. 
1
H NMR 
(DMSO-d6, 400 MHz):  (ppm) 7.86 – 7.02 (m, 19H, H2, H3, H5, H6, H2', 
H3', H5', H6', H3''-6'', H2'''-H6''', NH2), 5.86 (dd, 1H, CH), 4.11 (dd, 1H, CH2), 
3.21(dd, 1H, CH2). 
13
C NMR (DMSO-d6, 100 MHz): δ (ppm) 159.3, 157.2, 
151.6, 143.9, 143.5, 132.2, 130.5, 129.5, 128.8, 128.6, 128.4, 128.1, 127.4, 
126.6, 121.8, 120.7, 118.9, 117.6, 113.2, 55.3, 39.5.  
 
5.2.1.2.1.3.16.     4-(5-(3-chlorophenyl)-3-(4-phenoxyphenyl)-4,5-dihydro-
1H-pyrazol-1-yl)benzenesulfonamide (6f). Yield: 60%, m.p. = 218 – 220 °C 
from MeOH; Anal. Calc. for C27H22ClN3O3S: C 64.34, H 4.40, Cl 7.03, N 
8.34, S 6.36; found C 64.58, H 4.41, Cl 7.01, N 8.36, S 6.37. 
1
H NMR 
(DMSO-d6, 400 MHz):  (ppm) 7.66 – 7.10 (m, 19H, H2, H3, H5, H6, H2', 
H3', H5', H6', H2'', H4'', H5'', H6'', H2'''-H6''', NH2), 5.70 (dd, 1H, CH), 3.99 
(dd, 1H, CH2); 3.27 (dd, 1H, CH2). 
13
C NMR (DMSO-d6, 100 MHz): δ (ppm) 
159.3, 157.4, 152.0, 144.9, 143.9, 134.1, 130.0, 129.7, 129.4, 128.4, 127.4, 
126.7, 126.6, 125.0, 121.8, 120.8, 118.9, 117.6, 116.7, 59.9, 40.3. 
 
5.2.1.2.1.3.17.     4-(5-(4-chlorophenyl)-3-(4-phenoxyphenyl)-4,5-dihydro-
1H-pyrazol-1-yl)benzenesulfonamide (6g). Yield: 60%, m.p. = 105 – 107 
°C from EtOH; Anal. Calc. for C27H22ClN3O3S: C 64.34, H 4.40, Cl 7.03, N 
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8.34, S 6.36; found C 64.53, H 4.40, Cl 7.05, N 8.36, S 6.37. 
1
H NMR 
(CDCl3, 400 MHz):  (ppm) 7.76 – 7.07 (m, 17H, H2, H3, H5, H6, H2', H3', 
H5', H6', H2'', H3'', H5'', H6'', H2'''-H6'''), 5.37 (dd, 1H, CH), 4.96 (s, 2H, 
NH2), 3.92 (dd, 1H, CH2), 3.19 (s, 1H, CH2). 
13
C NMR (CDCl3, 100 MHz): δ 
(ppm) 159.3, 157.0, 151.7, 143.7, 141.6, 132.3, 130.0, 129.4, 128.6, 128.3, 
127.4, 127.0, 121.8, 120.8, 118.9, 117.4, 114.1, 60.7, 40.1. 
 
5.2.1.2.1.3.18.  4-(3-(4-phenoxyphenyl)-5-(o-tolyl)-4,5-dihydro-1H-pyrazol- 
1-yl)benzenesulfonamide (6h). Yield: 28%, m.p. = 200 – 204 °C from EtOH; 
Anal. Calc. for C28H25N3O3S: C 69.54, H 5.21, N 8.69, S 6.63; found C 69.80, 
H 5.19, N 8.66, S 6.61. 
1
H NMR (DMSO-d6, 400 MHz):  (ppm) 7.85 – 6.90 
(m, 19H, H2, H3, H5, H6, H2', H3', H5', H6', H3''-6'', H2'''-H6''', NH2), 5.74(dd, 
1H, CH), 4.05 (dd, 1H, CH2), 3.10 (dd, 1H, CH2), 2.51(s, 3H, CH3). 
13
C NMR 
(DMSO-d6, 100 MHz): δ (ppm) 159.3, 157.0, 151.7, 143.5, 141.8, 134.7, 130.2, 
129.5, 129.3, 128.4, 127.4, 126.6, 125.5, 123.1, 121.8, 120.8,  118.9, 117.6, 
113.8, 57.9, 40.3, 19.1.  
 
5.2.1.2.1.3.19.  4-(3-(4-phenoxyphenyl)-5-(m-tolyl)-4,5-dihydro-1H-pyrazol- 
1-yl)benzenesulfonamide (6i). Yield: 37%, m.p. = 159 – 163 °C from 
MeOH; Anal. Calc. for C28H25N3O3S: C 69.54, H 5.21, N 8.69, S 6.63; found 
C 69.78, H 5.20, N 8.72, S 6.65. 
1
H NMR (CDCl3, 400 MHz):  (ppm) 7.78 – 
7.07 (m, 17H, H2, H3, H5, H6, H2', H3', H5', H6', H2'', H4'', H5'', H6'', H2'''-
H6'''), 5.36 (dd, 1H, CH), 4.74 (s, 2H, NH2), 3.93 (dd, 1H, CH2), 3.24 (dd, 1H, 
CH2), 2.23 (s, 3H, CH3). 
13
C NMR (CDCl3, 100 MHz): δ (ppm) 159.3, 156.8, 
151.7, 143.8, 143.4, 138.2, 129.8, 129.5, 128.6, 128.4, 127.4,  126.7, 123.8, 
121.8, 120.8, 118.9, 117.6, 113.8, 60.7, 40.0, 21.6. 
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5.2.1.2.1.3.20.  4-(3-(4-phenoxyphenyl)-5-(p-tolyl)-4,5-dihydro-1H-pyrazol- 
1-yl)benzenesulfonamide (6j). Yield: 60%, m.p. = 131 – 135 °C from 
MeOH; Anal. Calc. for C28H25N3O3S: C 69.54, H 5.21, N 8.69, S 6.63; found 
C 69.80, H 5.23, N 8.67, S 6.64. 
1
H NMR (CDCl3, 400 MHz):  (ppm) 7.94 – 
7.07 (m, 17H, H2, H3, H5, H6, H2', H3', H5', H6', H2'', H3'', H5'', H6'', H2'''-
H6'''), 5.37 (dd, 1H, CH), 4.80 (s, 2H, NH2), 3.86 (dd, 1H, CH2), 3.22(dd, 1H, 
CH2), 2.38 (s, 3H, CH3). 
13
C NMR (CDCl3, 100 MHz): δ (ppm) 158.8, 156.8, 
152.0, 143.8, 140.5, 136.4, 130.0, 129.5, 129.3, 128.8, 128.4, 127.4, 125.5, 
121.8, 118.9, 117.6, 113.8, 60.1, 40.2, 21.3. 
 
5.2.1.2.1.3.21.  4-(3-(4-(benzyloxy)phenyl)-5-phenyl-4,5-dihydro-1H-pyrazol- 
1-yl)benzenesulfonamide (7a). Yield: 39%, m.p. = 169 – 172 °C from C6H6; 
Anal. Calc. for C28H25N3O3S: C 69.54, H 5.21, N 8.69, S 6.63; found C 69.29, 
H 5.19, N 8.72, S 6.65. 
1
H NMR (DMSO-d6, 400 MHz):  (ppm) 7.74 – 7.01 
(m, 20H, H2, H3, H5, H6, H2', H3', H5', H6', H2''-H6'', H2'''-H6''', NH2), 5.59 
(dd, 1H, CH), 5.57 (s, 2H, CH2), 3.93 (dd, 1H, CH2), 3.15 (dd, 1H, CH2). 
13
C 
NMR (DMSO-d6, 100 MHz): δ (ppm) 161.3, 151.7, 143.8, 143.5, 136.7, 
129.5, 128.9, 128.7, 128.5, 128.4, 127.6, 127.1, 126.8, 126.4, 120.8, 114.4, 
113.7, 70.8, 60.2, 40.1.  
 
5.2.1.2.1.3.22.  4-(3-(4-(benzyloxy)phenyl)-5-(2-fluorophenyl)-4,5-dihydro- 
1H-pyrazol-1-yl)benzenesulfonamide (7b). Yield: 25%, m.p. = 188 – 192 
°C from MeOH; Anal. Calc. for C28H24FN3O3S: C 67.05, H 4.82, F 3.79, N 
8.38, S 6.39; found C 66.81, H 4.83, F 3.80, N 8.40, S 6.41. 
1
H NMR 
(DMSO-d6, 400 MHz):  (ppm) 7.79 – 7.08 (m, 19H, H2, H3, H5, H6, H2', 
H3', H5', H6', H3''-6'', H2'''-H6''', NH2), 5.79 (dd, 1H, CH), 5.20 (s, 2H, CH2), 
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4.01 (dd, 1H, CH2), 3.26 (dd, 1H, CH2). 
13
C NMR (DMSO-d6, 100 MHz): δ 
(ppm) 161.3, 159.4 (d), 151.7, 143.8, 136.5, 129.5, 128.3, 128.7, 128.6, 
128.5(d), 128.2 (d), 127.6, 127.1, 124.1, 120.8, 115.3 (d), 114.4, 113.8, 108.8 
(d), 70.5, 53.6, 40.0.  
 
5.2.1.2.1.3.23.  4-(3-(4-(benzyloxy)phenyl)-5-(3-fluorophenyl)-4,5-dihydro- 
1H-pyrazol-1-yl)benzenesulfonamide (7c). Yield: 60%, m.p. = 170 – 173 °C 
from C6H6; Anal. Calc. for C28H24FN3O3S: C 67.05, H 4.82, F 3.79, N 8.38, S 
6.39; found C 66.84, H 4.1, F 3.80, N 8.35, S 6.37. 
1
H NMR (DMSO-d6, 400 
MHz):  (ppm) 7.78 – 7.07 (m, 19H, H2, H3, H5, H6, H2', H3', H5', H6', H2'', 
H4'', H5'', H6'', H2'''-H6''', NH2), 5.66 (dd, 1H, CH), 5.21 (s, 2H, CH2), 3.96 
(dd, 1H, CH2), 3.23 (dd, 1H, CH2). 
13
C NMR (DMSO-d6, 100 MHz): δ (ppm) 
162.7 (d), 161.3, 151.5, 145.1 (d), 143.8, 136.7, 130.1 (d), 129.5, 128.9, 
128.7, 128.6, 127.6, 127.2, 122.5, 120.8, 116.7, 114.4, 113.9 (d), 113.5 (d), 
70.1, 60.1, 40.3.  
 
5.2.1.2.1.3.24.  4-(3-(4-(benzyloxy)phenyl)-5-(4-fluorophenyl)-4,5-dihydro- 
1H-pyrazol-1-yl)benzenesulfonamide (7d). Yield: 45%, m.p. = 136 – 140 
°C from MeOH; Anal. Calc. for C28H24FN3O3S: C 67.05, H 4.82, F 3.79, N 
8.38, S 6.39; found C 67.27, H 4.83, F 3.79, N 8.41, S 6.41. 
1
H NMR 
(DMSO-d6, 400 MHz):  (ppm) 7.78 – 7.07 (m, 19H, H2, H3, H5, H6, H2', 
H3', H5', H6', H2'', H3'', H5'', H6'', H2'''-H6''', NH2), 5.65 (dd, 1H, CH), 5.21 
(s, 2H, CH2), 3.94 (dd, 1H, CH2), 3.54 (dd, 1H, CH2). 
13
C NMR (DMSO-d6, 
100 MHz): δ (ppm) 161.3, 160.8 (d), 151.7, 143.1, 139.1 (d), 136.7, 129.5, 
129.8, 128.7, 128.6, 128.4 (d), 127.6, 127.1, 120.8, 115.3 (d), 114.3, 113.7, 
70.4, 60.1, 39.8. 
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5.2.1.2.1.3.25.  4-(3-(4-(benzyloxy)phenyl)-5-(2-chlorophenyl)-4,5-dihydro- 
1H-pyrazol-1-yl)benzenesulfonamide (7e). Yield: 52%, m.p. = 184 – 188 °C 
from C6H6; Anal. Calc. for C28H24ClN3O3S: C 64.92, H 4.67, Cl 6.84, N 8.11, 
S 6.19; found C 65.15, H 4.68, Cl 6.82, N 8.08, S 6.21. 
1
H NMR (DMSO-d6, 
400 MHz):  (ppm) 7.79 – 7.00 (m, 19H, H2, H3, H5, H6, H2', H3', H5', H6', 
H3''-6'', H2'''-H6''', NH2), 5.81(dd, 1H, CH), 5.20 (s, 2H, CH2), 4.04 (dd, 1H, 
CH2), 3.17 (dd, 1H, CH2). 
13
C NMR (DMSO-d6, 100 MHz): δ (ppm) 161.3, 
151.6, 143.8, 143.5, 136.7, 132.2, 129.6, 128.9, 128.7, 128.6, 128.4, 128.3, 
128.0, 127.6, 127.0, 126.6, 120.8, 116.7, 114.2, 70.8, 55.3, 39.4.   
 
5.2.1.2.1.3.26.  4-(3-(4-(benzyloxy)phenyl)-5-(3-chlorophenyl)-4,5-dihydro-
1H-pyrazol-1-yl)benzenesulfonamide (7f). Yield: 63%, m.p. = 134 – 136 °C 
from C6H6; Anal. Calc. for C28H24ClN3O3S: C 64.92, H 4.67, Cl 6.84, N 
8.11, S 6.19; found C 65.13, H 4.66, Cl 6.86, N 8.14, S 6.17. 
1
H NMR 
(DMSO-d6, 400 MHz):  (ppm) 7.77 – 7.06 (m, 17H, H2, H3, H5, H6, H2', 
H3', H5', H6', H2'', H4'', H5'', H6'', H2'''-H6'''), 5.34 (dd, 1H, CH), 5.17 (s, 2H, 
CH2), 4.76 (s, 2H, NH2), 3.91(dd, 1H, CH2), 3.21(dd, 1H, CH2). 
13
C NMR 
(DMSO-d6, 100 MHz): δ (ppm) 161.3, 151.7, 144.9, 143.8, 136.6, 134.1, 
129.9, 129.5, 128.9, 128.7, 128.6, 127.6, 127.1, 126.8, 126.7, 125.1, 120.8, 
116.7, 114.4, 70.2, 59.9, 40.1. 
 
5.2.1.2.1.3.27.  4-(3-(4-(benzyloxy)phenyl)-5-(4-chlorophenyl)-4,5-dihydro-
1H-pyrazol-1-yl)benzenesulfonamide (7g). Yield: 40%, m.p. = 98 – 102 °C 
from C6H6; Anal. Calc. for C28H24ClN3O3S: C 64.92, H 4.67, Cl 6.84, N 8.11, 
S 6.19; found C 64.69, H 4.66, Cl 6.82, N 8.13, S 6.17. 
1
H NMR (DMSO-d6): 
 (ppm) 7.55 – 7.05 (m, 17H, H2, H3, H5, H6, H2', H3', H5', H6', H2'', H3'', 
H5'', H6'', H2'''-H6'''), 5.34 (dd, 1H, CH), 5.16 (s, 2H, CH2), 4.83 (s, 2H, 
NH2), 3.90 (dd, 1H, CH2), 3.18 (dd, 1H, CH2). 
13
C NMR (DMSO-d6, 100 
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MHz): δ (ppm) 161.3, 151.7, 143.8, 141.6, 136.7, 132.3, 129.5, 128.9, 128.7, 
128.5, 128.2, 127.6, 127.1, 127.0, 120.8, 116.7, 114.3, 70.8, 60.4, 40.1. 
 
5.2.1.2.1.3.28.  4-(3-(4-(benzyloxy)phenyl)-5-(o-tolyl)-4,5-dihydro-1H-
pyrazol-1-yl)benzenesulfonamide (7h). Yield: 33%, m.p. = 230 – 234 °C 
from CH3CN; Anal. Calc. for C29H27N3O3S: C 70.00, H 5.47, N 8.44, S 6.44; 
found C 69.76, H 5.48, N 8.41, S 6.46. 
1
H NMR (DMSO-d6, 400 MHz):  
(ppm) 7.77 – 6.88 (m, 19H, Ar, NH2), 5.69 (dd, 1H, CH), 5.19 (s, 2H, CH2), 
4.02 (dd, 1H, CH2), 3.07 (dd, 1H, CH2), 2.50 (s, 3H, CH3). 
13
C NMR (DMSO-
d6, 100 MHz): δ (ppm) 161.4, 151.7, 143.8, 141.8, 136.7, 134.7, 130.1, 129.5, 
128.9, 128.7, 128.6, 127.6, 127.1, 126.6, 125.5, 123.1, 120.8, 116.7, 114.4, 
70.7, 60.1, 40.5, 19.0. 
 
5.2.1.2.1.3.29.        4-(3-(4-(benzyloxy)phenyl)-5-(m-tolyl)-4,5-dihydro-1H-
pyrazol-1-yl)benzenesulfonamide (7i). Yield: 29%, m.p. = 131 – 134 °C 
from EtOH; Anal. Calc. for C29H27N3O3S: C 70.00, H 5.47, N 8.44, S 6.44; 
found C 69.75, H 5.48, N 8.42, S 6.43. 
1
H NMR (DMSO-d6, 400 MHz):  
(ppm) 7.78 – 7.05 (m, 19H, H2, H3, H5, H6, H2', H3', H5', H6', H3''-6'', H2'''-
H6''', NH2), 5.56 (dd, 1H, CH), 5.21 (s, 2H, CH2), 3.26 (dd, 1H, CH2), 2.55 (s, 
3H, CH3), 2.52 (dd, 1H, CH2). 
13
C NMR (DMSO-d6, 100 MHz): δ (ppm) 
161.3, 151.7, 143.8, 143.4, 138.2, 129.5,  128.9, 128.7, 128.6, 128.6, 128.4, 
127.6, 127.1, 126.9, 126.7, 123.9, 120.8, 116.7, 114.4, 70.8, 57.9, 40.3, 21.6. 
 
5.2.1.2.1.3.30.         4-(3-(4-(benzyloxy)phenyl)-5-(p-tolyl)-4,5-dihydro-1H-
pyrazol-1-yl)benzenesulfonamide (7j). Yield: 39%, m.p. = 135 – 137 °C 
from MeOH; Anal. Calc. for C29H27N3O3S: C 70.00, H 5.47, N 8.44, S 6.44; 
found C 70.27, H 5.47, N 8.47, S 6.46. 
1
H NMR (DMSO-d6, 400 MHz):  
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(ppm) 8.11 – 7.05 (m, 17H, H2, H3, H5, H6, H2', H3', H5', H6', H2'', H3'', 
H5'', H6'', H2'''-H6'''), 5.19 (dd, 1H, CH), 5.16 (s, 2H, CH2), 4.77 (s, 2H, 
NH2), 3.88 (dd, 1H, CH2), 3.21(dd, 1H, CH2), 2.46 (s, 3H, CH3). 
13
C NMR 
(DMSO-d6, 100 MHz): δ (ppm) 161.3, 151.7, 143.8, 140.5, 136.7, 136.4, 
129.5, 128.9, 128.8, 128.7, 128.6, 127.6, 127.1, 125.3, 120.8, 116.7, 114.4, 
70.9, 60.4, 40.0, 21.4. 
 
5.2.1.2.1.4. General procedure for the synthesis of the (1E,4E)-1,5-
diphenylpenta-1,4-dien-3-ones (8a-c).  
The appropriate benzaldehyde (18 mmol) and acetone (9 mmol) were 
added to a solution of potassium hydroxide (45 mml) in water (20 ml) and 
ethanol (15 ml). The mixture was stirred for 30 min at room temperature. 
After this period, the precipitate was filtered, washed with water, dried and 
crystallized from suitable solvent.  
 
5.2.1.2.1.4.1.  (1E,4E)-1,5-diphenylpenta-1,4-dien-3-one (8a). Yield 90%, 
m.p. 105 – 107 °C  from EtOH. 1H-NMR (CDCl3, 400 MHz): δ (ppm) 7.79 (d, 
2H, Hβ, Jα-β = 16.0 Hz), 7.65 – 7.64 (m, 4H, H2, H6, H2', H6'), 7.45 – 7.43 (m, 
6H, H3, H4, H5, H3', H4', H5'), 7.13 (d, 2H, Hα, Jα-β = 16.0 Hz). 
13
C NMR 
(CDCl3, 100 MHz): δ (ppm) 188.6, 142.2, 135.2, 128.6, 128.5, 127.9, 123.3.    
 
5.2.1.2.1.4.2. (1E,4E)-1,5-bis(4-chlorophenyl)penta-1,4-dien-3-one (8b). 
Yield 85%, m.p. 121 – 125 °C from EtOH. 1H-NMR (CDCl3, 400 MHz): δ 
(ppm) 7.72 (d, 2H, Hβ, Jα-β = 16.0 Hz), 7.56 – 7.48(m, 4H, H2, H6, H2', H6'), 
7.41 – 7.39 (m, 4H, 4H, H3, H5, H3', H5'), 7.07 (d, 2H, Hα, Jα-β = 16.0 Hz). 
13
C 
NMR (CDCl3, 100 MHz): δ (ppm) 189.1, 142.8, 133.5, 133.3, 129.0, 128.7, 
122.9.   
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5.2.1.2.1.4.3. (1E,4E)-1,5-bis(4-fluorophenyl)penta-1,4-dien-3-one (8c). 
Yield 95%, m.p. 120 – 123 °C from EtOH. 1H-NMR (CDCl3, 400 MHz): δ 
(ppm) 7.71 (d, 2H, Hβ, Jα-β = 16.0 Hz), 7.71 – 7.61 (m, 4H, H2, H6, H2', H6'), 
7.15 – 7.10 (m, 4H, H3, H5, H3', H5'), 7.05 (d, 2H, Hα, Jα-β = 15.6 Hz). 
13
C 
NMR (CDCl3, 100 MHz): δ (ppm) 188.8, 162.1, 142.2, 130.8, 130.4, 123.3, 
115.4. 
 
5.2.1.2.1.4.4. (1E,4E)-1,5-di-p-tolylpenta-1,4-dien-3-one (8d). Yield 95%, 
m.p. 112 – 115 °C from C6H6.  
1
H-NMR (CDCl3, 400 MHz, 400 MHz): δ 
(ppm) 7.76 (d, 2H, Hβ, Jα-β = 16.0 Hz), 7.54 – 7.33 (m, 4H, H2, H6, H2', H6'), 
7.29 – 7.04 (m, 4H, H3, H5, H3', H5'), 6.73 (d, 2H, Hα, Jα-β = 15.6 Hz), 2.41 
(s, 6H, CH3). 
13
C NMR (CDCl3, 100 MHz): δ (ppm): 188.8, 142.4, 137.6, 
132.5, 129.9, 128.5, 123.3, 21.4. 
 
5.2.1.2.1.4.5. (1E,4E)-1,5-bis(4-methoxyphenyl)penta-1,4-dien-3-one (8e). 
Yield 88%, m.p. 127 – 130 ° C from EtOH. 1H-NMR (CDCl3, 400 MHz): δ (ppm) 
7.74 (d, 2H, Hβ, Jα-β = 16.0 Hz), 7.60 – 7.58 (m, 4H, H2, H6, H2', H6'), 6.99 – 
6.94 (m, 6H, H3, H5, H3', H5', Hα), 3.87 (s, 6H, OCH3). 
13
C NMR (CDCl3, 100 
MHz): δ (ppm): 188.6, 159.8, 142.4, 130.2, 127.5, 123.3, 114.2, 55.8. 
 
5.2.1.2.1.5. General procedure for the synthesis of the (E)-1,5-
diphenyl-3-styryl-4,5-dihydro-1H-pyrazoles (9a-o). 
A solution of the suitable chalcone (8a-e) (18 mmol) and the 
appropriate phenylhydrazine (27 mmol) in ethanol (70 ml) and HCl 2N (0.2 
ml) was refluxed for 10h with stirring. After cooling, the solid was filtered, 
washed with water, dried and crystallized from suitable solvent.  
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5.2.1.2.1.5.1. (E)-1,5-diphenyl-3-styryl-4,5-dihydro-1H-pyrazole (9a). 
Yield 29%, m.p. 170 – 173 °C from EtOH; Anal. Calc. for C23H20N2: C 85.15, 
H 6.21, N 8.63; found C 85.46, H 6.23, N 8.60. 
1
H-NMR (CDCl3, 400 MHz): 
δ (ppm) 7.57 – 7.20 (m, 13H, H2- H6, H3', H5', H2''- H6'', Hβ), 7.11 (d, 2H, 
H2', H6', J = 7.6 Hz), 6.86 (t, 1H, H4', J = 6.8 Hz), 6.55 (d, 1H, Hα, Jα-β = 
16.4 Hz), 5.28 (dd, 1H, CH, J = 12.0 Hz, J = 6.8 Hz), 3.74 (dd, 1H, CH2, Jgem 
= 16.8 Hz, J = 12.0 Hz),   3.05 (dd, 1H, CH2, Jgem = 16.8 Hz, J = 6.8 Hz). 
13
C 
NMR (CDCl3, 100 MHz): δ (ppm) 154.9, 143.8, 143.5, 135.9, 135.2, 129.5, 
128.6, 128.5, 128.1, 127.9, 126.9, 126.7, 116.7, 116.3, 120.8, 60.9, 40.9. 
 
5.2.1.2.1.5.2.      (E)-5-(4-chlorophenyl)-3-(4-chlorostyryl)-1-phenyl-4,5-
dihydro-1H-pyrazole (9b). Yield 30%, m.p. 221 – 223 °C from EtOH; Anal. 
Calc. for C23H18Cl2N2: C 74.24, H 4.61, Cl 18.03, N 7.12; found C 74.00, H 
4.61, Cl 18.08, N 7.10. 
1
H-NMR (CDCl3, 400 MHz): δ (ppm) 7.37 – 7.23 (m, 
11H, H2, H3, H5, H6, H3', H5', H2'', H3'', H5'', H6'', Hβ), 6.99 (d, 2H, H2', 
H6', J = 7.6 Hz), 6.83 (t, 1H, H4', J = 6.8 Hz), 6.52 (d, 1H, Hα, Jα-β = 16.4 
Hz), 5.26 (dd, 1H, CH, J = 12.0 Hz, J = 6.8 Hz), 3.71 (dd, 1H, CH2, Jgem = 
16.8 Hz, J = 12.0 Hz), 2.98 (d, 1H, CH2, Jgem = 16.8 Hz, J = 6.8 Hz). 
13
C 
NMR (CDCl3, 100 MHz): δ (ppm) 154.9, 143.8, 141.6, 135.9, 133.5, 133.3, 
132.3, 129.5, 129.0, 128.7, 128.6, 127.2, 120.8, 120.5, 116.7, 60.9, 40.9. 
 
5.2.1.2.1.5.3.         (E)-5-(4-fluorophenyl)-3-(4-fluorostyryl)-1-phenyl-4,5-
dihydro-1H-pyrazole (9c). Yield 75%, m.p. 195 – 199 °C from EtOH; Anal. 
Calc. for C23H18F2N2: C 76.85, H 5.03, F 10.54, N 7.77; found C 76.63, H 
5.05, F 10.52, N 7.77. 
1
H-NMR (CDCl3, 400 MHz): δ (ppm) 7.43 – 7.02 (m, 
13H, H2, H3, H5, H6, H2', H3', H5', H6', H2'', H3'', H5'', H6'', Hβ), 6.85 (t, 
1H, H4', J = 6.8 Hz), 6.54 (d,1H, Hα, Jα-β = 16.4 Hz), 5.26 (dd, 1H, CH, J = 
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12.0 Hz, J = 6.8 Hz), 3.73(dd, 1H, CH2, Jgem = 16.8 Hz, J = 12.0 Hz), 3.0 (dd, 
1H, CH2, Jgem = 16.8 Hz, J = 6.8 Hz). 
13
C NMR (CDCl3, 100 MHz): δ (ppm): 
162.1 (d), 160.9 (d), 154.9, 143.8, 139.1, 135.7, 130.8, 130.4 (d), 129.5, 128.5 
(d), 120.9, 120.7, 116.7, 115.4 (d), 115.1 (d), 60.8, 40.5.  
 
5.2.1.2.1.5.4. (E)-3-(4-methylstyryl)-1-phenyl-5-(p-tolyl)-4,5-dihydro-1H-
pyrazole (9d). Yield 76%, m.p. 184 – 187 °C from EtOH; Anal. 
Calc.C25H24N2: C 85.19, H 6.86, N 7.95; found C 84.88, H 6.87, N 7.93. 
1
H-
NMR (CDCl3, 400 MHz): δ (ppm) 7,36 (d, 2H, H2'', H6'', J = 7.2 Hz), 7.28 – 
7.18 (m, 9H, H2, H3, H5, H6, H3', H5', H3'', H5'', Hβ), 7.03 (d, 2H, H2', H6', J 
= 7.6 Hz), 6.79 (t, 1H, H4', J = 6.8 Hz) 6.55 (d,1H, Hα, Jα-β = 16.4 Hz), 5.24 
(dd, 1H, CH, J = 12.0 Hz, J = 6.8 Hz), 3.71 (dd, 1H, CH2, Jgem = 16.8 Hz, J = 
12.0 Hz), 3.01 (dd, 1H, CH2, Jgem = 16.8 Hz, J = 6.8 Hz), 2.38 (s, 3H, CH3), 
2.35 (s, 3H, CH3). 
13
C NMR (CDCl3, 100 MHz): δ (ppm) 155.1, 144.0, 140.5, 
139.2, 137.5, 136.4, 135.9, 129.5, 128.9, 128.9, 125.3, 120.8, 120.2, 116.7, 
115.1, 60.9, 40.8, 21.3.   
 
5.2.1.2.1.5.5.     (E)-5-(4-methoxyphenyl)-3-(4-methoxystyryl)-1-phenyl-
4,5-dihydro-1H-pyrazole (9e). Yield 60%, m.p. 150 – 152 °C from EtOH; 
Anal. Calc. for C25H24N2O2: C 78.10, H 6.29, N 7.29; found C 78.38, H 6.30, 
N 7.27. 
1
H-NMR (CDCl3, 400 MHz): δ (ppm) 7.43 – 6.79 (m, 14H, H2, H3, 
H5, H6, H2', H3', H4', H5', H6', H2'', H3'', H5'', H6'', Hβ), 6.54 (d, 1H, Hα, Jα-
β = 16.4), 5.21(dd, 1H, CH, J = 12.0 Hz, J = 6.8 Hz), 3.75 (m, 7H, OCH3, 
OCH3, CH2), 2.64 (d, 1H, CH, Jgem = 16.8 Hz, J = 6.8 Hz). 
13
C NMR (CDCl3, 
100 MHz): δ (ppm) 159.8, 158.6, 154.9, 143.8, 135.9, 135.8, 130.2, 129.5, 
127.5, 126.6, 119.9, 120.8, 116.7, 114.2, 114.1, 59.9, 55.8, 40.9,  
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5.2.1.2.1.5.6.     (E)-3-(4-methylstyryl)-1-phenyl-5-(p-tolyl)-4,5-dihydro-
1H-pyrazole (9f). Yield 77%, m.p. 170 – 174  °C from EtOH; Anal. Calc. for 
C24H22N2: C 85.17, H 6.55, N 8.28; found C 84.89, H 6.56, N 8.31. 
1
H-NMR 
(CDCl3, 400 MHz): δ (ppm) 7.46 (d, 2H, H2'', H6'', J = 7.6 Hz), 7.38 – 7.23 
(m, 9H, H2-, H6, H3'', H4'', H5'', Hβ), 7.0 ( d, 2H, H2', H6', J = 8.0 Hz) 6.94 
(d, 2H, H3', H5', J = 8.4 Hz),  6.55 (d, 1H, Hα, Jα-β = 16.4 Hz), 5.25 (dd, 1H, 
CH, J = 12.0 Hz, J = 6.8 Hz), 3.73 (dd, 1H, CH2, Jgem = 16.8 Hz, J = 12.0 Hz), 
3.03 (dd, 1H, CH2, Jgem = 16.8 Hz, J = 6.8 Hz), 2.25 (s, 3H, CH3). 
13
C NMR 
(CDCl3, 100 MHz): δ (ppm) 154.9, 143.5, 140.8, 135.9, 135.2, 129.8, 129.6, 
128.6, 128.5, 127.9, 126.9, 126.7, 120.8, 120.1, 113.4, 60.7, 40.1, 21.3.  
 
5.2.1.2.1.5.7.  (E)-5-(4-chlorophenyl)-3-(4-chlorostyryl)-1-(p-tolyl)-4,5-
dihydro-1H-pyrazole (9g). Yield 82%, m.p. 171 – 172 °C from EtOH; Anal. 
Calc. for C24H20Cl2N2: C 70.77, H 4.95, Cl 17.41, N 6.88; found C 70.99, H 
4.94, Cl 17.36, N 6.86. 
1
H-NMR (CDCl3, 400 MHz): δ (ppm) 7.38 – 7.17 (m, 
9H, 9H, H2- H6, H3'', H4'', H5'', Hβ), 7.01 (d, 2H, H2', H6', J = 8.0 Hz), 6.90 
(d, 2H, H3', H5', J = 8.4 Hz), 6.49 (d, 1H, Hα, Jα-β = 16.4 Hz), 5.23(dd, 1H, 
CH, J = 12.0 Hz, J = 6.8 Hz), 3.70 (dd, 1H, CH2,  Jgem = 16.8 Hz, J = 12.0 
Hz), 2.97 (dd, 1H, CH2, Jgem = 16.8 Hz, J = 6.8 Hz), 2.26 (s, 3H, CH3). 
13
C 
NMR (CDCl3, 100 MHz): δ (ppm): 155.0, 141.6, 140.2, 134.9, 133.5, 133.3, 
132.3, 129.8, 129.6, 129.0, 128.7, 128.6, 127.2, 120.6, 113.4, 60.9, 40.9, 22.2.  
 
5.2.1.2.1.5.8.     (E)-5-(4-fluorophenyl)-3-(4-fluorostyryl)-1-(p-tolyl)-4,5-
dihydro-1H-pyrazole (9h). Yield 72%, m.p. 155 – 160 °C from EtOH; Anal. 
Calc. for C24H20F2N2: C 76.99, H 5.38, F 10.15, N 7.48; found C 77.20, H 
5.39, F 10.14, N 7.49. 
1
H-NMR (CDCl3, 400 MHz): δ (ppm) 7.44 - 7.25 (m, 
4H, H2'', H3'', H5'', H6''), 7.15 (d, 1H, Hβ, Jα-β = 16.4 Hz), 7.08 – 7.0 (m, 6H, 
H2, H3, H5, H6, H2', H6'), 6.91 (d, 2H, H3', H5', J = 7.2 Hz) 6.52 (d, 1H, Hα, 
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Jα-β = 16.4 Hz), 5.23 (dd, 1H, CH, J = 12.4 Hz, J = 6.4 Hz), 3.69 (d, 1H, CH2, 
Jgem = 16.8 Hz, J = 12.4 Hz), 2.98 (d, 1H, CH2, Jgem = 16.8 Hz, J = 6.4 Hz), 
2.25 (s, 3H, CH3). 
13
C NMR (CDCl3, 100 MHz): δ (ppm) 162.1 (d), 160.9 (d), 
154.9, 140.8, 139.1, 135.9, 130.8, 130.4 (d), 129.8, 129.6, 128.5 (d), 120.8, 
115.4 (d), 115.3 (d), 113.4, 60.9, 40.9, 21.5.  
 
5.2.1.2.1.5.9.          (E)-3-(4-methylstyryl)-1,5-di-p-tolyl-4,5-dihydro-1H-
pyrazole (9i). Yield 73%, m.p. 150 – 155 °C from EtOH; Anal. Calc. for 
C26H26N2: C 85.21, H 7.15, N 7.64; found C 85.00, H 7.17, N 7.61. 
1
H-NMR 
(CDCl3, 400 MHz): δ (ppm) 7.34 (d, 2H, H2'', H6'', J = 7.6 Hz), 7.28 – 7.16 
(m, 7H, H2, H3, H5, H6, H3'', H5'', Hβ), 7.00 (d, 2H, H3', H5', J = 8.4 Hz), 
6.94 (d, 2H, H2', H6', J = 8.4Hz), 6.54, (d, 1H, Hα, Jα-β = 16.4 Hz), 5.20 (dd, 
1H, CH, J = 12.4 Hz, J = 6.4 Hz), 3.69 (dd, 1H, CH2, Jgem = 16.8 Hz, J = 12.4 
Hz), 2.99 (dd,1H, CH2, Jgem = 16.8 Hz, J = 6.4 Hz), 2.37 (s, 3H, CH3), 2.34 (s, 
3H, CH3), 2.24 (s, 3H, CH3). 
13
C NMR (CDCl3, 100 MHz): δ (ppm) 154.9, 
140.8, 140.5, 139.2, 137.6, 136.4, 135.0, 129.9, 129.4, 128.8, 128.3, 125.3, 
119.9, 114.1, 59.8, 39.8, 22.0, 21.9, 21.2.  
 
5.2.1.2.1.5.10.  (E)-5-(4-methoxyphenyl)-3-(4-methoxystyryl)-1-(p-tolyl)-
4,5-dihydro-1H-pyrazole (9j). Yield 83%, m.p. 171 – 175 °C from EtOH; 
Anal. Calc. for C26H26N2O2: C 78.36, H 6.58, N 7.03; found C 78.64, H 6.58, 
N 7.01. 
1
H-NMR (CDCl3, 400 MHz): δ (ppm) 7.39 – 6.89 (m, 13H, H2, H3, 
H5, H6, H2', H3', H5', H6', H2'', H3'', H5'', H6'', Hβ), 6.53 (d, 1H, Hα, Jα-β = 
16.4 Hz), 5.15 (dd, 1H, CH, J = 12.4 Hz, J = 6.4 Hz), 3.76 (m, 7H, OCH3, 
OCH3, CH2), 2.97 (dd,1H, CH2, Jgem = 16.8 Hz, J = 6.4 Hz), 2.31 (s, 3H, 
CH3). 
13
C NMR (CDCl3, 100 MHz) δ (ppm): 159.8, 158.6, 154.9, 140.8, 
135.9, 135.8, 130.2, 129.8, 129.6, 127.5, 126.6, 120.7, 114.2, 114.1, 113.4, 
60.9, 55.8, 41.0, 22.2. 
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5.2.1.2.1.5.11.       (E)-4-(5-phenyl-3-styryl-4,5-dihydro-1H-pyrazol-1-yl) 
benzenesulfonamide (9k). Yield 80%, m.p. 272 – 275 °C from EtOH; Anal. 
Calc. for C23H21N3O2S: C 68.46, H 5.25, N 10.41, S 7.95; found C 68.70, H 
5.26, N 10.39, S 7.93. 
1
H-NMR (DMSO-d6, 400 MHz): δ (ppm) 7.6 – 7.03 
(m,17H, H2- H6, H2', H3', H5', H6', H2''- H6'', Hβ, NH2), 6.89 (d, 1H, Hα, Jα-
β = 16.4 Hz), 5.62 (dd, 1H, CH,  J = 12.4 Hz, J = 6.4 Hz), 3.82 (dd, 1H, CH2, 
Jgem = 16.8 Hz, J = 12.4 Hz), 3.06 (dd, 1H, CH2, Jgem = 16.8 Hz, J = 6.4 Hz). 
13
C NMR (DMSO-d6, 100 MHz) δ (ppm) 156.2, 147.0, 143.5, 135.9, 135.2, 
130.3, 129.3, 128.6, 128.5, 128.2, 127.9, 126.9, 126.7, 120.2, 113.8, 60.7, 
41.0.   
 
5.2.1.2.1.5.12.    (E)-4-(5-(4-chlorophenyl)-3-(4-chlorostyryl)-4,5-dihydro-
1H-pyrazol-1-yl)benzenesulfonamide (9l). Yield 50%, m.p. 155 – 157 °C 
from EtOH; Anal. Calc. for C23H19Cl2N3O2S: C 58.48, H 4.05, Cl 15.01, N 
8.90, S 6.79; found C 58.65, H 4.06, Cl 14.97, N 8.88, S 6.80. 
1
H-NMR 
(DMSO-d6, 400 MHz): δ (ppm) 7.74  – 7.59 (m, 4H, H2, H6, H3', H5'),7.44 – 
7.41(m, 4H, H3, H5, H2'', H6''), 7.32 – 7.19 (m, 3H, H3'', H5'', Hβ ), 7.03 – 
7.01 (m, 4H, H2', H6', NH2 ), 6.89 (d, 1H, Hα, Jα-β = 16.4 Hz), 5.67 (dd, 1H, 
CH, J = 12.4 Hz, J = 6.4 Hz), 3.84 (dd, 1H, CH2,  Jgem = 16.8 Hz, J = 12.4 Hz), 
3.05 (dd, 1H, CH2, Jgem = 16.8 Hz, J = 6.4 Hz). 
13
C NMR (DMSO-d6, 100 
MHz) δ (ppm) 154.9, 147.0, 141.6, 135.9, 133.5, 133.3, 132.3, 130.0, 129.3, 
129.0, 128.7, 128.6, 127.2, 121.2, 114.0, 408, 61.2.  
 
5.2.1.2.1.5.13.    (E)-4-(5-(4-fluorophenyl)-3-(4-fluorostyryl)-4,5-dihydro-
1H-pyrazol-1-yl)benzenesulfonamide (9m). Yield 46%, m.p. 209 – 211 °C 
from EtOH; Anal. Calc. for C23H19F2N3O2S: C 62.86, H 4.36, F 8.65, N 9.56, S 
7.30; found C 63.03, H 4.37, F 8.62, N 9.59, S 7.29. 
1
H-NMR (DMSO-d6, 400 
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MHz): δ (ppm) 7.67 – 7.58 (m, 4H, H3', H5', H2'', H6''), 7.26 – 7.16 (m, 7H, 
H2, H3, H5, H6, H5'', H6'', Hβ), 7.04 – 7.01 (m, 4H, H2', H6', NH2), 6.90 (d, 
1H, Hα, Jα-β = 16.4 Hz), 5.65 (dd, 1H, CH, J = 12.4 Hz, J = 6.4 Hz), 3,7(dd, 
1H, CH2, Jgem = 16.8 Hz, J = 12.4 Hz), 3,0 (dd, 1H,  CH2, Jgem = 16.8 Hz, J = 
6.4 Hz). 
13
C NMR (DMSO-d6, 100 MHz) δ (ppm) 162.11 (d), 160.92 (d), 
155.28, 147.87, 139.13, 136.24, 130.89, 130.46 (d), 130.11, 129.37, 128.50 (d) 
121.58, 116.19, 115.55 (d), 114.33 (d), 61.6, 41.5.    
 
5.2.1.2.1.5.14.          (E)-4-(3-(4-methylstyryl)-5-(p-tolyl)-4,5-dihydro-1H-
pyrazol-1-yl)benzenesulfonamide (9n). Yield 77%, m.p. 215 – 218 °C from 
EtOH; Anal. Calc. for C25H25N3O2S: C 69.58, H 5.84, N 9.74, S 7.43; found C 
69.79, H 5.82, N 9.72, S 7.44. 
1
H-NMR (DMSO-d6, 400 MHz): δ (ppm) 7.58 
– 7.48 (m, 4H, H3', H5', H2'', H6'', ), 7.23 – 6.99 (m, 11H, H2, H3, H5, H6, 
H2', H6', H3'', H5'', Hβ, NH2), 6.84 (d, 1H, Hα, Jα-β = 16.4 Hz), 5.55 (dd, 1H, 
CH, J = 12.4 Hz, J = 6.4 Hz), 3.77(dd, 1H, CH2, Jgem = 16.8 Hz, J = 12.4 Hz), 
3.01 (dd,1H, CH2, Jgem = 16.8 Hz, J = 6.4 Hz), 2.31 (s, 3H, CH3), 2.25 (s, 3H, 
CH3). 
13
C NMR (DMSO-d6, 100 MHz): δ (ppm)  155.02, 146.91, 140.55, 
139.23, 137.68, 136.46, 135.94, 130.07, 129.35, 128.93, 128.81, 128.55, 
125.34, 120.81, 115.11, 62.27, 42.12, 24.31.    
 
5.2.1.2.1.5.15.          (E)-4-(5-(4-methoxyphenyl)-3-(4-methoxystyryl)-4,5-
dihydro-1H-pyrazol-1-yl)benzenesulfonamide (9o). Yield 88%, m.p. 200 – 
203 °C from EtOH; Anal. Calc. for C25H25N3O4S: C 64.78, H 5.44, N 9.06, S 
6.92; found C 64.99, H 5.44, N 9.03, S 6.93.  
1
H-NMR (DMSO-d6, 400 
MHz): δ (ppm) 7.57 – 7.53 (m, 4H, H3', H5', H2'', H6''), 7.14 – 6.88 (m, 11H, 
H2, H3, H5, H6, H2', H6', H3'', H5'', Hβ, NH2), 6.83 (d, 1H, Hα, Jα-β = 16.4 
Hz), 5.54 (dd, 1H, CH, J = 12.4 Hz, J = 6.4 Hz), 3.73 (m,7H, CH2, OCH3, 
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OCH3), 3.01 (dd, 1H, CH2, Jgem = 16.8 Hz, J = 6.4 Hz). 
13
C NMR (DMSO-d6, 
100 MHz): δ (ppm) 159.82, 158.65, 154.91, 147.02, 135.97, 135.85, 130.21, 
130.03, 129.32, 127.51, 126.64, 120.80, 114.12, 113.87, 60.91, 55.89, 41.14.  
  
5.2.1.2.2. Biology 
The cytotoxicity and antiviral assays were performed by Prof. Roberta 
Loddo, Department of  Biomedical Sciences, Microbiology and Virology 
Section, University of Cagliari. 
The new compounds were evaluated following the experimental 
protocol described in chapter 5.1.1.3. and 5.1.2.1.  
 
5.2.1.2.3. Time of addition assay 
A time-of-addition experiment was carried out with BHK-21 cells. The 
confluent monolayers of BHK-21 cells, seed in 96-well tissue culture plates 
were inoculated at room temperature with 50000 PFU of YFV, corresponding 
to a multiplicity of infection of 1 PFU/cell. After adsorption for 60 min, the 
monolayers were washed two times with maintenance medium in the presence 
of FBS inactivated and incubated with the same medium at 5% CO2 and 37 
°C. The test medium containing 10 × EC50 compound 7a and 7b 
concentration or 4 × EC50 6-Azauridine concentration was added at –1 to 0 
(adsorption), 0 to 2, 2 to 4, 4 to 6, 6 to 8, 8 to 10. After each incubation 
period, the monolayers were washed two times with maintenance medium and 
incubated with fresh medium until 20 hrs post-infection. Then, after 24–36 
hrs post-infection the CPE was evaluated and the monolayers were collected, 
centrifuged and frozen at -80 °C. The viral titre was determined by a plaque 
reduction assay. 
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5.2.2. Conclusions and perspectives 
The antiviral screening of the novel series of 1,3,5-trisubstituted 
pyrazolines (4a-i, 5a-j, 6a-j, 7a-j, 9a-o) has led to identification of new hit 
compounds with promising activity against YFV and BVDV. SAR studies 
showed that the presence of a sulfonamide group at the para position of the 
N1-phenyl ring is a requirement for anti-YFV potency in a low micromolar 
range. Several benzenesulfonamides exhibited up to 40-fold higher potency 
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against YFV than the reference inhibitor 6-Azauridine. However, while 
compounds 5a-j, 6a-j and 9a-o suffered from significant cytotoxicity, the 
benzyloxy derivatives 7a-j presented a better selectivity due to the low 
cytotoxicity. For the high potency against YFV coupled with low 
cytotoxicity, compounds 7a and 7b were selected for time of addition 
experiments. These studies showed a similar behavior of 7a, 7b and 6-
Azauridine, however, further investigations are necessary for the elucidation 
of the mechanism of action. The new hit compounds will be submitted to a 
further systematic optimization process addressed not only to the 
improvement of potency but also to the decrease of cytotoxicity. 
 
